Difunctional molecules
Patent Information
- Application Number
- JP2023530164
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-22
- Filing Date
- 2021-11-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current anti-PD-L1 antibodies exhibit low affinity and efficacy, leading to suboptimal treatment outcomes with potential toxic side effects, and additional biomarkers are needed to improve the clinical use of PD-1/PD-L1 targeted therapies.
Development of bifunctional molecules comprising a moiety that binds to PD-L1 and a moiety that blocks the activity of IL-1 or stimulates anti-tumor immunity, such as through TGF-β inhibition, to enhance therapeutic efficacy and reduce side effects.
The bifunctional molecules demonstrate improved binding affinity and therapeutic efficacy, potentially overcoming limitations of single-target antibodies by modulating both PD-L1 and IL-1 pathways, thereby enhancing anti-tumor responses and reducing immunosuppression.
Smart Images

Figure 2022105817000001
Abstract
Description
[Technical Field]
[0001]
[0001] This disclosure generally relates to novel bifunctional molecules that target immune checkpoint molecules (e.g., PD-L1) and block the activity of or stimulate immunity to anti-tumor immunosuppressive (ATIS) cytokines (e.g., IL-1 or TGFβ). [Background technology]
[0002]
[0002] Programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2 are important co-inhibitory molecules in regulating T cell-mediated immune responses. PD-1 is a type I membrane protein containing a single extracellular immunoglobulin superfamily (IgSF) V-set domain that is expressed on the surface of activated T cells in peripheral tissues (Zhang X et al., Immunity, 2004, 20(3):337-347). PD-L1 and PD-L2 are commonly expressed on dendritic cells and macrophages, and their ectodomains consist of a membrane-distal IgSF V-set and a membrane-proximal IgSF C-set domain (Latchman Y et al., Nature Immunology, 2001, 2(3):261-268). Ligation of PD-1 with its two ligands initiates co-inhibitory signaling through the cytoplasmic domain of PD-1, which contains an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, resulting in activation of SHP phosphatases, which downregulate TCR signaling by dephosphorylating effector molecules involved in signal transduction (Chemnitz JM et al., J. Immunol., 2004, 173(2):945-954). As a result, PD-1 signaling prevents excessive or harmful inflammation and maintains immune tolerance to self-antigens under normal conditions (Collins AV et al., Immunity, 2002, 17(2):201-210).
[0003] PD-L1 also negatively regulates T cell function through its interaction with another receptor, B7.1 (also known as B7-1 or CD80). Formation of PD-L1 / PD-1 and PD-L1 / B7.1 complexes negatively regulates T cell receptor signaling, resulting in the subsequent downregulation of T cell activation and suppression of antitumor immune activity (Butte MJ et al., Immunity, 2007, 27(1):111-122).
[0004] PD-L1 is often overexpressed in various tumors, and its interaction with PD-1 on T cells allows cancer cells to evade T cell-mediated immune responses (Okazaki T et al., Nature immunology, 2013, 14(12):1212-1218). Thus, blocking PD-1 / PD-L1 interaction can restore T cell activation and antitumor responses (Callahan MK et al., Immunity, 2016, 44(5):1069-1078). The success of antibody-based PD-1 / PD-L1 blockade therapies, such as atezolizumab (Tecentriq®) (Rittmeyer A et al., The Lancet, 2017, 389(10066):255-265), avelumab (Bavencio®) (Hamilton G et al., Expert Opinion on Biological Therapy, 2017, 17(4):515-523), and durvalumab (Imfinzi®) (Brower V, The Lancet Oncology, 2016, 17(7):e275), has led to significant advances in the fight against human cancer, particularly solid tumors. Although a correlation has been shown between PD-L1 expression by tumor cells and / or infiltrating immune cells and clinical response to PD-1 / PD-L1-targeted therapy, this correlation is not complete (Herbst, R. et al., Nature 515, 563-567 (2014); Taube JM et al., Clinical cancer research, 2014, 20(19):5064-5074). Only a small proportion of PD-L1-positive tumors respond to these treatments, and certain PD-L1-negative tumors are nonetheless responsive to treatment. This raises the possibility that additional factors determine patient response to PD-1 / PD-L1-targeted therapy, and that additional predictive biomarkers must be identified to improve the clinical use of these agents.
[0005]
[0005] Mariathasan S et al. found that the lack of response was associated with a transforming growth factor beta (TGF-β) signaling signature in fibroblasts (Mariathasan S et al., Nature, 2018, 554(7693):544-548). David JM et al. also found that TGF-β, a pleiotropic cytokine known to induce epithelial-mesenchymal transition (EMT) and suppress antitumor immunity, could upregulate tumor PD-L1 expression in several epithelial NSCLC cell lines, and the upregulation was associated with phosphorylation of Smad2, a key downstream effector of TGF-β signaling (David JM et al., Oncoimmunology, 2017, 6(10):e1349589). In mice, therapeutic administration of a TGF-β blocking antibody combined with anti-PD-L1 reduced TGF-β signaling in stromal cells, promoted T cell entry into the tumor center, and induced vigorous antitumor immunity and tumor regression (Mariathasan S et al., Nature, 2018, 554(7693):544-548). Summary of the Invention [Problem to be solved by the invention]
[0006]
[0006] However, the low affinity of anti-PD-L1 antibodies still presents a challenge for achieving high treatment efficacy and low toxic side effects.
[0007]
[0007] Therefore, there is a need for therapeutic molecules that have high binding affinity to PD-L1, improved therapeutic efficacy, and reduced toxic side effects. [Means for solving the problem]
[0008] Throughout this disclosure, the articles "a," "an," and "the" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an antibody" means one antibody or more than one antibody.
[0009]
[0009] In one aspect, the present disclosure provides a bifunctional molecule comprising a first portion that binds to an immune checkpoint molecule and a second portion that blocks the activity of interleukin-1 (IL-1).
[0010]
[0010] In certain embodiments, the first portion comprises an agonist of an immunostimulatory checkpoint molecule optionally selected from the group consisting of CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278), and ICOSLG (CD275), CD2, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, and CD83.
[0011]
[0011] In certain embodiments, the first portion comprises an antagonist of an immunoinhibitory checkpoint molecule optionally selected from the group consisting of A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), SIGLEC9 (CD329), CD160, LAIR1, 2B4 (CD244), CD47 and B7-H5.
[0012]
[0012] In one particular embodiment, the immune checkpoint molecule is PD-L1.
[0013]
[0013] In certain embodiments, the first portion comprises an antibody or antigen-binding fragment thereof against PD-L1, and the second portion comprises an IL-1 binding portion or an IL-1 receptor (IL-1R) binding portion.
[0014] In certain embodiments, the IL-1 binding portion comprises IL-1R or an IL-1 binding fragment or variant thereof, or an antibody to IL-1 or an antigen-binding fragment thereof.
[0015]
[0015] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region and / or a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102 and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab and gevokizumab.
[0016]
[0016] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 having the sequence of SEQ ID NO: 104 or SEQ ID NO: 112, an HCDR2 having the sequence of SEQ ID NO: 105 or SEQ ID NO: 113, and an HCDR3 having the sequence of SEQ ID NO: 106 or SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 having the sequence of SEQ ID NO: 107 or SEQ ID NO: 115, an LCDR2 having the sequence of SEQ ID NO: 108 or SEQ ID NO: 116, and an LCDR3 having the sequence of SEQ ID NO: 109 or SEQ ID NO: 117.
[0017]
[0017] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 having the sequence of SEQ ID NO: 104, an HCDR2 having the sequence of SEQ ID NO: 105, and an HCDR3 having the sequence of SEQ ID NO: 106, and / or a light chain variable region comprising an LCDR1 having the sequence of SEQ ID NO: 107, an LCDR2 having the sequence of SEQ ID NO: 108, and an LCDR3 having the sequence of SEQ ID NO: 109.
[0018]
[0018] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 having the sequence of SEQ ID NO: 112, an HCDR2 having the sequence of SEQ ID NO: 113, and an HCDR3 having the sequence of SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 having the sequence of SEQ ID NO: 115, an LCDR2 having the sequence of SEQ ID NO: 116, and an LCDR3 having the sequence of SEQ ID NO: 117.
[0019]
[0019] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102, SEQ ID NO: 110, and homologous sequences thereof having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103, SEQ ID NO: 111, and homologous sequences thereof having at least 80% sequence identity thereto.
[0020]
[0020] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto.
[0021]
[0021] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and its homologous sequences having at least 80% sequence identity thereto.
[0022] In certain embodiments, the IL-1R binding moiety comprises an interleukin-1 receptor antagonist or a fragment or variant thereof, or an antibody to IL-1R or an antigen-binding fragment thereof.
[0023]
[0023] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and / or a light chain variable region derived from an antibody selected from the group consisting of spesolimab, astegolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034 and CSC012.
[0024] In another aspect, the bifunctional molecule comprises a first portion that binds to PD-L1 and a second portion that a) blocks the activity of an immunosuppressive cytokine or b) stimulates immunity, wherein the first portion comprises an antibody or antigen-binding fragment thereof against PD-L1, comprising a heavy chain variable (VH) region and / or a light chain variable (VL) region, wherein the heavy chain variable region is a) HCDR1 comprising DYYMN (SEQ ID NO: 1) or a homologous sequence having at least 80% sequence identity thereto; b) an HCDR2 comprising DINPNNX1X2TX3YNHKFKG (SEQ ID NO: 19) or a homologous sequence having at least 80% sequence identity thereto; and c) HCDR3 comprising WGDGPFAY (SEQ ID NO: 3) or a homologous sequence having at least 80% sequence identity thereto and / or The light chain variable region is d) LCDR1 comprising a sequence selected from the group consisting of KASQNVX4X5X6VA (SEQ ID NO: 20) or a homologous sequence having at least 80% sequence identity thereto; e) LCDR2 comprising a sequence selected from the group consisting of SX7SX8RYT (SEQ ID NO: 21) or a homologous sequence having at least 80% sequence identity thereto; and f) LCDR3 comprising a sequence selected from the group consisting of QQYSNYPT (SEQ ID NO: 6) or a homologous sequence having at least 80% sequence identity thereto. Including, In the formula, X1 is G or A, X2 is G or D or Q or E or L, X3 is S or M or Q or L or V, X4 is G or P or K, X5 is A or G, X6 is A or I, X7 is A or N or R or V, and X8 is N or H or V or D.
[0025] In certain embodiments, the heavy chain variable region comprises: a) HCDR1 comprising the sequence SEQ ID NO: 1; b) an HCDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 18, and c) an HCDR3 comprising the sequence of SEQ ID NO: 3; and / or The light chain variable region is d) LCDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9; e) LCDR2 comprising a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12, and f) LCDR3 comprising the sequence of SEQ ID NO: 6 Includes:
[0026] In certain embodiments, the heavy chain variable region comprises: a) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 2, and an HCDR3 comprising the sequence of SEQ ID NO: 3; b) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 13, and an HCDR3 comprising the sequence of SEQ ID NO: 3; c) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 14, and an HCDR3 comprising the sequence of SEQ ID NO: 3; d) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 15, and an HCDR3 comprising the sequence of SEQ ID NO: 3; e) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 17, and an HCDR3 comprising the sequence of SEQ ID NO: 3; and f) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 18, and an HCDR3 comprising the sequence of SEQ ID NO: 3 is selected from the group consisting of:
[0027] In certain embodiments, the light chain variable region comprises: a) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; b) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 9, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; c) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 8, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; d) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 12, and an LCDR3 comprising the sequence of SEQ ID NO: 6; and e) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 11, and an LCDR3 comprising the sequence of SEQ ID NO: 6. is selected from the group consisting of:
[0028] In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 further comprises one or more of the heavy chains HFR1, HFR2, HFR3, and HFR4, and / or one or more of the light chains LFR1, LFR2, LFR3, and LFR4; a) HFR1 comprises the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCKASGYX9FT (SEQ ID NO: 40) or a homologous sequence having at least 80% sequence identity thereto; b) HFR2 is WVRQAPGQX 10LEWMG (SEQ ID NO: 41) or a homologous sequence having at least 80% sequence identity thereto; c) The HFR3 sequence is RVTX 16 TVDX 11 SISTAYMELSRLRSDDTAVYYCX 12 X 13 (SEQ ID NO: 42) or a homologous sequence having at least 80% sequence identity thereto; d) HFR4 comprises the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 25) or a homologous sequence having at least 80% sequence identity thereto; e) LFR1 comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 26) or a homologous sequence having at least 80% sequence identity thereto; f) LFR2 is WYQQKPGKX 14 PKLLIY (SEQ ID NO: 43) or a homologous sequence having at least 80% sequence identity thereto; g) LFR3 is GVPX 15 RFSGSGSGTDFTX 17 TISSLQPEDIATYYC (SEQ ID NO: 44) or a homologous sequence having at least 80% sequence identity thereto; h) LFR4 comprises the amino acid sequence of FGQGTKLEIK (SEQ ID NO: 29) or a homologous sequence having at least 80% sequence identity thereto; wherein X9 is T or V; 10 is G or S, and X 11 is T or K, and X 12 is A or V, and X 13 is R or K, and X 14 is A or S, and X 15 is S or D, and X 16 is M or V, and X 17 is F or L.
[0029] In one particular embodiment, HFR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 22 and 30; HFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 23 and 31; HFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 24 and 32-35; HFR4 comprises the sequence of SEQ ID NO: 25, LFR1 comprises a sequence from the group consisting of SEQ ID NO: 26; LFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 27 and 36; LFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 28, and 37 to 38, 39, and 45; LFR4 comprises the sequence of SEQ ID NO:29.
[0030]
[0030] In certain embodiments, the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and homologous sequences thereof having at least 80% sequence identity thereto.
[0031]
[0031] In certain embodiments, the light chain variable region comprises a sequence selected from the group consisting of SEQ ID NO:47, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and homologous sequences thereof having at least 80% sequence identity thereto.
[0032]
[0032] In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 comprises a pair of heavy chain and light chain variable region sequences selected from the group consisting of SEQ ID NOs: 49 / 54, 50 / 54, 51 / 54, 52 / 54, 49 / 55, 50 / 55, 51 / 55, 52 / 55, 58 / 62, 58 / 63, 58 / 64, 58 / 65, 59 / 62, 59 / 63, 59 / 64, 59 / 65, 60 / 62, 60 / 63, 60 / 64 and 60 / 65.
[0033]
[0033] In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 further comprises one or more amino acid residue substitutions or modifications that still retain specific binding specificity and / or affinity to PD-L1.
[0034]
[0034] In certain embodiments, at least one of the substitutions or modifications is in one or more of the CDR sequences and / or in one or more non-CDR regions of the VH or VL sequence.
[0035]
[0035] In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 further comprises an immunoglobulin constant region, optionally a human Ig constant region, or optionally a human IgG constant region.
[0036] In certain embodiments, the constant region comprises the Fc region of human IgG1, IgG2, IgG3, or IgG4.
[0037]
[0037] In certain embodiments, the Fc region of human IgG1 comprises SEQ ID NO: 80, or a variant thereof having at least 80% (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity thereto.
[0038] In certain embodiments, the constant region comprises an Fc variant that has reduced effector function relative to a corresponding wild-type Fc region, hi certain embodiments, the Fc region comprises one or more amino acid residue modifications or substitutions that result in reduced effector function relative to SEQ ID NO:80.
[0039] In certain embodiments, the Fc region comprises one or more amino acid residue substitutions selected from the group consisting of 220S, 226S, 228P, 229S, 233P, 234V, 234G, 234A, 234F, 234A, 235A, 235G, 235E, 236E, 236R, 237A, 237K, 238S, 267R, 268A, 268Q, 269R, 297A, 297Q, 297G, 309L, 318A, 322A, 325L, 328R, 330S, 331S, and any combination thereof, wherein the numbering of residues in the Fc region is that of the EU index as in Kabat.
[0040]
[0040] In certain embodiments, the Fc region comprises a combination of mutations selected from the group consisting of: a) K322A, L234A and L235A; b) P331S, L234F and L235E; c) L234A and L235A; c) N297A; d) N297Q; e) N297G; f) L235E; g) L234A and L235A (IgG1); h) F234A and L235A (IgG4); i) H268Q, V309L, A330S and P331S (IgG2); j) V234A, G237A, P238S, H268A, V309L, A330S and P331S (IgG2), where the numbering of residues in the Fc region is that of the EU index as in Kabat.
[0041]
[0041] In one particular embodiment, the Fc variant comprises the amino acid sequence of SEQ ID NO:81.
[0042]
[0042] In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 is humanized.
[0043]
[0043] In certain embodiments, the antigen-binding fragment is a diabody, Fab, Fab', F(ab')2, Fd, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (ds diabody), single-chain antibody molecule (scFv), scFv dimer (bivalent diabody), multispecific antibody, camelized single domain antibody, nanobody, domain antibody and bivalent domain antibody.
[0044]
[0044] In certain embodiments, the antibody or antigen-binding fragment thereof is capable of binding to both human PD-L1 and cynomolgus PD-L1.
[0045]
[0045] In certain embodiments, the first portion comprises an antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof provided herein for binding to PD-L1.
[0046] In certain embodiments, the immunosuppressive cytokine comprises a cytokine in the transforming growth factor beta (TGF-β) superfamily, IL-1, or vascular endothelial growth factor (VEGF).
[0047]
[0047] In certain embodiments, immunosuppressive cytokines in the TGF-β superfamily include TGF-β, bone morphogenetic proteins (BMPs), activins, NODAL, and growth and differentiation factors (GDFs).
[0048] In certain embodiments, the immunosuppressive cytokine is TGF-β.
[0049] In certain embodiments, the second moiety comprises a TGF-β binding moiety.
[0050]
[0050] In certain embodiments, the TGF-β binding moiety comprises a soluble TGFβ receptor (TGFβR) or a TGF-β binding fragment or variant thereof, or an antibody to TGFβ and an antigen-binding fragment thereof.
[0051]
[0051] In certain embodiments, the soluble TGFβR comprises the extracellular domain (ECD) of TGFβR or a TGF-β-binding fragment or variant thereof.
[0052]
[0052] In certain embodiments, the TGFβR is selected from the group consisting of TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), TGFβ receptor III (TGFβRIII), and any combination thereof.
[0053] In certain embodiments, the TGFβR is TGFβRII.
[0054] In certain embodiments, TGFβRII selectively binds to TGFβ1 over TGFβ2 and TGFβ3.
[0055] In certain embodiments, the TGFβ1 is human TGFβ1 or mouse TGFβ1.
[0056]
[0056] In certain embodiments, the ECD of TGFβR comprises the amino acid sequence of SEQ ID NO: 66, 79, 78, 77, or a sequence having at least 80% sequence identity thereto while still retaining specific binding specificity and / or affinity to TGF-β.
[0057] In certain embodiments, the second moiety comprises an IL-1 binding moiety or an IL-1 receptor (IL-1R) binding moiety.
[0058]
[0058] In certain embodiments, the IL-1 binding moiety comprises a soluble IL-1R, an IL-1 binding fragment or variant of IL-1R, or an antibody to IL-1 or an antigen-binding fragment thereof.
[0059]
[0059] In certain embodiments, the IL-1 binding portion comprises the extracellular domain (ECD) of IL-1RI, IL-1RI, the ECD of IL-1RI, IL-1RII, or the ECD of IL-1RII, or IL-1RAP, or the ECD of IL-1RAP, an IL-1 binding fragment or variant of either IL-1sRI or IL-1sRII.
[0060]
[0060] In certain embodiments, the IL-1R binding portion comprises IL-1Ra or an IL-1-binding fragment or variant thereof, or an antibody to IL-1R or an antigen-binding fragment thereof.
[0061]
[0061] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and / or a light chain variable region derived from an antibody selected from the group consisting of spesolimab, astegolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034 and CSC012.
[0062]
[0062] In certain embodiments, the IL-1R binding portion comprises the amino acid sequence of SEQ ID NO: 67 or 76, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 67 or 76, or an IL-1 binding fragment or variant thereof.
[0063] In certain embodiments, the IL-1 is IL-1α or IL-1β.
[0064] In certain embodiments, the IL-1β is human IL-1β.
[0065]
[0065] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region and / or a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102 and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab and gevokizumab.
[0066]
[0066] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 having the sequence of SEQ ID NO: 104 or SEQ ID NO: 112, an HCDR2 having the sequence of SEQ ID NO: 105 or SEQ ID NO: 113, and an HCDR3 having the sequence of SEQ ID NO: 106 or SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 having the sequence of SEQ ID NO: 107 or SEQ ID NO: 115, an LCDR2 having the sequence of SEQ ID NO: 108 or SEQ ID NO: 116, and an LCDR3 having the sequence of SEQ ID NO: 109 or SEQ ID NO: 117.
[0067]
[0067] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104, an HCDR2 comprising the sequence of SEQ ID NO: 105, and an HCDR3 comprising the sequence of SEQ ID NO: 106, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107, an LCDR2 comprising the sequence of SEQ ID NO: 108, and an LCDR3 comprising the sequence of SEQ ID NO: 109.
[0068]
[0068] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 117.
[0069]
[0069] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102, SEQ ID NO: 110, and homologous sequences thereof having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103, SEQ ID NO: 111, and homologous sequences thereof having at least 80% sequence identity thereto.
[0070]
[0070] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto.
[0071]
[0071] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and its homologous sequences having at least 80% sequence identity thereto.
[0072]
[0072] In certain embodiments, the bifunctional molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:118 or SEQ ID NO:120, and / or a light chain comprising the amino acid sequence of SEQ ID NO:119 or SEQ ID NO:121.
[0073] In certain embodiments, the second portion stimulates anti-tumor immunity and comprises an immunostimulatory polypeptide.
[0074]
[0074] In certain embodiments, the immunostimulatory polypeptide comprises interleukin (IL)-2 (IL-2), IL-15, IL-21, IL-10, IL-12, IL-23, IL-27, IL-35, granulocyte-macrophage colony-stimulating factor (GM-CSF), soluble CD4, soluble LAG-3, or IFN-α, or a functional equivalent thereof.
[0075]
[0075] In certain embodiments, the soluble LAG-3 comprises the extracellular domain (ECD) of LAG-3 or an MHCII-binding fragment or variant thereof.
[0076] In certain embodiments, the second moiety stimulates anti-tumor immunity and comprises an antagonist of immunoinhibitory receptor signaling.
[0077] In certain embodiments, the immunoinhibitory receptor is signal-regulatory protein alpha (SIRPα).
[0078]
[0078] In certain embodiments, the second portion blocks the interaction between CD47 and SIRPα.
[0079]
[0079] In certain embodiments, the second portion comprises a CD47-binding domain or a SIRPα-binding domain.
[0080]
[0080] In certain embodiments, the CD47-binding domain comprises soluble SIRPα or a CD47-binding fragment or variant thereof, or an anti-CD47 antibody or an antigen-binding fragment thereof.
[0081]
[0081] In certain embodiments, the soluble SIRPα comprises the extracellular domain (ECD) of SIRPα or a CD47-binding fragment or variant thereof.
[0082]
[0082] In certain embodiments, the soluble SIRPα comprises the amino acid sequence of SEQ ID NO: 84, or an amino acid sequence having at least 80% sequence identity thereto that still retains binding specificity for CD47.
[0083]
[0083] In certain embodiments, the SIRPα binding domain comprises soluble CD47 or a SIRPα binding fragment or variant thereof, or an anti-SIRPα antibody or an antigen-binding fragment thereof.
[0084]
[0084] In certain embodiments, the soluble CD47 comprises the extracellular domain (ECD) of CD47 or a SIRPα-binding fragment or variant thereof, an anti-SIRPα antibody or an antigen-binding fragment thereof.
[0085] In certain embodiments, the bifunctional molecule further comprises a linker connecting the first portion and the second portion.
[0086]
[0086] In certain embodiments, the linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.
[0087] In certain embodiments, the linker comprises the amino acid sequence of ((G)nS)m, where m and n are independently integers selected from 0 to 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10). In certain embodiments, n is 2, 3, 4, or 5, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In certain embodiments, the linker comprises the amino acid sequence of SEQ ID NO:68.
[0088] In certain embodiments, the bifunctional molecule comprises one or more second moieties.
[0089] In certain embodiments, at least one of the second moieties is linked to the N-terminus or C-terminus of the polypeptide chain of the first moiety.
[0090]
[0090] In certain embodiments, at least one of the second portions is linked to a) the N-terminus or C-terminus of the heavy chain of the first portion, or b) the N-terminus or C-terminus of the light chain of the first portion.
[0091]
[0091] In certain embodiments, at least one of the second portions is linked to the C-terminus of the heavy chain constant region of the first portion.
[0092]
[0092] In certain embodiments, each of the second portions is linked to the C-terminus of each heavy chain constant region of the first portion.
[0093]
[0093] In certain embodiments, the bifunctional molecule comprises more than one second moiety each linked to the N-terminus of the heavy chain of the first moiety, the C-terminus of the heavy chain of the first moiety, the N-terminus of the light chain of the first moiety, the C-terminus of the light chain of the first moiety, or any combination thereof.
[0094]
[0094] In certain embodiments, the bifunctional molecule comprises a homodimeric heavy chain or a heterodimeric heavy chain.
[0095]
[0095] In certain embodiments, the heavy chain is heterodimeric with respect to the presence or position of the second moiety.
[0096]
[0096] In certain embodiments, the heterodimeric heavy chain comprises one heavy chain having the second portion and the other heavy chain without it.
[0097]
[0097] In certain embodiments, the heterodimeric heavy chain further comprises a heterodimeric Fc region that is associated to prevent homodimerization and / or to favor heterodimerization.
[0098]
[0098] In certain embodiments, the first and heterodimeric Fc regions are capable of associating into heterodimers via knobs-into-holes, hydrophobic interactions, electrostatic interactions, hydrophilic interactions, or increased mobility.
[0099]
[0099] In certain embodiments, the heterodimeric Fc region comprises Y349C, T366S, L368A or Y407V or any combination thereof in one Fc region and S354C or T366W or a combination thereof in another Fc region, wherein the numbering of residues in the Fc regions is that of the EU index as in Kabat.
[0100]
[0100] In certain embodiments, the bifunctional molecule is further linked to one or more conjugate moieties.
[0101]
[0101] In certain embodiments, the conjugate moiety comprises a clearance-modifying agent, a chemotherapeutic agent, a toxin, a radioisotope, a lanthanide, a luminescent label, a fluorescent label, an enzyme substrate label, a DNA alkylating agent, a topoisomerase inhibitor, a tubulin binding agent, or another anti-cancer drug such as an androgen receptor inhibitor.
[0102]
[0102] In another aspect, the present disclosure further provides a pharmaceutical composition or kit comprising a bifunctional molecule provided herein and a pharmaceutically acceptable carrier.
[0103]
[0103] In another aspect, the present disclosure further provides isolated polynucleotides encoding the bifunctional molecules provided herein.
[0104]
[0104] In another aspect, the present disclosure further provides a vector comprising an isolated polynucleotide provided herein.
[0105]
[0105] In another aspect, the present disclosure further provides a host cell comprising the vector provided herein.
[0106]
[0106] In another aspect, the present disclosure further provides a method of expressing a bifunctional molecule provided herein, comprising culturing a host cell provided herein under conditions in which the vector is expressed.
[0107]
[0107] In another aspect, the present disclosure further provides a method of treating, preventing, or alleviating a PD-L1-associated disease in a subject, comprising administering to the subject a therapeutically effective amount of a bifunctional molecule provided herein, and / or a pharmaceutical composition or kit provided herein.
[0108]
[0108] In certain embodiments, the disease is an immune-related disease or disorder, cancer, an autoimmune disease, or an infectious disease.
[0109] In certain embodiments, the cancer is selected from the group consisting of lung cancer (e.g., non-small cell lung cancer), liver cancer, pancreatic cancer, breast cancer, bronchial cancer, bone cancer, liver and bile duct cancer, ovarian cancer, testicular cancer, kidney cancer, bladder cancer, head and neck cancer, spinal cancer, brain cancer, cervical cancer, uterine cancer, endometrial cancer, colon cancer, colorectal cancer, prostate cancer, gastro-esophageal cancer, rectal cancer, anal cancer, gastrointestinal cancer, skin cancer, pituitary cancer, stomach cancer, vaginal cancer, thyroid cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, sarcoma, teratoma, glioma, and adenocarcinoma.
[0110]
[0110] In certain embodiments, the subject has been identified as having PD-L1-expressing cancer cells.
[0111]
[0111] In certain embodiments, the subject is a human.
[0112] In certain embodiments, the method further comprises administering a therapeutically effective amount of a second therapeutic agent.
[0113]
[0113] In certain embodiments, the second therapeutic agent is selected from a chemotherapeutic agent, an anti-cancer drug, radiation therapy, an immunotherapy agent, an anti-angiogenic agent, a targeted therapy agent, a cell therapy agent, a gene therapy agent, a hormone therapy agent, or a cytokine.
[0114]
[0114] In another aspect, the present disclosure provides use of a bifunctional molecule provided herein in the manufacture of a medicament for treating a PD-L1-associated disease or condition in a subject.
[0115]
[0115] In another aspect, the present disclosure provides a method of treating, preventing, or alleviating a disease or condition in a subject that would benefit from suppression of immunosuppressive cytokines, from induction of a sustained immune response, or from stimulation of anti-tumor immunity, comprising administering an effective amount of a bifunctional molecule provided herein.
[0116] In certain embodiments, the immunosuppressive cytokine is TGFβ.
[0117] In certain embodiments, the disease or condition is a TGF-β-associated disease or condition.
[0118] In certain embodiments, the TGF-β-related disease is cancer, a fibrotic disease, or a renal disease.
[0119] In certain embodiments, the immunosuppressive cytokine is IL-1.
[0120] In certain embodiments, the disease or condition is an IL-1 associated disease or condition.
[0121]
[0121] In certain embodiments, the disease or condition would benefit from stimulation of anti-tumor immunity by inhibiting immunoinhibitory receptor signaling, for example, SIRPα signaling. [Brief explanation of the drawings]
[0122] [Figure 1]
[0122] Figure 1 shows the binding of humanized 4B6 antibody to human PD-L1 by ELISA. [Figure 2]
[0123] Figure 2 shows the binding of Hu4B6_HgLa to human PD-L1 by ELISA. [Figure 3]
[0124] Figures 3A-C show binding of AM-4B6-IgG1-TGFβRII variants to PD-L1 by ELISA. [Figure 4]
[0125] FIG. 4 shows the affinity ranking of AM-4B6-IgG1-TGFβII variants using flow cytometry. [Figure 5]
[0126] Figures 5A and 5B show blockade of PD-L1 / PD-1 or PD-L1 / B7-1 by AM-4B6-IgG1-TGFβII variant. [Figure 6]
[0127] Figure 6 shows PD-L1 / PD-1 blockade by AM-4B6-IgG1-TGFβII variants using a cell-based assay. [Figure 7]
[0128] FIG. 7 shows SDS-PAGE of AM4B6_hIgG1_TBRII(20-136) expressed using a stable cell line. [Figure 8]
[0129] Figures 8A and 8B show binding to human PD-L1 or cynomolgus PD-L1 by ELISA analysis. [Figure 9-1]
[0130] Figures 9A-9C show binding to human PD-L1 and other members of the B7 family and other members of the TGFβ superfamily by ELISA analysis. [Figure 9-2]
[0130] Figures 9A-9C show binding to human PD-L1 and other members of the B7 family and other members of the TGFβ superfamily by ELISA analysis. [Figure 10-1]
[0131] Figures 10A-10F show binding to PD-L1 expressing cells by FACS analysis. [Figure 10-2]
[0131] Figures 10A-10F show binding to PD-L1 expressing cells by FACS analysis. [Figure 10-3]
[0131] Figures 10A-10F show binding to PD-L1 expressing cells by FACS analysis. [Figure 11]
[0132] Figure 11 shows binding to human PD-L1 on activated human T cells by FACS analysis. [Figure 12]
[0133] Figures 12A-B show blocking of human PD-L1 binding to human PD-1 or cynomolgus PD-L1 binding to cynomolgus PD-1 by ELISA analysis. [Figure 13]
[0134] Figure 13 shows simultaneous binding to hPD-L1 and TGFb1 by ELISA analysis. [Figure 14]
[0135] Figure 14 shows the blockade of hPD-L1 / hPD-1 using a reporter assay. [Figure 15]
[0136] FIG. 15 shows blockade of TGFβ1 signaling using a TGF-β reporter HEK-293 cell line. [Figure 16]
[0137] FIG. 16 shows the effect of AM4B6-hIgG1-TGFβRII′ on IFNγ release from PBMC stimulated with tuberculin (TB). [Figure 17]
[0138] Figures 17A-B show anti-tumor activity in the MC38-hPD-L1 tumor model. [Figure 18]
[0139] 18A-18B show antitumor activity in the H460 tumor model. [Figure 19]
[0140] Figures 19A-B show anti-tumor activity in the EMT6-hPD-L1 tumor model. [Figure 20]
[0141] Figures 20A-C show pharmacokinetic and pharmacodynamic studies of AM4B6-hIgG1-TGFβII in vivo. [Figure 21]
[0142] Figure 21 shows the binding activity of AM4B6-hIgG1-IL-1RA to human PD-L1 by ELISA. [Figure 22]
[0143] Figure 22 shows the binding activity of AM4B6-hIgG1-IL-1RA to human PD-L1 by FACS analysis. [Figure 23]
[0144] Figure 23 shows PD-L1 / PD-1 blockade by AM4B6-hIgG1-IL-1RA using a cell-based assay. [Figure 24]
[0145] FIG. 24 shows the blocking activity of AM4B6-IgG1-IL-1RA against human IL-1β by ELISA. [Figure 25]
[0146] FIG. 25 shows the blocking activity of AM4B6-hIgG1-IL-1RA against human IL-1β on reporter cells. [Figure 26]
[0147] FIG. 26 shows the SEC-HPLC purity of the asymmetric bifunctional antibody. [Figure 27]
[0148] Figure 27 shows the binding of bifunctional molecules to human PD-L1 as measured by ELISA. [Figure 28]
[0149] FIG. 28 shows the binding of bifunctional molecules to human CD47 as measured by ELISA. [Figure 29]
[0150] Figure 29 shows the binding activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs to hIL-1β protein in ELISA. [Figure 30]
[0151] Figure 30 shows the binding activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs to hPD-L1 protein by ELISA. [Figure 31]
[0152] Figure 31 shows the binding of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 to PD-L1-expressing 293T cells by FACS. [Figure 32]
[0153] Figure 32 shows the cell-based PD1 / PD-L1 blocking activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6. [Figure 33]
[0154] Figure 33 shows the blocking activity of IgG-scFv-XOMA052-AM4B6 against human IL-1β on HDF cells. [Figure 34]
[0155] FIG. 34 shows the blocking activity of IgG-scFv-ACZ885-AM4B6 against hIL-1β on reporter cells. DETAILED DESCRIPTION OF THE INVENTION
[0123]
[0156] The following description of the present disclosure is merely intended to illustrate various embodiments of the present disclosure. As such, the specific modifications discussed are not to be construed as limiting the scope of the present disclosure. It will be apparent to those skilled in the art that various equivalents, modifications and alterations can be made without departing from the scope of the present disclosure, and it is understood that such equivalent embodiments are included herein. All references cited herein, including publications, patents and patent applications, are incorporated herein by reference in their entirety.
[0124] definition
[0157] As used herein, the term "antibody" includes any immunoglobulin, monoclonal, polyclonal, multivalent, bivalent, monovalent, multispecific, or bispecific antibody that binds to a specific antigen. Natural, intact antibodies contain two heavy (H) chains and two light (L) chains. Mammalian heavy chains are classified as alpha, delta, epsilon, gamma, and mu, each consisting of a variable region (VH) and a first, second, third, and optionally fourth constant region (CH1, CH2, CH3, and CH4, respectively); mammalian light chains are classified as lambda or kappa, each consisting of a variable region (VL) and a constant region. Antibodies have a "Y" shape, with the stem of the Y consisting of the second and third constant regions of two heavy chains linked together via disulfide bonds. Each arm of the Y contains the variable region and first constant region of a single heavy chain bound to the variable and constant regions of a single light chain. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions of both chains generally contain three highly variable loops called complementarity-determining regions (CDRs) (light chain CDRs include LCDR1, LCDR2, and LCDR3, and heavy chain CDRs include HCDR1, HCDR2, and HCDR3).The CDR boundaries for the antibodies and antigen-binding fragments disclosed herein may be defined or identified by the conventions of Kabat, IMGT, Chothia, or Al-Lazikani (Al-Lazikani, B., Chothia, C., Lesk, AM, J. Mol. Biol., 273(4), 927 (1997); Chothia, C. et al., J. Mol. Biol. Dec 5; 186(3):651-63 (1985); Chothia, C. and Lesk, AM, J. Mol. Biol., 196, 901 (1987); Chothia, C. et al., Nature. Dec 21-28; 342(6252):877-83 (1989); Kabat EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991); Marie-Paule Lefranc et al., Developmental and Comparative Immunology, 27:55-77 (2003); Marie-Paule Lefranc et al., Immunome Research, 1(3), (2005); Marie-Paule Lefranc, Molecular Biology of B cells (2nd ed.), chapter 26, 481-514, (2015)). The three CDRs are inserted between adjacent stretches known as framework regions (FRs) (light chain FRs including LFR1, LFR2, LFR3, and LFR4, heavy chain FRs including HFR1, HFR2, HFR3, and HFR4), which are more conserved than the CDRs and form a scaffold supporting the highly variable loops. The constant regions of the heavy and light chains are not involved in antigen binding but exhibit various effector functions. As used herein, the term "effector function" refers to a cell-mediated or complement-mediated cytotoxic effect resulting from the interaction between the Fc region of an antibody and the C1q complement protein or Fc receptor (FcR) on an immune cell.Exemplary effector functions include, but are not limited to, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chains. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of alpha, delta, epsilon, gamma, and mu heavy chains, respectively. Some major antibody classes are divided into subclasses, such as IgG1 (gamma 1 heavy chain), IgG2 (gamma 2 heavy chain), IgG3 (gamma 3 heavy chain), IgG4 (gamma 4 heavy chain), IgA1 (alpha 1 heavy chain), or IgA2 (alpha 2 heavy chain).
[0125]
[0158] In certain embodiments, the antibodies provided herein encompass any antigen-binding fragment thereof. As used herein, the term "antigen-binding fragment" refers to an antibody fragment formed from a portion of an antibody containing one or more CDRs, or any other antibody fragment that binds to an antigen but does not contain the intact native antibody structure. Examples of antigen-binding fragments include, but are not limited to, diabodies, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (ds diabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), diabodies, multispecific antibodies, camelized single-domain antibodies, nanobodies, domain antibodies, and bivalent domain antibodies. Antigen-binding fragments can bind to the same antigen as the parent antibody.
[0126]
[0159] With respect to antibodies, "Fab" refers to the portion of an antibody consisting of a single light chain (both variable and constant regions) linked by disulfide bonds to the variable region and first constant region of a single heavy chain.
[0127]
[0160] "Fab'" refers to a Fab fragment that includes part of the hinge region.
[0128]
[0161] "F(ab')2" refers to a Fab' dimer.
[0129]
[0162] With respect to antibodies (e.g., of the IgG, IgA, or IgD isotype), "Fc" refers to the portion of the antibody consisting of the second and third constant domains of a first heavy chain linked via disulfide bonds to the second and third constant domains of a second heavy chain. For antibodies of the IgM and IgE isotypes, the Fc further comprises a fourth constant domain. The Fc portion of an antibody is responsible for various effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), but does not function in antigen binding.
[0130]
[0163] With respect to antibodies, "Fv" refers to the minimum fragment of an antibody that retains a complete antigen-binding site. The Fv fragment consists of the variable region of a single light chain bound to the variable region of a single heavy chain.
[0131]
[0164] A "single-chain Fv antibody" or "scFv" refers to an engineered antibody consisting of a light chain variable region and a heavy chain variable region linked together either directly or via a peptide linker sequence (Huston JS et al., Proc Natl Acad Sci USA, 85:5879 (1988)).
[0132]
[0165] "Single chain Fv-Fc antibody" or "scFv-Fc" refers to an engineered antibody consisting of an scFv linked to the Fc region of an antibody.
[0133]
[0166] "Camelized single domain antibodies," "heavy chain antibodies," or "HCAbs" are antibodies that contain two V HIt refers to antibodies that contain heavy chains but do not contain light chains (Riechmann L. and Muyldermans S., J Immunol Methods. Dec 10;231(1-2):25-38(1999); Muyldermans S., J Biotechnol. Jun;74(4):277-302(2001); WO94 / 04678; WO94 / 25591; U.S. Patent No. 6,005,079). Heavy chain antibodies were originally derived from camelids (camels, dromedaries, and llamas). Although lacking light chains, camelized antibodies have a standard antigen-binding repertoire (Hamers-Casterman C. et al., Nature. Jun 3; 363(6428):446-8(1993); Nguyen VK. et al., Immunogenetics. Apr; 54(1):39-47(2002); Nguyen VK. et al., Immunology. May; 109(1):93-101(2003)). The variable domain of a heavy chain antibody (VHH domain) represents the smallest known antigen-binding unit generated by the adaptive immune response (Koch-Nolte F. et al., FASEB J. Nov; 21(13):3490-8. Epub 2007 Jun 15(2007)).
[0134]
[0167] "Nanobody" refers to an antibody fragment consisting of a VHH domain from a heavy chain antibody and two constant domains, CH2 and CH3.
[0135]
[0168] A "diabody" or "dAb" comprises a small antibody fragment having two antigen-binding sites, the fragment comprising a VH domain connected to a VL domain in the same peptide chain (VH-VL or VL-VH) (see, e.g., Holliger P. et al., Proc Natl Acad Sci USA. Jul 15;90(14):6444-8 (1993); EP404097; WO93 / 11161). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain, thereby creating two antigen-binding sites. The antigen-binding sites may target the same or different antigens (or epitopes). In certain embodiments, a "bispecific dsdiabody" is a diabody that targets two different antigens (or epitopes).
[0136]
[0169] "Domain antibody" refers to an antibody fragment containing only the variable region of the heavy chain or the variable region of the light chain. In certain cases, two or more VH domains are covalently linked using a peptide linker to create a bivalent or multivalent domain antibody. The two VH domains of a bivalent domain antibody can target the same or different antigens.
[0137]
[0170] As used herein, the term "valent" refers to the presence of a specified number of antigen-binding sites in a given molecule. The term "monovalent" refers to an antibody or antigen-binding fragment having only one antigen-binding site; the term "multivalent" refers to an antibody or antigen-binding fragment having multiple antigen-binding sites. Thus, the terms "bivalent," "tetravalent," and "hexavalent" refer to the presence of two, four, and six binding sites, respectively, in an antigen-binding molecule. In some embodiments, an antibody or antigen-binding fragment thereof is bivalent.
[0138]
[0171] As used herein, a "bispecific" antibody refers to an artificial antibody that has fragments derived from two different monoclonal antibodies and is capable of binding to two different epitopes. The two epitopes may be on the same antigen, or they may be on two different antigens.
[0139]
[0172] In certain embodiments, an "scFv dimer" is a bivalent diabody or bispecific scFv (BsFv) comprising a VH-VL moiety (linked by a peptide linker) dimerized with another VH-VL moiety such that the VH' of one moiety is combined with the VL' of the other moiety to form two binding sites that can target the same antigen (or epitope) or different antigens (or epitopes). In other embodiments, an "scFv dimer" is a bispecific diabody comprising VH1-VL2 (also linked by a peptide linker) combined with VL1-VH2 (linked by a peptide linker) such that VH1 and VL1 are combined and VH2 and VL2 are combined, with each combined pair having a different antigen specificity.
[0140]
[0173] "dsFv" refers to a disulfide-stabilized Fv fragment in which the link between the variable region of a single light chain and the variable region of a single heavy chain is a disulfide bond. In some embodiments, a "(dsFv)2" or "(dsFv-dsFv')" comprises three peptide chains: two VH moieties linked by a peptide linker (e.g., a long flexible linker) and connected via disulfide bridges to two VL moieties, respectively. In some embodiments, a dsFv-dsFv' is bispecific, with each disulfide-paired heavy and light chain having a different antigen specificity.
[0141]
[0174] As used herein, the term "chimeric" refers to an antibody or antigen-binding fragment having a portion of a heavy and / or light chain from one species and the remaining portion of a heavy and / or light chain from another species. In an illustrative example, a chimeric antibody may contain a constant region from a human and a variable region from a non-human animal, such as from a mouse. In some embodiments, the non-human animal is a mammal, such as a mouse, rat, rabbit, goat, sheep, guinea pig, or hamster.
[0142]
[0175] As used herein, the term "humanized" means that the antibody or antigen-binding fragment contains CDRs derived from a non-human animal, FR regions derived from a human, and, where applicable, constant regions derived from a human.
[0143]
[0176] As used herein, the term "affinity" refers to the strength of the non-covalent interactions between an immunoglobulin molecule (i.e., an antibody) or fragment thereof and an antigen.
[0144]
[0177] As used herein, the term "specific binding" or "specifically binds" refers to a non-random binding reaction between two molecules, e.g., an antibody and an antigen. Specific binding is, for example, a K D value, i.e., the ratio of the dissociation rate to the association rate (k off / k on The binding affinity can be characterized by the K D can be determined by using any conventional method known in the art, including, but not limited to, surface plasmon resonance, octet, microscale thermophoresis, HPLC-MS, and FACS assays. -6 M (e.g., ≦5x10 -7 M, ≤2x10 -7 M, ≤10 -7 M, ≤5x10 -8 M, ≤2x10 -8 M, ≤10 -8 M, ≤5x10 -9 M, ≤4x10 -9 M, ≤3x10-9 M, ≤2x10 -9 M or ≤ 10 -9 M)'s K D The value may indicate the specific binding between the antibody or antigen-binding fragment thereof and PD-L1 (e.g., human PD-L1 or cynomolgus PD-L1).
[0145]
[0178] As used herein, the ability to "compete for binding to PD-L1" refers to the ability of a first antibody or antigen-binding fragment to inhibit, to any detectable extent, the binding interaction between PD-L1 and a second anti-PD-L1 antibody. In certain embodiments, an antibody or antigen-binding fragment that competes for binding to PD-L1 inhibits the binding interaction between PD-L1 and the second anti-PD-L1 antibody by at least 85%, or at least 90%. In certain embodiments, this inhibition may be greater than 95%, or greater than 99%.
[0146]
[0179] As used herein, the term "amino acid" refers to an organic compound containing an amine (-NH2) and a carboxyl (-COOH) functional group along with a side chain specific to each amino acid. In this disclosure, the names of amino acids are also represented as standard one-letter or three-letter codes, summarized below.
[0147] [Table 1]
[0148]
[0180] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding naturally occurring amino acids, as well as to naturally occurring and non-naturally occurring amino acid polymers.
[0149]
[0181] "Conservative substitution" in relation to amino acid sequence refers to the replacement of an amino acid residue with a different amino acid residue having a side chain with similar physicochemical properties.For example, conservative substitution can be made among amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu and Ile), among amino acid residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn and Gln), among amino acid residues with acidic side chains (e.g., Asp, Glu), among amino acid residues with basic side chains (e.g., His, Lys and Arg), or among amino acid residues with aromatic side chains (e.g., Trp, Tyr and Phe).As is known in the art, conservative substitution usually does not significantly change the conformational structure of protein, thereby maintaining the biological activity of protein.
[0150]
[0182] With respect to amino acid sequences (or nucleic acid sequences), "percent (%) sequence identity" is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical with the amino acid (or nucleic acid) residues in a reference sequence, after aligning the sequences, optionally introducing gaps to achieve maximum correspondence. Alignment for purposes of determining percent amino acid (or nucleic acid) sequence identity can be achieved using publicly available tools such as BLASTN, BLASTp (available at the US National Center for Biotechnology Information (NCBI) website; see also Altschul SF et al., J. Mol. Biol., 215:403-410 (1990); Stephen F. et al., Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 (available at the European Bioinformatics Institute website; see also Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin MA et al., Bioinformatics (Oxford, England), 23(21):2947-8 (2007)), and ALIGN or Megalign (DNASTAR) software. Those skilled in the art can use the default parameters provided by the tool or can customize the alignment options, for example, by selecting a suitable algorithm. In certain embodiments, non-identical residue positions may differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upward to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those skilled in the art.See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331, incorporated herein by reference.
[0151]
[0183] As used herein, a "homologous sequence" refers to a polynucleotide sequence (or its complementary strand) or amino acid sequence that, when optionally aligned, has at least 80% (e.g., at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity to another sequence.
[0152]
[0184] An "isolated" material is artificially altered from its natural state. When an "isolated" composition or material exists in nature, it has been altered or removed from its original environment, or both. For example, a polynucleotide or polypeptide that naturally occurs in a living animal is not "isolated," but the same polynucleotide or polypeptide is "isolated" if it is sufficiently separated from the materials with which it naturally coexists so that it exists in a substantially pure state. Isolated "nucleic acid" or "polynucleotide" are used interchangeably and refer to the sequence of an isolated nucleic acid molecule. In certain embodiments, an "isolated antibody or antigen-binding fragment thereof" refers to an antibody or antigen-binding fragment that has a purity of at least 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% as determined by electrophoretic methods (e.g., SDS-PAGE, isoelectric focusing, capillary electrophoresis) or chromatographic methods (e.g., ion exchange chromatography or reverse-phase HPLC).
[0153]
[0185] The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, such as mammals and non-mammals, including non-human primates, mice, rats, cats, rabbits, sheep, dogs, cows, chickens, amphibians, and reptiles. Except where noted, the terms "patient" and "subject" are used interchangeably herein.
[0154]
[0186] As used herein, "treating" a condition or "treatment" thereof includes preventing or alleviating the condition, slowing the onset or development of the condition, reducing the risk of developing the condition, preventing or delaying the onset of symptoms associated with the condition, reducing or terminating symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or any combination thereof.
[0155]
[0187] As used herein, the term "vector" refers to a vehicle into which a genetic element can be operably inserted to cause expression of the genetic element, such as to produce the protein, RNA, or DNA encoded by the genetic element, or to replicate the genetic element. A vector can be used to transform, transduce, or transfect a host cell to cause expression of the genetic element it carries within the host cell. Examples of vectors include plasmids, phagemids, cosmids, artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs), bacteriophages, such as lambda phage or M13 phage, and animal viruses. A vector can contain various elements for regulating expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selectable elements, and reporter genes. In addition, a vector can contain an origin of replication. A vector can also contain materials that aid its entry into a cell, including, but not limited to, viral particles, liposomes, or protein coatings. A vector can be an expression vector or a cloning vector. The present disclosure provides vectors (e.g., expression vectors) containing nucleic acid sequences provided herein encoding an antibody or antigen-binding fragment thereof, at least one promoter (e.g., SV40, CMV, EF-1α) operably linked to the nucleic acid sequence, and at least one selectable marker.
[0156]
[0188] As used herein, a "host cell" refers to a cell into which an exogenous polynucleotide and / or vector has been introduced.
[0157]
[0189] As used herein, the term "soluble" refers to the ability of a molecule (eg, a protein) to be dissolved in a solvent, such as a liquid or aqueous environment.
[0158]
[0190] As used herein, the terms "transforming growth factor beta" and "TGFβ" refer to any TGFβ family protein having any full-length, native amino acid sequence of TGF-beta from a subject (e.g., a human), including latent forms and associated or unassociated complexes of precursor and mature TGFβ ("latent TGFβ"). Reference herein to such TGFβs is understood to refer to any one of the currently identified forms, including the TGFβ1, TGFβ2, and TGFβ3 isoforms and latent versions thereof, as well as any one of the yet-to-be-identified human TGFβ species derived from the sequence of any known TGFβ and including polypeptides that are at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, and even more preferably at least about 95% homologous to the sequence. The specific terms "TGFβ1," "TGFβ2," and "TGFβ3" refer to TGF-beta as defined in the literature, e.g., Derynck et al., Nature, Cancer Res., 47:707 (1987); Seyedin et al., J. Biol. Chem., 261:5693-5695 (1986); deMartin et al., EMBO J., 6:3673 (1987); Kuppner et al., Int. J. Cancer, 42:562 (1988). The terms "transforming growth factor beta," "TGFβ," "TGF beta," "TGF-β," and "TGF-beta" are used interchangeably in the present disclosure.
[0159]
[0191] As used herein, the term "human TGFβ1" refers to the TGFβ1 protein encoded by the human TGFB1 gene (e.g., wild-type human TGFB1 gene). An exemplary wild-type human TGFβ1 protein is provided by GenBank accession number NP_000651.3. As used herein, the term "human TGFβ2" refers to the TGFβ2 protein encoded by the human TGFB2 gene (e.g., wild-type human TGFB2 gene). Exemplary wild-type human TGFβ2 proteins are provided by GenBank accession numbers NP_001129071.1 and NP_003229.1. As used herein, the term "human TGFβ3" refers to the TGFβ3 protein encoded by the human TGFB3 gene (e.g., wild-type human TGFB3 gene). Exemplary wild-type human TGFβ3 proteins are provided by GenBank Accession Nos. NP_003230.1, NP_001316868.1 and NP_001316867.1.
[0160]
[0192] As used herein, the terms "mouse TGFβ1," "mouse TGFβ2," and "mouse TGFβ3" refer to the TGFβ1 protein, TGFβ2 protein, and TGFβ3 protein encoded by the mouse TGFB1 gene (e.g., wild-type mouse TGFB1 gene), mouse TGFB2 gene (e.g., wild-type mouse TGFB2 gene), and mouse TGFB3 gene (e.g., wild-type mouse TGFB3 gene), respectively. Exemplary wild-type mouse (Mus musculus) TGFβ1 proteins are provided by GenBank accession numbers NP_035707.1 and CAA08900.1. Exemplary wild-type mouse TGFβ2 proteins are provided by GenBank accession number NP_033393.2. Exemplary wild-type mouse TGFβ3 proteins are provided by GenBank accession number AAA40422.1.
[0161]
[0193] As used herein, the term "TGFβ receptor" refers to any receptor that binds to at least one TGFβ isoform. Generally, TGFβ receptors include TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII) or TGFβ receptor III (TGFβRIII).
[0162]
[0194] With respect to humans, the term "TGFβ receptor I" or "TGFβRI" refers to the human TGFβ receptor type 1 sequence, including wild-type TGFβRI and all isoforms and variants thereof known to be capable of binding at least one TGFβ isoform. An exemplary amino acid sequence of wild-type TGFβRI is available under GenBank accession number ABD46753.1 or UniProtKB-P36897, and is also included herein as SEQ ID NO: 69. A variant TGFβRI may have a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69 and retain at least 25%, 35%, 50%, 75%, 90%, 95%, or 99% of the TGFβ binding activity of the wild-type sequence (e.g., SEQ ID NO: 69).
[0163]
[0195] With respect to humans, the term "TGFβ receptor II" or "TGFβRII" refers to the human TGFβ receptor type 2 isoform A sequence, including wild-type TGFβRII and all isoforms and variants thereof known to be capable of binding at least one TGFβ isoform. An exemplary amino acid sequence of wild-type TGFβRII isoform A or isoform 1 is available under GenBank accession number NP_001020018.1 or UniProtKB-P37173-1 and is included herein as SEQ ID NO: 70, and wild-type TGFβRII isoform B is available under GenBank accession number NP_003233.4 or UniProtKB-P37173-2 and is included herein as SEQ ID NO: 71. The variant TGFβRII may have a sequence with at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 70 or 71 and retain at least 25%, 35%, 50%, 75%, 90%, 95% or 99% of the TGFβ binding activity of the wild-type sequence (e.g., SEQ ID NO: 70 or 71).
[0164]
[0196] With respect to humans, the term "TGFβ receptor III" or "TGFβRIII" refers to the human TGFβ receptor type 3 sequence, including wild-type TGFβRII and all isoforms and variants. An exemplary amino acid sequence of wild-type TGFβRIII is available under GenBank accession number NP_003234.2 or UniProtKB-Q03167, and is included herein as SEQ ID NO: 72.
[0165]
[0197] As used herein, with respect to a particular reference protein or peptide, the term "variant" refers to a modified version of the reference protein or peptide, e.g., a functional equivalent, fragment, fusion, derivative, mimetic, or any combination thereof, that has an amino acid sequence with at least 70% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity to the reference sequence and retains at least 25% (e.g., 35%, 50%, 75%, 90%, 95%, or 99%) of the biological or binding activity of the reference sequence (e.g., the wild-type sequence). A variant can be a fragment, mutant, fusion, truncation, or any combination thereof of the reference protein or peptide.
[0166]
[0198] As used herein, the term "interleukin-1" or "IL-1" includes IL-1α and IL-1β, their precursors (e.g., pro-IL-1α and pro-IL-1β), isoforms and variants.
[0167]
[0199] As used herein, the term "human IL-1α" refers to the IL-1α protein encoded by the human IL1A gene (e.g., wild-type human IL1A gene), as well as isoforms and variants. An exemplary wild-type human IL1α protein is provided by UniProtKB-P01583.
[0168]
[0200] As used herein, the term "human IL-1β" refers to the IL-1β protein encoded by the human IL1B gene (e.g., a wild-type human IL1B gene). An exemplary wild-type human IL1β protein is provided by GenBank Accession No. NP_000567.1 or under UniProtKB-C9JVK0.
[0169]
[0201] As used herein, the term "IL-1 receptor" or "IL-1R" refers to a receptor capable of binding to IL-1, including all wild-type receptors, isoforms, and variants thereof that can bind to IL-1. Generally, there are two types of IL-1 receptors: IL-1 receptor I (IL-1RI) and IL-1 receptor II (IL-1RII). IL-1RII acts as a decoy receptor that binds to ligands without transmitting signals. Proteolytic cleavage of IL-1RII results in the formation of soluble receptors, such as IL-1sRI and IL-1sRII, that bind to ligands without transmitting signals (see Thomas G. Kennedy, Chapter VB2., Encyclopedia of Hormones, 2003, for details). IL-1sRI and IL-1sRII are proteolytic cleavage products of IL-1RII and can be a group of extracellular domain fragments of IL-1RII. The term IL-1R is also intended to encompass the co-receptor IL-1RAP, which can associate with IL-1RI bound to IL-1β to form a high-affinity interleukin-1 receptor complex that mediates interleukin-1-dependent activation of NF-kappa-B and other pathways.
[0170]
[0202] As used herein, the term "IL-1RI" includes wild-type IL-1RI and all isoforms and variants thereof that are capable of binding to IL-1α and / or IL-1β. An exemplary amino acid sequence of wild-type IL-1RI is available under UniProtKB-P14778 and is included herein as SEQ ID NO: 73.
[0171]
[0203] As used herein, the term "IL-1RII" includes wild-type IL-1RII and all isoforms and variants thereof that are capable of binding to IL-1α and / or IL-1β. An exemplary amino acid sequence of wild-type IL-1RII is available under UniProtKB-P27930 and is included herein as SEQ ID NO: 75.
[0172]
[0204] As used herein, the term "IL-1RAP" includes wild-type IL-1RAP and all isoforms and variants thereof that are capable of binding to IL-1R bound to IL-1β. An exemplary amino acid sequence of wild-type IL-1RAP is available under UniProtKB-Q9NPH3 and is included herein as SEQ ID NO: 74.
[0173]
[0205] As used herein, the term "IL-1sRI" includes all soluble forms of IL-1RI that can be produced by proteolytic cleavage involving metalloproteinases. Naturally occurring IL-1sRI can have a molecular weight ranging from about 45 kDa to 60 kDa. The term also encompasses all isoforms and variants of IL-1sRI that are capable of binding to IL-1α and / or IL-1β.
[0174]
[0206] As used herein, the term "IL-1sRII" includes all soluble forms of IL-1RII that can be produced by proteolytic cleavage involving metalloproteinases. Naturally occurring IL-1sRII can have a molecular weight ranging from about 45 kDa to 60 kDa. The term can also encompass all isoforms and variants of IL-1sRII that are capable of binding to IL-1α and / or IL-1β.
[0175]
[0207] As used herein, the term "IL-1 receptor antagonist" generally includes any protein that can compete with IL-1α or IL-1β for binding to the IL-1 receptor and inhibit the activity of IL-1α or IL-1β. IL-1 receptor antagonists can include naturally occurring antagonists such as IL-1Ra, IL-1sRI, and IL-1sRII, as well as other artificial antagonists that can block the binding of IL-1α or IL-1β to the IL-1 receptor, particularly IL-1RI.
[0176]
[0208] As used herein, the term "IL-1Ra" includes wild-type IL-1Ra and all isoforms and variants thereof that are capable of binding to IL-1α and / or IL-1β. An exemplary amino acid sequence of wild-type IL-1Ra is available under UniProtKB-P18510 and is included herein as SEQ ID NO: 76.
[0177]
[0209] As used herein, "cancer" refers to any medical condition characterized by malignant cell proliferation or neoplasia, abnormal growth, invasion, or metastasis, and may be benign or malignant, and includes both solid tumors and non-solid cancers (e.g., hematological malignancies) such as leukemia. As used herein, "solid tumor" refers to a solid mass of neoplastic and / or malignant cells.
[0178]
[0210] The term "pharmaceutically acceptable" indicates that the specified carrier, vehicle, diluent, excipient(s) and / or salt is generally chemically and / or physically compatible with other ingredients included in the formulation and physiologically compatible with the recipient thereof.
[0179]
[0211] Reference herein to "about" a value or parameter includes (and describes) embodiments directed to that value or parameter per se. For example, a description referring to "about X" includes the description of "X." Numerical ranges are inclusive of the numbers defining the range. Generally speaking, the term "about" refers to the specified value of the variable, and all values of the variable within experimental error of the specified value (e.g., within a 95% confidence interval for the mean) or within 10 percent of the specified value, whichever is greater.
[0180]
[0212] The term "fusion" or "fused," when used in reference to amino acid sequences (e.g., peptides, polypeptides, or proteins), refers to the combination of two or more amino acid sequences into a single, non-naturally occurring amino acid sequence, for example, by chemical conjugation or recombinant means. A fused amino acid sequence can be produced by genetic recombination of two encoding polynucleotide sequences and expressed by introducing a construct containing the recombinant polynucleotide into a host cell.
[0181]
[0213] The term "pharmaceutically acceptable" indicates that the specified carrier, vehicle, diluent, excipient(s) and / or salt is generally chemically and / or physically compatible with other ingredients included in the formulation and physiologically compatible with the recipient thereof.
[0182] I. Bifunctional molecules that target immune checkpoint molecules and block IL-1 activity
[0214] The present disclosure provides bifunctional molecules comprising a first portion that binds to an immune checkpoint molecule and a second portion that blocks the activity of interleukin-1 (IL-1). The bifunctional molecules provided herein enable blocking and / or reducing IL-1 activity in the tumor microenvironment by blocking the interaction between IL-1 and the IL-1 receptor, comprising either an IL-1-binding portion or an IL-1 receptor (IL-1R)-binding portion (i.e., the second portion of the bifunctional molecule). The IL-1-binding portion and / or the IL-1R-binding portion can be linked to a portion (i.e., the first portion of the bifunctional molecule) that targets an immune checkpoint molecule that can be found on the surface of certain tumor cells or immune cells.
[0183]
[0215] IL-1 is a pro-inflammatory cytokine. Inflammation is a key component of the tumor microenvironment, and IL-1 plays a key role in carcinogenesis and tumor progression (A. Mantovani et al., Immunol Rev. 2018 Jan;281(1):57-61). IL-1 acts at multiple levels of tumor initiation and progression, including driving chronic, therapy-resistant inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSCs) and macrophage recruitment, invasion, and metastasis (ibid.).
[0184]
[0216] Immune checkpoint molecules are expressed on certain immune cells, such as T cells, natural killer cells, etc. Some cancer cells also express certain immune checkpoint molecules that can block the activation of immune checkpoints, thereby allowing the cancer cells to evade immune system surveillance.
[0185]
[0217] By reducing IL-1 in the tumor microenvironment and reducing checkpoint blockade, the present disclosure provides novel bifunctional molecules that may be useful for treating immune checkpoint-associated diseases such as cancer, autoimmune diseases, and infectious diseases.
[0186]
[0218] In certain embodiments, the first portion comprises an agonist of an immune checkpoint molecule having immunostimulatory or costimulatory activity, including, but not limited to, CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278) and ICOSLG (CD275), CD2, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, and CD83.
[0187]
[0219] In certain embodiments, the first portion comprises an inhibitor of a checkpoint molecule having immunoinhibitory or co-inhibitory activity, including, but not limited to, A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), SIGLEC9 (CD329), CD160, LAIR1, 2B4 (CD244), CD47, and B7-H5.
[0188]
[0220] In certain embodiments, the immune checkpoint molecule is PD-L1. In certain embodiments, the first portion comprises an antibody portion against PD-L1 or an antigen-binding fragment thereof. In certain embodiments, the first portion comprises an antagonist antibody portion against PD-L1 or an antigen-binding fragment thereof.
[0189]
[0221] In certain embodiments, the second moiety comprises an IL-1 binding moiety or an IL-1 receptor (IL-1R) binding moiety.
[0190]
[0222] Both IL-1α and IL-1β are proinflammatory and bind to IL-1R. Upon binding to IL-1α or IL-1β, IL-1R can recruit both IL-1R accessory proteins and the adaptor protein MyD88 to the receptor complex, resulting in the activation of downstream signaling cascades and ultimately the activation of a wide variety of immune and inflammatory genes. The present inventors have found that blocking the activity of IL-1 or its binding to IL-1R is useful in combination with modulation of immune checkpoint molecules.
[0191]
[0223] In certain embodiments, the IL-1 is IL-1α or IL-1β. In certain embodiments, the IL-1β is human IL-1β.
[0192]
[0224] In certain embodiments, the second portion comprises an IL-1-binding portion. In certain embodiments, the IL-1-binding portion specifically binds to IL-1α or IL-1β. In certain embodiments, the IL-1-binding portion comprises a soluble IL-1R, an IL-1-binding fragment or variant of IL-1R, or an antibody or antigen-binding fragment thereof to IL-1.
[0193]
[0225] The soluble IL-1R can be a domain or fragment of IL-1R, such as the extracellular domain (ECD) of IL-1R. Alternatively, the soluble IL-1R can be IL-1sRI or IL-1sRII, which are naturally soluble isoforms capable of binding IL-1.
[0194]
[0226] Those skilled in the art will understand that truncated fragments of IL-1RI, or the ECD of IL-1RI, or IL-1RII, or the ECD of IL-1RII, or IL-1RAP, or the ECD of IL-1RAP, or IL-1sRI or IL-1sRII may be sufficient to bind to IL-1 (e.g., IL-1α or IL-1β) so long as such fragments contain the IL-1-binding domain. Thus, the present disclosure also encompasses all IL-1-binding fragments or variants of IL-1RI, the ECD of IL-1RII, or the ECD of IL-1RII, or IL-1RAP, or the ECD of IL-1RAP, IL-1sRI and IL-1sRII. In certain embodiments, the IL-1-binding portion comprises the amino acid sequence of SEQ ID NO: 73, 74, or 75, or an IL-1-binding fragment or variant thereof. In certain embodiments, the IL-1 binding portion comprises an amino acid sequence having at least 80% sequence identity to any of SEQ ID NOs: 73, 74, and 75, or an IL-1 binding fragment or variant thereof.
[0195]
[0227] In certain embodiments, the IL-1 binding portion comprises an antibody or antigen-binding fragment thereof against IL-1. Antibodies or antigen-binding fragments thereof against IL-1 may also be used, so long as such antibodies or antigen-binding fragments are capable of interfering with the binding of IL-1 (e.g., IL-1α or IL-1β) to IL-1R.
[0196]
[0228] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region and / or a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102, and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab, and gevokizumab.
[0197]
[0229] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104 or SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 105 or SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 106 or SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107 or SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 108 or SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 109 or SEQ ID NO: 117.
[0198]
[0230] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104, an HCDR2 comprising the sequence of SEQ ID NO: 105, and an HCDR3 comprising the sequence of SEQ ID NO: 106, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107, an LCDR2 comprising the sequence of SEQ ID NO: 108, and an LCDR3 comprising the sequence of SEQ ID NO: 109.
[0199]
[0231] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 117.
[0200]
[0232] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102, SEQ ID NO: 110, and homologous sequences thereof having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103, SEQ ID NO: 111, and homologous sequences thereof having at least 80% sequence identity thereto.
[0201]
[0233] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto.
[0202]
[0234] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and homologous sequences thereof having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and homologous sequences thereof having at least 80% sequence identity thereto. In certain embodiments, the second portion comprises an IL-1R-binding portion.
[0203]
[0235] In certain embodiments, the IL-1R binding portion comprises IL-1Ra, or an IL-1R-binding fragment or variant thereof. IL-1Ra is an antagonist of IL-1R and can compete with IL-1α or IL-1β for binding to IL-1R. Similarly, one skilled in the art will understand that truncated fragments of IL-1Ra may be sufficient to be useful in binding to IL-1R and / or in competing with IL-1α or IL-1β. In certain embodiments, the IL-1R binding portion comprises a truncated form of IL-1Ra. In certain embodiments, the IL-1R binding portion comprises the amino acid sequence of SEQ ID NO: 67 or 76, or any IL-1-binding fragment or variant thereof. In certain embodiments, the IL-1R binding portion comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 67 or 76, or any IL-1-binding fragment or variant thereof. Those skilled in the art will understand that variants of wild-type IL-1Ra may also be useful in the present disclosure, so long as such variants are able to compete with IL-1α or IL-1β for binding to IL-1R.
[0204]
[0236] In certain embodiments, the IL-1R binding portion comprises an antibody to IL-1R or an antigen-binding fragment thereof. Antibodies to IL-1R or antigen-binding fragments thereof may also be used, so long as such antibodies or antigen-binding fragments are capable of competing with IL-1α or IL-1β for binding to IL-1R.
[0205]
[0237] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and / or a light chain variable region from an antibody selected from the group consisting of spesolimab, astegolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034, and CSC012.
[0206] II. Bifunctional molecules and second moieties targeting PD-L1
[0238] The therapeutic efficacy of PD-1 / PD-L1 axis checkpoint inhibitors (e.g., PD-L1 antibodies) may be limited when the tumor microenvironment ("TME") is rich in immunosuppressive cytokines. Such immunosuppressive cytokine signaling in the localized microenvironment may reduce tumor-infiltrating T cells and bias them toward Tregs, attenuating the activation of immune effector cells.
[0207]
[0239] In one aspect, the present disclosure provides novel bifunctional molecules comprising a first portion that binds to PD-L1 and a second portion that a) blocks the activity of an immunosuppressive cytokine or b) stimulates anti-tumor immunity. The molecule can be a compound, peptide, polypeptide, protein, or any combination thereof. The second portion can restore an immune response in the tumor microenvironment by either blocking immunosuppressive activity or cytokines, or by increasing or stimulating immunity.
[0208]
[0240] In certain embodiments, the bifunctional molecules provided herein comprise a first moiety that binds to PD-L1 (i.e., a PD-L1-binding moiety), and a second moiety that blocks the activity of an immunosuppressive cytokine.
[0209]
[0241] In certain embodiments, the immunosuppressive cytokines include cytokines in the transforming growth factor beta (TGF-β) superfamily, IL-1, or vascular endothelial growth factor (VEGF). In certain embodiments, the immunosuppressive cytokines in the TGF-β superfamily include bone morphogenetic proteins (BMPs), activins, NODAL, and growth differentiation factors (GDFs).
[0210]
[0242] In certain embodiments, the immunosuppressive cytokine is TGF-β. In certain embodiments, the immunosuppressive cytokine is IL-1.
[0211]
[0243] In certain embodiments, the second portion comprises a TGFβ-binding portion. In certain embodiments, the second portion comprises an IL-1-binding portion. As used herein, the terms "binding portion" and "binding fragment" refer to a portion or fragment capable of specifically binding to a target molecule or complex. The term "TGFβ-binding portion" refers to a portion capable of specifically binding to one or more family members or isoforms of the TGFβ family (e.g., TGFβ1, TGFβ2, or TGFβ3). Similarly, the term "IL-1-binding portion" refers to a portion capable of specifically binding to one or more family members of the IL-1 family (e.g., IL-1α, IL-1β).
[0212]
[0244] In certain embodiments, the bifunctional molecules provided herein comprise a first portion that binds to PD-L1 (i.e., a PD-L1-binding portion) and a second portion that stimulates anti-tumor immunity. In certain embodiments, the second portion comprises an immunostimulatory polypeptide, or a functional equivalent thereof, or a variant thereof. In certain embodiments, the immunostimulatory polypeptide is interleukin (IL)-2 (IL-2), IL-15, IL-21, IL-10, IL-12, IL-23, IL-27, IL-35, granulocyte-macrophage colony-stimulating factor (GM-CSF), soluble CD4, soluble LAG-3, or IFN-α, or a functional equivalent thereof.
[0213]
[0245] In certain embodiments, the second moiety comprises an antagonist of immunoinhibitory receptor signaling, hi certain embodiments, the immunoinhibitory receptor is SIRPα.
[0214]
[0246] In certain embodiments, the bifunctional molecule comprises one or more second parts.In certain embodiments, one or more of the second parts can be of the same type, for example, each of them can block the activity of immunosuppressive cytokines, or each of them can stimulate anti-tumor immunity.In certain embodiments, one or more of the second parts can be of different types.In certain embodiments, each of the second parts can have the same sequence, or can have differences in amino acid sequence.
[0215] i.TGFβ binding part
[0247] In certain embodiments, the TGFβ binding moiety comprises a soluble TGFβ receptor (TGFβR) or a TGFβ binding fragment or variant thereof, or an antibody to TGFβ and an antigen-binding fragment thereof.
[0216]
[0248] A "TGFβ binding moiety" may also be referred to in this disclosure as a "TGFβ Trap." Thus, a protein that targets both PD-L1 and TGFβ may also be referred to in this disclosure as an "anti-PD-L1 / TGFβ Trap."
[0217]
[0249] In certain embodiments, the TGFβ binding moiety binds to human and / or mouse TGFβ. In certain embodiments, the TGFβ binding moiety is capable of antagonizing and / or inhibiting the TGFβ signaling pathway. In certain embodiments, the TGFβ binding moiety is capable of antagonizing and / or inhibiting TGFβ.
[0218]
[0250] In the present disclosure, a TGFβ-binding moiety can include any moiety that specifically binds to one or more family members or isoforms of the TGFβ family. In certain embodiments, a TGFβ-binding moiety includes a moiety that binds to TGFβ1 (e.g., human TGFβ1), TGFβ2 (e.g., human TGFβ2), and / or TGFβ3 (e.g., human TGFβ3), or a variant thereof with similar or improved TGFβ-binding affinity. In certain embodiments, a TGFβ-binding moiety includes a moiety that binds to TGFβ1 (e.g., human TGFβ1). In certain embodiments, a TGFβ-binding moiety includes a moiety that binds to TGFβ2 (e.g., human TGFβ2). In certain embodiments, a TGFβ-binding moiety includes a moiety that binds to TGFβ3 (e.g., human TGFβ3). In certain embodiments, a TGFβ-binding moiety includes a moiety that specifically binds to both TGFβ1 (e.g., human TGFβ1) and TGFβ2 (e.g., human TGFβ2). In certain embodiments, a TGFβ-binding moiety comprises a moiety that specifically binds to both TGFβ1 (e.g., human TGFβ1) and TGFβ3 (e.g., human TGFβ3). In certain embodiments, a TGFβ-binding moiety comprises a moiety that specifically binds to both TGFβ2 (e.g., human TGFβ2) and TGFβ3 (e.g., human TGFβ3). In certain embodiments, a TGFβ-binding moiety comprises a moiety that specifically binds to each of TGFβ1 (e.g., human TGFβ1), TGFβ2 (e.g., human TGFβ2), and TGFβ3 (e.g., human TGFβ3). One skilled in the art will understand that a TGFβ-binding moiety that binds to one family member or isoform of the TGFβ family may be capable of binding with similar or higher affinity to one or more other family members or isoforms of the TGFβ family.
[0219]
[0251] In certain embodiments, the TGFβ binding moiety comprises a moiety that selectively binds to TGFβ1 over TGFβ2 and / or over TGFβ3.
[0220]
[0252] In certain embodiments, the TGFβ binding moiety comprises a moiety that specifically binds to human TGFβ1 and mouse TGFβ1 with similar affinity.
[0221]
[0253] In certain embodiments, a TGFβ-binding moiety of the present disclosure comprises a soluble TGFβ receptor (TGFβR) or a TGFβ-binding fragment or variant thereof.
[0222]
[0254] Exemplary TGFβ receptors include TGFβRI, TGFβRII and TGFβRIII. In certain embodiments, the TGFβ receptor is selected from the group consisting of TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), TGFβ receptor III (TGFβRIII) and any combination thereof. In certain embodiments, the TGFβ receptor is TGFβRI (e.g., human TGFβRI). In certain embodiments, the TGFβ receptor is TGFβRII (e.g., human TGFβRII). In certain embodiments, the TGFβ receptor is TGFβRIII (e.g., human TGFβRIII).
[0223]
[0255] In certain embodiments, the TGFβ-binding portion comprises the extracellular domain (ECD) of a TGFβ receptor (e.g., a human TGFβ receptor) or a TGFβ-binding fragment or variant thereof. In certain embodiments, the ECD of the TGFβ receptor comprises the ECD of TGFβRI (e.g., human TGFβRI), the ECD of TGFβRII (e.g., human TGFβRII), the ECD of TGFβRIII (e.g., human TGFβRIII), or any combination thereof. In certain embodiments, the ECD of TGFβRII comprises the amino acid sequence of SEQ ID NO: 66, 79, or an amino acid sequence having at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity thereto while still retaining binding specificity to TGFβ. In certain embodiments, the ECD of TGFβRI comprises the amino acid sequence of SEQ ID NO: 77, or an amino acid sequence having at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity thereto while still retaining binding specificity for TGFβ. In certain embodiments, the ECD of TGFβRIII comprises the amino acid sequence of SEQ ID NO: 78, or an amino acid sequence having at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity thereto while still retaining binding specificity for TGFβ.
[0224]
[0256] In certain embodiments, the TGFβ-binding moiety comprises an antibody against TGFβ and an antigen-binding fragment thereof. Exemplary anti-TGFβ antibodies include fresolimumab and meterimumab, as well as anti-TGFβ antibodies or antigen-binding fragments thereof described in, for example, US7494651B2, US8383780B2, US8012482B2, and WO2017141208A1, each of which is incorporated by reference in its entirety.
[0225]
[0257] In certain embodiments, the TGFβ binding portion comprises a combination of one or more ECDs of one or more TGFβ receptors, and / or one or more anti-TGFβ antibodies or antigen-binding fragments thereof.
[0226]
[0258] The one or more ECDs may be the same or different. For example, the TGFβ binding moiety may contain identical repeats of the ECD of a TGFβ receptor, or alternatively may contain a combination of different ECD sequences from the same TGFβ receptor, or alternatively may contain a combination of different ECDs from different TGFβ receptors. Similarly, the one or more anti-TGFβ antibodies may be the same or different.
[0227]
[0259] In certain embodiments, the TGFβ binding portion comprises a combination (or fusion) of ECDs selected from the group consisting of the ECD of TGFβRI (e.g., human TGFβRI), the ECD of TGFβRII (e.g., human TGFβRII), the ECD of TGFβRIII (e.g., human TGFβRIII), or any combination thereof.
[0228]
[0260] In certain embodiments, the TGFβ binding moiety comprises a combination (or fusion) of one or more anti-TGFβ antibodies or antigen-binding fragments thereof.
[0229]
[0261] In certain embodiments, the TGFβ binding portion comprises a combination (or fusion) of ECDs selected from the group consisting of the ECD of TGFβRI (e.g., human TGFβRI), the ECD of TGFβRII (e.g., human TGFβRII), the ECD of TGFβRIII (e.g., human TGFβRIII), one or more anti-TGFβ antibodies or antigen-binding fragments thereof, or any combination thereof.
[0230] ii.IL-binding portion
[0262] In certain embodiments, the second portion comprises an IL-1 binding portion. In certain embodiments, the IL-1 is IL-1α or IL-1β. In certain embodiments, the IL-1β is human IL-1β.
[0231]
[0263] In certain embodiments, the IL-1 binding moiety specifically binds to IL-1α or IL-1β. In certain embodiments, the IL-1 binding moiety comprises a moiety that selectively binds to IL-1β over IL-1α, or that selectively binds to IL-1α over IL-1β.
[0232]
[0264] In certain embodiments, the IL-1 binding moiety comprises a soluble IL-1R, an IL-1 binding fragment or variant of IL-1R, or an antibody to IL-1 or an antigen-binding fragment thereof.
[0233]
[0265] Soluble IL-1R may comprise a domain or fragment or variant of IL-1R, such as the extracellular domain (ECD) of IL-1R. Alternatively, soluble IL-1R may comprise IL-1sRI or IL-1sRII, which are naturally soluble isoforms capable of binding IL-1.
[0234]
[0266] Those skilled in the art will understand that a truncated fragment of IL-1R, or the ECD of IL-1R, or IL-1sRI or IL-1sRII may be sufficient to bind to IL-1 (e.g., IL-1α or IL-1β) so long as such fragment contains the IL-1-binding domain. Accordingly, the IL-1-binding moieties provided herein may also include an IL-1-binding fragment of any of IL-1R, the ECD of IL-1R, IL-1sRI, and IL-1sRII. In certain embodiments, the IL-1-binding moiety comprises the amino acid sequence of SEQ ID NO: 73, 74, or 75, or an IL-1-binding fragment or variant thereof. In certain embodiments, the IL-1-binding moiety comprises an amino acid sequence having at least 80% sequence identity to any of SEQ ID NOs: 73, 74, and 75, or an IL-1-binding fragment or variant thereof.
[0235]
[0267] In certain embodiments, the IL-1 binding portion comprises an antibody or antigen-binding fragment thereof against IL-1. Antibodies or antigen-binding fragments thereof against IL-1 may also be used, so long as such antibodies or antigen-binding fragments can interfere with the binding of IL-1 (e.g., IL-1α or IL-1β) to IL-1R.
[0236]
[0268] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region and / or a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102, and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab, and gevokizumab.
[0237]
[0269] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104 or SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 105 or SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 106 or SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107 or SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 108 or SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 109 or SEQ ID NO: 117.
[0238]
[0270] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104, an HCDR2 comprising the sequence of SEQ ID NO: 105, and an HCDR3 comprising the sequence of SEQ ID NO: 106, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107, an LCDR2 comprising the sequence of SEQ ID NO: 108, and an LCDR3 comprising the sequence of SEQ ID NO: 109.
[0239]
[0271] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 114, and / or a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 117.
[0240]
[0272] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102, SEQ ID NO: 110, and homologous sequences thereof having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103, SEQ ID NO: 111, and homologous sequences thereof having at least 80% sequence identity thereto.
[0241]
[0273] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto.
[0242]
[0274] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and its homologous sequences having at least 80% sequence identity thereto, and / or a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and its homologous sequences having at least 80% sequence identity thereto.
[0243]
[0275] In certain embodiments, the IL-1-binding moiety comprises a combination of one or more moieties selected from the group consisting of IL-1R, the ECD of IL-1R, IL-1sRI, IL-1sRII, an antibody to IL-1, an IL-1-binding fragment of any of these, and any combination thereof. Such one or more moieties may be linked by a direct bond or by a suitable linker.
[0244]
[0276] In certain embodiments, the IL-1R binding portion comprises IL-1Ra, or an IL-1R-binding fragment or variant thereof. IL-1Ra is an antagonist of IL-1R and can compete with IL-1α or IL-1β for binding to IL-1R. Similarly, one skilled in the art will understand that truncated fragments of IL-1Ra may be sufficient to be useful in binding to IL-1R and / or in competing with IL-1α or IL-1β. In certain embodiments, the IL-1R binding portion comprises a truncated form of IL-1Ra. In certain embodiments, the IL-1R binding portion comprises the amino acid sequence of SEQ ID NO: 67, or any IL-1-binding fragment or variant thereof. In certain embodiments, the IL-1R binding portion comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 67, or any IL-1-binding fragment or variant thereof. Those skilled in the art will understand that variants of wild-type IL-1Ra may also be useful in the present disclosure, so long as such variants are capable of competing with IL-1α or IL-1β for binding to IL-1R.
[0245]
[0277] In certain embodiments, the IL-1R binding portion comprises an antibody to IL-1R or an antigen-binding fragment thereof. Antibodies to IL-1R or antigen-binding fragments thereof may also be used, so long as such antibodies or antigen-binding fragments can compete with IL-1α or IL-1β for binding to IL-1R.
[0246]
[0278] In certain embodiments, the IL-1R binding moiety comprises a combination of one or more moieties selected from the group consisting of IL-1Ra, an antibody to IL-1R, any IL-1R binding fragment or variant thereof, and any combination thereof. Such one or more moieties may be linked by a direct bond or by a suitable linker.
[0247]
[0279] In certain embodiments, the antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and / or a light chain variable region from an antibody selected from the group consisting of spesolimab, astegolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034, and CSC012.
[0248] iii. Immunostimulatory polypeptides
[0280] In certain embodiments, the second portion comprises an immunostimulatory polypeptide, or a functional equivalent thereof, or a variant thereof, hi certain embodiments, the immunostimulatory polypeptide is soluble CD4, soluble LAG-3, or a functional equivalent thereof.
[0249]
[0281] In certain embodiments, the soluble LAG-3 comprises the extracellular domain (ECD) of LAG-3 or an MHC class II (MHCII)-binding fragment or variant thereof.
[0250]
[0282] LAG-3 (Uniprot number: Q61790) is a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily and containing 503 amino acids. Lag-3 contains an intracellular domain (ICD), a transmembrane domain (TMD), and an extracellular domain (ECD). The ECD contains four Ig-like domains, i.e., D1 to D4, where D1 contains nine β-strands, A, B, C, C', C'', D, E, F, and G. Between the C and C' strands, there is an additional sequence of approximately 30 amino acids that forms an "extra loop." Such an "extra loop" has been reported to be involved in the interaction between LAG-3 and MHC II. In certain embodiments, soluble LAG-3 contains the amino acid sequence of the extra loop, the D1 domain, the D1 plus D2 domain, or any MHC II-binding fragment or variant thereof. In certain embodiments, the soluble LAG-3 comprises the amino acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, or an MHC II-binding fragment or variant of any of these.
[0251]
[0283] LAG-3 is expressed in activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its primary ligand is MHC class II, which it binds to with higher affinity than CD4. A connecting peptide (CP) is present between the D4 and TMD of LAG-3, where cleavage occurs in the presence of metalloproteinases ADAM10 and / or ADAM17, producing cleaved soluble LAG-3. See, for example, Huard et al., Proc Natl Acad Sci USA 1997;94:5744-9; Workman et al., J Immunol 2002;169:5392-5. doi:10.4049 / jimmunol.169.10.5392; and Lawrence et al., J Immunother Cancer. 2015;3(Suppl 2):P216, which are incorporated herein by reference.
[0252]
[0284] LAG-3 also encodes an alternative splice variant that translates into a soluble form of LAG-3. Soluble LAG-3 activates antigen-presenting cells (APCs) through MHCII signaling, resulting in increased antigen-specific T cell responses in vivo. For example, soluble LAG-3 has been reported to activate dendritic cells (DCs) and participate in the pro-inflammatory activity of cytokine-activated (e.g., TNF-α and / or IL-12-activated) bystander T cells, and can directly activate DCs. See, for example, Triebel, Trends Immunol., 2003, 24:619-622, incorporated herein by reference.
[0253]
[0285] In certain embodiments, the soluble LAG-3 comprises eftiragimode alfa (IMP321) or an MHC II-binding fragment or variant thereof. IMP321 is a soluble, dimeric recombinant form of LAG-3. IMP321 induces a sustained immune response by stimulating dendritic cells through MHC II molecules. Combination therapy of MP321 with anti-PD-1 or anti-PD-L1 antibodies has been shown to synergistically activate T cells (particularly CD8+ T cells). See, e.g., Luc et al., Future Oncol Actions Search in PubMed Search in NLM Catalog Add to Search. 2019 Jun;15(17):1963-1973. doi:10.2217 / fon-2018-0807. Epub 2019 Apr 12.; Julio et al., Journal of Clinical Oncology, Volume 37, Issue 15; and US10874713B, which are incorporated herein by reference.
[0254] iv. Antagonists of immunoinhibitory receptor signaling
[0286] In certain embodiments, the second moiety comprises an antagonist of immunoinhibitory receptor signaling, hi certain embodiments, the immunoinhibitory receptor is SIRPα.
[0255]
[0287] As used herein, the term "SIRPα" is interchangeable with the term "signal-regulatory protein alpha" to refer to an inhibitory receptor expressed primarily on myeloid and dendritic cells. SIRPα belongs to the SIRP family, which also includes several other transmembrane glycoproteins, including SIRPβ and SIRPγ. Each member of the SIRP family contains three similar extracellular Ig-like domains, as well as distinct transmembrane and cytoplasmic domains.
[0256]
[0288] SIRPα can bind to CD47, delivering a "don't eat me" signal to inhibit phagocytosis, and blocking CD47-mediated engagement of SIRPα on phagocytes can result in the elimination of live cells carrying the "eat me" signal. CD47 is a widely expressed transmembrane glycoprotein with an extracellular N-terminal IgV domain, five transmembrane domains, and a short C-terminal intracellular tail. CD47 functions as a cellular ligand for SIRPα. Tumor cells often overexpress CD47 to avoid macrophage-mediated destruction. The interaction between CD47 and SIRPα has been shown to be involved in the regulation of macrophage-mediated phagocytosis (Takenaka et al., Nature Immunol., 8(12):1313-1323, 2007).
[0257]
[0289] In certain embodiments, the second moiety blocks the interaction between CD47 and SIRPα. In various preclinical models, treatments that block the interaction between CD47 and SIRPα stimulate cancer cell phagocytosis in vitro and anti-tumor immune responses in vivo.
[0258]
[0290] The second portion may comprise a CD47-binding domain or a SIRPα-binding domain. In certain embodiments, the immunoinhibitory receptor is signal-regulatory protein alpha (SIRPα). In certain embodiments, the second portion blocks the interaction between CD47 and SIRPα. In certain embodiments, the second portion comprises a CD47-binding domain or a SIRPα-binding domain. In certain embodiments, the CD47-binding domain comprises a soluble SIRPα or a CD47-binding fragment thereof, or an anti-CD47 antibody or an antigen-binding fragment thereof.
[0259]
[0291] In certain embodiments, the soluble SIRPα comprises the extracellular domain (ECD) of SIRPα or a CD47-binding fragment or variant thereof. In certain embodiments, the soluble SIRP comprises the amino acid sequence of SEQ ID NO: 84, or an amino acid sequence having at least 80% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity that still retains binding specificity for CD47. Optionally, the soluble SIRP is an engineered high-affinity SIRP variant that potently antagonizes CD47 on cancer cells but does not itself induce macrophage phagocytosis. In certain embodiments, the SIRP variant comprises one or more mutations selected from the group consisting of L4V, L4I, V6I, V6L, A21V, V27I, V27L, I31T, I31S, I31F, E47V, E47L, K53R, E54Q, H56P, H56R, V63I, S66T, S66G, K68R, V92I, F94L, F94V and F103V compared to SEQ ID NO: 98.In certain embodiments, the SIRPα variants are: 1) V27I, K53R, S66T, K68R, F103V; 2) L4V, V27L, E47V, K53R, E54Q, S66G, K68R, V92I; 3) L4V, V6I, A21V, V27I, I31T, E47L, K53R, H56P, S66T, K68R, F94 L;4)V6I, V27I, I31S, E47V, K53R, E54Q, H56P, S66G, V92I, F94L;5)L4I, A21V, V27I, I31F , E47V, K53R, E54Q, H56R, S66G, F94V, F103V;6)L4V, V6I, V27I, I31F, E47V, K53R, H56R, S6 6G, K68R, V92I, F94L; 7) L4V, V6L, I31F, E47V, K53R, H56P, S66G, V92I, F103V; 8) V6I, V27 I, I31F, E47L, K53R, E54Q, H56P, S66T;9)L4V, V6I, V27I, I31F, E47V, K53R, E54Q, H56P, V 63, S66T, K68R, V92I; 10) V6I, V27I, I31T, E47V, K53R, E54Q, H56P, S66G, K68R, V92I, F103V; and 11) V6I, V27I, I31F, E47V, K53R, E54Q, H56P, S66T, V92I. See, for example, Kipp Weiskopf et al., Science 341, 88 (2013), which is incorporated herein by reference.
[0260]
[0292] In certain embodiments, the SIRPα-binding domain comprises soluble CD47 or a SIRPα-binding fragment thereof, or an anti-SIRPα antibody or an antigen-binding fragment thereof. In certain embodiments, the soluble CD47 comprises the extracellular domain (ECD) of CD47 or a SIRPα-binding fragment thereof, an anti-SIRPα antibody or an antigen-binding fragment thereof.
[0261]
[0293] In certain embodiments, the CD47-binding domain comprises an anti-CD47 antibody and an antigen-binding fragment thereof. Exemplary anti-CD47 antibodies include, but are not limited to, humanized 5F9, B6H12, and ZF1 antibodies. See Lu et al., OncoTargets and Therapy, Volume 13, DOI https: / / doi.org / 10.2147 / OTT.S249822, incorporated herein by reference. In certain embodiments, the SIRPα-binding domain comprises an anti-SIRPα antibody or an antigen-binding fragment thereof. Exemplary anti-SIRPα antibodies include, but are not limited to, BI765064 and AL008. See, for example, WO2019073080A1, WO2019175218A1, and WO2018107058A1, incorporated herein by reference.
[0262]
[0294] In certain embodiments, the CD47 binding domain comprises a combination of one or more ECDs of one or more SIRPα, SIRPβ, or SIRPγ and / or one or more anti-CD47 antibodies or antigen-binding fragments thereof.
[0263]
[0295] One or more ECDs may be the same or different. For example, the CD47 binding domain may comprise the same repeat of the ECD of SIRPα, SIRPβ or SIRPγ, or alternatively, may comprise a combination of different ECD sequences from the same SIRPα, SIRPβ or SIRPγ, or alternatively, may comprise a combination of different ECDs from different SIRPα, SIRPβ or SIRPγ. Similarly, one or more anti-CD47 antibodies may be the same or different.
[0264]
[0296] In certain embodiments, the CD47 binding domain comprises a combination (or fusion) of ECDs selected from the group consisting of the ECD of SIRPα, the ECD of SIRPβ, the ECD of SIRPγ, or any combination thereof.
[0265]
[0297] In certain embodiments, the CD47 binding domain comprises a combination (or fusion) of one or more anti-CD47 antibodies or antigen-binding fragments thereof.
[0266]
[0298] In certain embodiments, the CD47 binding domain comprises a combination (or fusion) of an ECD selected from the group consisting of the ECD of SIRPα, the ECD of SIRPβ, the ECD of SIRPγ, one or more anti-CD47 antibodies or antigen-binding fragments thereof, or any combination thereof.
[0267] v.PD-L1 binding part
[0299] In certain embodiments, the bifunctional molecules provided herein comprise a first moiety that is a PD-L1 binding moiety.
[0268]
[0300] In certain embodiments, a PD-L1 binding moiety of the present disclosure binds to PD-L1 (e.g., human PD-L1 or cynomolgus PD-L1). In certain embodiments, a PD-L1 binding moiety of the present disclosure binds to human PD-L1. In certain embodiments, a PD-L1 binding moiety of the present disclosure binds to cynomolgus PD-L1.
[0269]
[0301] In certain embodiments, the PD-L1 binding moieties of the present disclosure comprise anti-PD-L1 antibody moieties. In certain embodiments, exemplary anti-PD-L1 antibodies are disclosed in the Anti-PD-L1 Antibodies section and Exemplary Anti-PD-L1 Antibodies section of this disclosure.
[0270]
[0302] In certain embodiments, the anti-PD-L1 antibody portion comprises one or more CDRs. In certain embodiments, the anti-PD-L1 antibody portion comprises one or more CDRs disclosed in the section on exemplary anti-PD-L1 antibodies of this disclosure. In certain embodiments, the anti-PD-L1 antibody portion comprises a heavy chain variable region (VH) and a light chain variable region (VL). In certain embodiments, the anti-PD-L1 antibody portion comprises the VH and VL of an anti-PD-L1 antibody disclosed in the section on exemplary anti-PD-L1 antibodies of this disclosure.
[0271]
[0303] In certain embodiments, the anti-PD-L1 antibody portion further comprises a heavy chain constant domain appended to the carboxyl terminus of the heavy chain variable region. In certain embodiments, the heavy chain constant region is derived from the group consisting of IgA, IgG, and IgM. In certain embodiments, the heavy chain constant region is derived from human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgM. In certain embodiments, the anti-PD-L1 antibody portion further comprises a light chain constant domain appended to the carboxyl terminus of the light chain variable region. In certain embodiments, the light chain constant region is derived from a kappa light chain or a lambda light chain. In certain embodiments, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 80 or 81. In certain embodiments, the light chain constant region comprises the amino acid sequence of SEQ ID NO: 82.
[0272] vi. The connection between the first part and the second part
[0304] In the present disclosure, the second moiety may be linked to any portion of the first moiety. For example, a second moiety, such as a TGFβ-binding moiety or an IL-1-binding moiety, may be linked to any suitable portion of the first moiety, such as a PD-L1-binding moiety (e.g., an anti-PD-L1 antibody moiety).
[0273]
[0305] In certain embodiments, the PD-L1 binding moiety comprises one or more polypeptide chains, such as an antibody heavy and light chain.
[0274]
[0306] In certain embodiments, the bifunctional molecule comprises one or more second moieties. In certain embodiments, at least one of the second moieties is linked to the amino terminus (N-terminus) or carboxyl (C-terminus) of the polypeptide chain of the first moiety. In certain embodiments, at least one of the second moieties is linked to the N-terminus or C-terminus of the heavy chain of the first moiety, or to the N-terminus or C-terminus of the light chain of the first moiety.
[0275]
[0307] In certain embodiments, at least one of the second portions is linked to the C-terminus of the heavy chain constant region of the first portion, and in certain embodiments, each of the second portions is linked to the C-terminus of each heavy chain constant region of the first portion.
[0276]
[0308] In certain embodiments, the bifunctional molecule comprises at least two second portions, each of which is linked to the C-terminus of each heavy chain of the first portion or the C-terminus of each light chain of the first portion. In certain embodiments, the bifunctional molecule comprises at least two second portions, each of which is linked to the N-terminus of each heavy chain of the first portion or the N-terminus of each light chain of the first portion.
[0277]
[0309] In certain embodiments, a bifunctional molecule comprises more than one second moiety linked to the N-terminus of the heavy chain of the first moiety, the C-terminus of the heavy chain of the first moiety, the N-terminus of the light chain of the first moiety, the C-terminus of the light chain of the first moiety, or any combination thereof. For example, a bifunctional molecule can comprise at least two second moieties, one of which is linked to the C-terminus of the heavy chain of the first moiety and the other of which is linked to the C-terminus of the light chain of the first moiety. For example, a bifunctional molecule can comprise at least two second moieties, one of which is linked to the N-terminus of the heavy chain of the first moiety and the other of which is linked to the N-terminus of the light chain of the first moiety.
[0278]
[0310] In certain embodiments, the one or more TGFβ-binding moieties, one or more IL-1-binding moieties, one or more immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4), or one or more CD47-binding moieties are linked to the anti-PD-L1 antibody moiety at one or more positions selected from the group consisting of: 1) the N-terminus of the heavy chain variable region, 2) the N-terminus of the light chain variable region, 3) the C-terminus of the heavy chain variable region; 4) the C-terminus of the light chain variable region; 5) the C-terminus of the heavy chain constant region; 6) the C-terminus of the light chain constant region, and 7) any combination thereof of the anti-PD-L1 antibody moiety.
[0279]
[0311] In certain embodiments, the bifunctional molecule comprises a homodimeric heavy chain. In certain embodiments, the bifunctional molecule comprises a heterodimeric heavy chain. The heavy chain is heterodimeric with respect to the presence or position of the second moiety. In certain embodiments, the heterodimeric heavy chain comprises one heavy chain having the second moiety and the other heavy chain not having it.
[0280] vii. Linker
[0312] The second moiety can be linked to the first moiety directly or via a linker. A direct linkage can be a chemical linkage (such as a covalent bond).
[0281]
[0313] In certain embodiments, the bifunctional molecule further comprises a linker connecting the first and second moieties. As used herein, the term "linker" can refer to any suitable bifunctional moiety that can react with at least two entities to be linked, thereby linking the entities to form one molecule, or maintaining the association of the entities in sufficiently close proximity. The linker can be incorporated into the resulting linked molecule or structure with or without its functional groups reacted.
[0282]
[0314] In certain embodiments, the linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.
[0283]
[0315] In certain embodiments, the linker comprises a peptide linker. The peptide linker may be made of amino acid residues linked together by peptide bonds. In certain embodiments, the peptide linker may further comprise one or more unnatural amino acids. In certain embodiments, the peptide linker comprises an amino acid sequence having at least 1, 2, 3, 4, 5, 8, 10, 15, 20, 30, 50 or more amino acid residues connected by peptide bonds, which can link two or more polypeptides. The peptide linker may or may not have a secondary structure.
[0284]
[0316] Any suitable peptide linker may be used. Numerous peptide linker sequences are known in the art; see, for example, Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993); Poljak et al., Structure 2:1121-1123 (1994). In certain embodiments, the peptide linker may comprise or consist of amino acid residues selected from the amino acids glycine, serine, alanine, methionine, asparagine, and glutamine. In some embodiments, the peptide linker may be made up predominantly of sterically unhindered amino acids, such as glycine and alanine. In some embodiments, the linker is polyglycine, polyalanine, a combination of glycine and alanine (e.g., poly(Gly-Ala)), or a combination of glycine and serine (e.g., poly(Gly-Ser)).
[0285]
[0317] In certain embodiments, the linker comprises an amino acid sequence of ((G)nS)m, where m and n are integers independently selected from 0 to 30, 1 to 29, 2 to 28, 3 to 27, 4 to 26, 5 to 25, 6 to 24, 7 to 23, 8 to 22, 9 to 21, 10 to 20, 11 to 19, 12 to 18, 13 to 17, 14 to 16, or 5. In certain embodiments, m is 4 and n is 4.
[0286]
[0318] In certain embodiments, the linker comprises the amino acid sequence of SEQ ID NO: 68. In certain embodiments, the linker comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 68.
[0287] viii. Anti-PD-L1 antibodies and antigen-binding fragments thereof
[0319] In certain embodiments, the PD-L1 binding portion of the bifunctional molecules provided herein comprises a portion that comprises an anti-PD-L1 antibody or antigen-binding fragment thereof. In certain embodiments, the anti-PD-L1 antibody and antigen-binding fragment thereof are capable of specifically binding to PD-L1.
[0288]
[0320] In certain embodiments, the anti-PD-L1 antibodies and antigen-binding fragments thereof provided herein have a K of 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, or 0.4 nM or less to human PD-L1 as measured by a Biacore assay. D Biacore assays are based on surface plasmon resonance technology, see e.g., Murphy, M. et al., Current protocols in protein science, Chapter 19, unit 19.14, 2006. In certain embodiments, K D The values are measured by the method described in Example 6 of this disclosure.
[0289]
[0321] The binding of the antibodies or antigen-binding fragments thereof provided herein to human PD-L1 can be measured using the "half-maximal effective concentration" (EC), which refers to the concentration of antibody at which 50% of its maximal binding is observed. 50 ) value. 50 The EC value can be measured by direct or indirect binding assays known in the art, such as enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS) assay, and other binding assays. In certain embodiments, the antibodies and antigen-binding fragments thereof provided herein have an EC value of 0.3 nM or less, 0.2 nM or less, 0.1 nM or less, or 0.09 nM or less as measured by ELISA. 50In certain embodiments, the antibodies or antigen-binding fragments thereof provided herein specifically bind to PD-L1 with an EC50 concentration of 1.4 nM or less, 1.3 nM or less, 1.2 nM or less, 1.1 nM or less, 1.0 nM or less, 0.3 nM or less, 0.25 nM or less, or 0.21 nM or less as measured by a FACS assay. 50 (i.e., 50% binding concentration) specifically binds to PD-L1.
[0290]
[0322] In some embodiments, the anti-PD-L1 antibodies or antigen-binding fragments provided herein specifically bind to PD-L1. In some embodiments, the anti-PD-L1 antibodies or antigen-binding fragments provided herein do not bind to other members of the B7 family.
[0291]
[0323] In certain embodiments, the anti-PD-L1 antibodies and antigen-binding fragments thereof provided herein are capable of blocking the interaction between PD-L1 and its binding partners (e.g., PD-1 and B7-1) with an IC50 of 2.2, 2.1, 2.0, 1.9, 1.8, or 1.2 μg / ml or less as measured by ELISA.
[0292]
[0324] In certain embodiments, the anti-PD-L1 antibodies and antigen-binding fragments thereof provided herein are capable of blocking the interaction between PD-L1 and its binding partner (e.g., PD-1) with an EC50 of 1.3, 1.2, 1.1, 1.0, 0.9, or 0.8 nM or less, as measured in a cell-based assay.
[0293] ix. Exemplary Anti-PD-L1 Antibodies and Antigen-Binding Fragments Thereof
[0325] In certain embodiments, the anti-PD-L1 antibodies (i.e., antibodies against PD-L1) and antigen-binding fragments thereof of the present disclosure comprise one or more (e.g., 1, 2, 3, 4, 5, or 6) CDRs comprising a sequence selected from the group consisting of DYYMN (SEQ ID NO: 1), DINPNNX1X2TX3YNHKFKG (SEQ ID NO: 19), WGDGPFAY (SEQ ID NO: 3), KASQNVX4X5X6VA (SEQ ID NO: 20), SX7SX8RYT (SEQ ID NO: 21), QQYSNYPT (SEQ ID NO: 6), where Xi is G or A, X2 is G or D or Q or E or L, X3 is S or M or Q or L or V, X4 is G or P or K, X5 is A or G, X6 is A or I, X7 is A or N or R or V, and X8 is N or H or V or D.
[0294]
[0326] In certain embodiments, the heavy chain variable region comprises: a) HCDR1 comprising the sequence SEQ ID NO: 1; b) an HCDR2 comprising a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 18, and c) an HCDR3 comprising the sequence of SEQ ID NO: 3; and / or The light chain variable region is d) LCDR1 comprising a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9; e) LCDR2 comprising a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12, and f) LCDR3 comprising the sequence of SEQ ID NO: 6 Includes:
[0295]
[0327] In certain embodiments, the heavy chain variable region comprises: g) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 2, and an HCDR3 comprising the sequence of SEQ ID NO: 3; h) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 13, and an HCDR3 comprising the sequence of SEQ ID NO: 3; i) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 14, and an HCDR3 comprising the sequence of SEQ ID NO: 3; j) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 15, and an HCDR3 comprising the sequence of SEQ ID NO: 3; and k) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 1, an HCDR2 comprising the sequence of SEQ ID NO: 17, and an HCDR3 comprising the sequence of SEQ ID NO: 3; and l) a heavy chain variable region comprising HCDR1 comprising the sequence of SEQ ID NO: 1, HCDR2 comprising the sequence of SEQ ID NO: 18, and HCDR3 comprising the sequence of SEQ ID NO: 3 is selected from the group consisting of:
[0296]
[0328] In certain embodiments, the light chain variable region comprises: a) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; b) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 9, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; c) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 8, an LCDR2 comprising the sequence of SEQ ID NO: 5, and an LCDR3 comprising the sequence of SEQ ID NO: 6; d) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 12, and an LCDR3 comprising the sequence of SEQ ID NO: 6; and e) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 4, an LCDR2 comprising the sequence of SEQ ID NO: 11, and an LCDR3 comprising the sequence of SEQ ID NO: 6. is selected from the group consisting of:
[0297]
[0329] As used herein, the antibody "4B6" refers to a monoclonal antibody comprising a heavy chain variable region having the sequence of SEQ ID NO:46 and a light chain variable region having the sequence of SEQ ID NO:47.
[0298]
[0330] In certain embodiments, the present disclosure provides anti-PD-L1 antibodies and antigen-binding fragments thereof that comprise one or more (e.g., one, two, three, four, five, or six) CDR sequences of antibody 4B6 or a variant of antibody 4B6, where the CDR boundaries are defined or identified according to the Kabat convention.
[0299]
[0331] In certain embodiments, the present disclosure provides anti-PD-L1 antibodies and antigen-binding fragments thereof comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HCDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 13, 14, 15, 17, and 18, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, and / or an LCDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 7, 8-9, an LCDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 10, 11-12, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
[0300]
[0332]
[0301] [Table 2]
[0302]
[0333]
[0303] [Table 3]
[0304]
[0334] CDRs are known to be involved in antigen binding. However, it has been found that not all six CDRs are essential or inalterable. In other words, one or more CDRs in the anti-PD-L1 antibody 4B6 can be replaced, altered, or modified while still substantially retaining the specific binding affinity to PD-L1.
[0305]
[0335] In certain embodiments, the antibodies and antigen-binding fragments thereof provided herein comprise suitable framework region (FR) sequences, so long as the antibodies and antigen-binding fragments thereof are capable of specifically binding to PD-L1. Although the CDR sequences provided in Table 1 above are derived from mouse antibodies, they can be grafted into any suitable FR sequences of any suitable species, such as mouse, human, rat, rabbit, among others, using suitable methods known in the art, such as recombinant techniques.
[0306]
[0336] In certain embodiments, the antibodies and antigen-binding fragments thereof provided herein are humanized. Humanized antibodies or antigen-binding fragments thereof are desirable for their reduced immunogenicity in humans. Humanized antibodies are chimeric in their variable regions because non-human CDR sequences are grafted onto human or substantially human FR sequences. Humanization of antibodies or antigen-binding fragments can essentially be carried out by substituting non-human (e.g., mouse) CDR genes for the corresponding human CDR genes in human immunoglobulin genes (see, for example, Jones et al., (1986) Nature 321:522-525; Riechmann et al., (1988) Nature 332:323-327; Verhoeyen et al., (1988) Science 239:1534-1536).
[0307]
[0337] Suitable human heavy and light chain variable domains can be selected to achieve this goal using methods known in the art. In an illustrative example, a "best-fit" approach can be used, in which a non-human (e.g., rodent) antibody variable domain sequence is screened or BLASTed against a database of known human variable domain sequences, and the human sequence that is closest to the non-human query sequence is identified and used as a human scaffold for grafting the non-human CDR sequences (see, e.g., Sims et al., (1993) J. Immunol. 151:2296; Chothia et al., (1987) J. Mot. Biol. 196:901). Alternatively, frameworks derived from the consensus sequence of all human antibodies can be used for grafting of non-human CDRs (see, e.g., Carter et al., (1992) Proc. Natl. Acad. Sci. USA, 89:4285; Presta et al., (1993) J. Immunol., 151:2623).
[0308]
[0338] In some embodiments, the present disclosure provides 12 humanized antibodies of 4B6, designated Hu4B6_Hg.2La.1, Hu4B6_Hg.2La.2, Hu4B6_Hg.2La.4, Hu4B6_Hg.2La.6, Hu4B6_Hg.3La.1, Hu4B6_Hg.3La.2, Hu4B6_Hg.3La.4, Hu4B6_Hg.3La.6, Hu4B6_Hg.5La.1, Hu4B6_Hg.5La.2, Hu4B6_Hg.5La.4, and Hu4B6_Hg.5La.6, respectively. The SEQ ID NOs for the heavy and light chain variable regions of each humanized 4B6 antibody are set forth in Table 5. The CDRs for each of the 12 humanized antibodies of 4B6 are set forth in Table 5 (underlined sequences). CDR boundaries were defined or identified according to the Kabat convention.
[0309]
[0339] Table 3a below shows the amino acid sequences of the variant CDRs for humanized 4B6, and Table 3b below shows the FRs for the humanized 4B6 heavy and light chain variable regions. Table 4 below shows the FR amino acid sequences for each heavy and light chain of the 12 humanized antibodies for chimeric antibody 4B6, which are designated Hu4B6_Hg.2La.1, Hu4B6_Hg.2La.2, Hu4B6_Hg.2La.4, Hu4B6_Hg.2La.6, Hu4B6_Hg.3La.1, Hu4B6_Hg.3La.2, Hu4B6_Hg.3La.4, Hu4B6_Hg.3La.6, Hu4B6_Hg.5La.1, Hu4B6_Hg.5La.2, Hu4B6_Hg.5La.4, and Hu4B6_Hg.5La.6, respectively. The heavy and light chain variable regions of these 12 humanized antibodies are shown in Table 5.
[0310]
[0340]
[0311] [Table 4]
[0312]
[0341]
[0313] [Table 5]
[0314]
[0342]
[0315] [Table 6]
[0316]
[0343] Table 5 below shows three variants of the humanized 4B6 heavy chain variable region (i.e., Hu4B6_Hg.2, Hu4B6_Hg.3 and Hu4B6_Hg.5) and four variants of the humanized 4B6 light chain variable region (i.e., AM4B6_La.1, AM4B6_La.2, AM4B6_La.4, AM4B6_La.6).
[0317] [Table 7-1]
[0318] [Table 7-2]
[0319]
[0344] In certain embodiments, the humanized anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are composed of substantially all human sequences except for the CDR sequences, which are non-human. In some embodiments, the variable region FRs and, if present, the constant region are derived completely or substantially from human immunoglobulin sequences. The human FR sequences and human constant region sequences may be derived from different human immunoglobulin genes, for example, the FR sequences from one human antibody and the constant region from another human antibody. In some embodiments, the humanized antibody or antigen-binding fragment thereof comprises human heavy chain HFR1-4 and / or light chain LFR1-4.
[0320]
[0345] In some embodiments, the human-derived FR region may contain the same amino acid sequence as the human immunoglobulin from which it is derived. In some embodiments, one or more amino acid residues in the human FR are replaced with the corresponding residues from the parent non-human antibody. This may be desirable in certain embodiments to create a humanized antibody or fragment thereof that closely resembles the non-human parent antibody structure, thereby optimizing binding characteristics (e.g., increasing binding affinity). In certain embodiments, the humanized antibody or antigen-binding fragment provided herein contains no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue substitutions in each of the human FR sequences, or no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue substitutions in all FR sequences of the heavy or light chain variable domain. In some embodiments, such amino acid residue changes may occur only in the heavy chain FR region, only in the light chain FR region, or in both chains. In certain embodiments, one or more amino acids in the human FR sequence are randomly mutated to increase binding affinity. In certain embodiments, one or more amino acids of the human FR sequence are backmutated to the corresponding amino acid(s) of the parent non-human antibody to increase binding affinity.
[0321]
[0346] In certain embodiments, the humanized anti-PD-L1 antibodies and antigen-binding fragments thereof of the present disclosure comprise a heavy chain HFR1 comprising the sequence of QVQLVQSGAEVKKPGASVKVSCKASGYX9FT (SEQ ID NO: 40), or a homologous sequence having at least 80% sequence identity thereto. 10 Heavy chain HFR2, RVTX comprising the sequence LEWMG (SEQ ID NO: 41) or a homologous sequence having at least 80% sequence identity thereto 16 TVDX 11 SISTAYMELSRLRSDDTAVYYCX 12 X 13(SEQ ID NO: 42) or a homologous sequence having at least 80% sequence identity thereto, and a heavy chain HFR4 having the sequence WGQGTLVTVSS (SEQ ID NO: 25) or a homologous sequence having at least 80% sequence identity thereto, wherein X9 is T or V; 10 is G or S, and X 11 is T or K, and X 12 is A or V, and X 13 is R or K.
[0322]
[0347] In certain embodiments, the humanized anti-PD-L1 antibodies and antigen-binding fragments thereof of the present disclosure comprise a light chain LFR1 comprising the sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 26), or a homologous sequence having at least 80% sequence identity thereto. 14 Light chain LFR2, GVPX comprising the sequence PKLLIY (SEQ ID NO: 43) or a homologous sequence having at least 80% sequence identity thereto 15 RFSGSGSGTDFTX 17 a light chain LFR3 comprising the sequence TISSLQPEDIATYYC (SEQ ID NO: 44) or a homologous sequence having at least 80% sequence identity thereto, and a light chain LFR4 comprising the sequence FGQGTKLEIK (SEQ ID NO: 29) or a homologous sequence having at least 80% sequence identity thereto, wherein X 14 is A or S, and X 15 is S or D, and X 16 is M or V, and X 17 is F or L.
[0323]
[0348] In certain embodiments, HFR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 22 and 30, HFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 23 and 31, HFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 24 and 32-35, HFR4 comprises the sequence of SEQ ID NO: 25, LFR1 comprises a sequence from the group consisting of SEQ ID NO: 26, LFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 27 and 36, LFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 28, and 37-38, 39, 45, and LFR4 comprises the sequence of SEQ ID NO: 29.
[0324]
[0349] In certain embodiments, the humanized anti-PD-L1 antibodies and antigen-binding fragments thereof of the present disclosure comprise the HFR1, HFR2, HFR3, and / or HFR4 sequences contained in a heavy chain variable region selected from the group consisting of Hu4B6_Hg.2 (SEQ ID NO: 58), AM4B6_Hg.3 (SEQ ID NO: 59), and AM4B6_Hg.5 (SEQ ID NO: 60).
[0325]
[0350] In certain embodiments, the humanized anti-PD-L1 antibodies and antigen-binding fragments thereof of the present disclosure comprise the LFR1, LFR2, LFR3, and / or LFR4 sequence contained in a light chain variable region selected from the group consisting of AM4B6_La.1 (SEQ ID NO: 62), AM4B6_La.2 (SEQ ID NO: 63), AM4B6_La.4 (SEQ ID NO: 64), and AM4B6_La.6 (SEQ ID NO: 65).
[0326]
[0351] In certain embodiments, the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, and homologous sequences thereof with at least 80% sequence identity thereto. In certain embodiments, the light chain variable region comprises a sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, and homologous sequences thereof with at least 80% sequence identity thereto. In certain embodiments, the antibody or antigen-binding fragment thereof against PD-L1 comprises a pair of heavy chain and light chain variable region sequences selected from the group consisting of SEQ ID NOs: 49 / 54, 50 / 54, 51 / 54, 52 / 54, 49 / 55, 50 / 55, 51 / 55, 52 / 55, 58 / 62, 58 / 63, 58 / 64, 58 / 65, 59 / 62, 59 / 63, 59 / 64, 59 / 65, 60 / 62, 60 / 63, 60 / 64, and 60 / 65.
[0327]
[0352] These exemplary humanized anti-PD-L1 antibodies retain specific binding ability or affinity to PD-L1, and in that aspect are better than the parent murine antibody 4B6.
[0328]
[0353] In some embodiments, the anti-PD-L1 antibodies or antigen-binding fragments provided herein comprise all or a portion of a heavy chain variable domain and / or all or a portion of a light chain variable domain. In one embodiment, the anti-PD-L1 antibodies or antigen-binding fragments provided herein are single-domain antibodies consisting of all or a portion of a heavy chain variable domain provided herein. Further information about such single-domain antibodies is available in the art (see, for example, U.S. Patent No. 6,248,516).
[0329]
[0354] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein further comprise an immunoglobulin (Ig) constant region, optionally comprising heavy and / or light chain constant regions. In certain embodiments, the heavy chain constant region comprises a CH1, hinge, and / or CH2-CH3 region (or optionally a CH2-CH3-CH4 region). In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein comprise a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgM. In certain embodiments, the light chain constant region comprises Cκ or Cλ. The constant regions of the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein may be identical to the wild-type constant region sequence, or may differ in one or more mutations.
[0330]
[0355] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein have specific binding affinity for human PD-L1 that is sufficient to provide diagnostic and / or therapeutic uses.
[0331]
[0356] The anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein can be monoclonal, polyclonal, humanized, chimeric, recombinant, bispecific, multispecific, labeled, bivalent, anti-idiotypic, or fusion proteins. Recombinant antibodies are antibodies prepared in vitro using recombinant methods rather than in an animal.
[0332]
[0357] In certain embodiments, the PD-L1 binding portion comprises an anti-PD-L1 antibody or antigen-binding fragment thereof that competes for binding to PD-L1 with an antibody or antigen-binding fragment thereof comprising a pair of heavy chain and light chain variable region sequences selected from the group consisting of SEQ ID NOs: 49 / 54, 50 / 54, 51 / 54, 52 / 54, 49 / 55, 50 / 55, 51 / 55, 52 / 55, 58 / 62, 58 / 63, 58 / 64, 58 / 65, 59 / 62, 59 / 63, 59 / 64, 59 / 65, 60 / 62, 60 / 63, 60 / 64 and 60 / 65.
[0333] x. Antibody variants
[0358] The anti-PD-L1 antibodies and antigen-binding fragments thereof provided herein also encompass various variants of the antibody sequences provided herein.
[0334]
[0359] In certain embodiments, antibody variants comprise one or more modifications or substitutions in one or more of the CDR sequences provided in Table 1 above, in one or more non-CDR sequences of the heavy chain variable region or light chain variable region provided in Tables 3a, 3b, and 5 above, and / or in the constant region (e.g., Fc region). Such variants retain the binding specificity of their parent antibodies to PD-L1 but have one or more desirable properties conferred by the modification(s) or substitution(s). For example, antibody variants may have improved antigen-binding affinity, improved glycosylation patterns, reduced risk of glycosylation, reduced deamination, reduced or eliminated effector function(s), improved FcRn receptor binding, increased pharmacokinetic half-life, pH sensitivity, and / or suitability for conjugation (e.g., introduction of one or more cysteine residues).
[0335]
[0360] The parent antibody sequence can be screened to identify suitable or preferred residues for modification or substitution using methods known in the art, such as "alanine scanning mutagenesis" (see, e.g., Cunningham and Wells (1989) Science, 244:1081-1085). Briefly, target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) can be identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine), and the modified antibodies can be produced and screened for desired properties. If substitution at a particular amino acid position demonstrates the desired functional change, then the position can be identified as a promising residue for modification or substitution. Promising residues can be further evaluated by substituting them with different types of residues (e.g., cysteine residues, positively charged residues, etc.).
[0336] xi. Affinity variants
[0361] Affinity variants of antibodies may contain modifications or substitutions in one or more CDR sequences provided in Table 1 above, in one or more FR sequences provided in Tables 3b and 4 above, or in the heavy or light chain variable region sequences provided in Table 5 above. FR sequences can be easily identified by one of ordinary skill in the art based on the CDR sequences in Table 1 above and the variable region sequences in Table 5 above, since it is well known in the art that a CDR region is flanked by two FR regions in a variable region. Affinity variants retain the specific binding affinity to PD-L1 of the parent antibody, or even have improved specific binding affinity to PD-L1 over the parent antibody. In certain embodiments, at least one (or all) substitution(s) in the CDR sequences, FR sequences, or variable region sequences comprise conservative substitutions.
[0337]
[0362] Those skilled in the art will understand that in the CDR sequences provided in Tables 1 and 3a above and the variable region sequences provided in Table 5 above, one or more amino acid residues can be substituted such that the resulting antibody or antigen-binding fragment still retains its binding affinity or ability to PD-L1, or has even improved binding affinity or ability. Various methods known in the art can be used to achieve this goal. For example, a library of antibody variants (such as Fab or scFv variants) can be generated and expressed using phage display technology, and then screened for binding affinity to PD-L1. As another example, computer software can be used to substantially simulate the binding of an antibody to PD-L1 and identify amino acid residues on the antibody that form the binding interface. Such residues can either be avoided for substitution to prevent a loss of binding affinity, or targeted for substitution to provide stronger binding.
[0338]
[0363] In certain embodiments, the humanized anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein comprise one or more amino acid residue substitutions in one or more CDR sequences and / or one or more FR sequences. In certain embodiments, the affinity variants comprise no more than a total of 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substitutions in the CDR and / or FR sequences.
[0339]
[0364] In certain embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises one, two, or three CDR sequences that have at least 80% (e.g., at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity to those(s) listed in Tables 1 and 3a above, while still retaining a level of specific binding affinity to PD-L1 that is similar to, or even greater than, that of its parent antibody.
[0340]
[0365] In certain embodiments, an anti-PD-L1 antibody or antigen-binding fragment thereof comprises one or more variable region sequences with at least 80% (e.g., at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity to one or more of the sequences listed in Table 5 above that still retain a similar or even higher level of specific binding affinity to PD-L1 than its parent antibody. In some embodiments, a total of 1 to 10 amino acids have been substituted, inserted, or deleted from the variable region sequences listed in Table 5 above. In some embodiments, the substitutions, insertions, or deletions occur in regions outside of the CDRs (e.g., in the FRs).
[0341] xii. Glycosylation variants
[0366] The anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein also encompass glycosylation variants, which may be obtained to either increase or decrease the extent of glycosylation of the antibody or binding fragment thereof.
[0342]
[0367] Anti-PD-L1 antibodies or antigen-binding fragments thereof may contain one or more modifications that introduce or remove glycosylation sites. A glycosylation site is an amino acid residue having a side chain to which a carbohydrate moiety (e.g., an oligosaccharide structure) can be attached. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue in a tripeptide sequence, such as asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline. O-linked glycosylation refers to the attachment of the sugar N-acetylgalactosamine, galactose, or xylose to one hydroxyamino acid, most commonly serine or threonine. Removal of a native glycosylation site can be conveniently achieved, for example, by altering the amino acid sequence so that one of the above-described tripeptide sequences (for N-linked glycosylation sites) or serine or threonine residues (for O-linked glycosylation sites) present in the sequence is substituted. New glycosylation sites can be created in a similar manner by introducing such tripeptide sequences or serine or threonine residues.
[0343]
[0368] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments provided herein contain one or more mutations that remove one or more deamidation sites. In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments provided herein contain a mutation at G55 in the heavy chain (e.g., G55A). These mutations have been tested and are not believed to adversely affect the binding affinity of the antibodies provided herein.
[0344] xiii. Cysteine engineered variants
[0369] The anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein also include cysteine engineered variants, which contain one or more introduced free cysteine amino acid residues.
[0345]
[0370] A free cysteine residue is one that is not part of a disulfide bond. Cysteine-engineered variants are useful, for example, for conjugation with cytotoxic and / or imaging compounds, labels, or radioisotopes, etc., at the engineered cysteine site, for example, via maleimide or haloacetyl. Methods for engineering antibodies or antigen-binding fragments thereof to introduce free cysteine residues are known in the art, see, for example, WO2006 / 034488.
[0346] xiv.Fc variants
[0371] The anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein also include Fc variants that contain one or more amino acid residue modifications or substitutions in the Fc region and / or hinge region to provide altered effector function, e.g., ADCC and CDC. Methods for altering ADCC activity by engineering antibodies have been described in the art, e.g., Shields RL, et al., J Biol Chem. 2001, 276(9):6591-604; Idusogie EE, et al., J Immunol. 2000, 164(8):4178-84; Steurer W, et al., J Immunol. 1995, 155(3):1165-74; Idusogie EE, et al., J Immunol. 2001, 166(4):2571-5; Lazar GA, et al., PNAS, 2006, 103(11):4005-4010; Ryan MC, et al., Mol. Cancer Ther. 2007, 6:3009-3018; Richards JO, et al., Mol. Cancer Ther. 2008, 7(8):2517-27; Shields See RL et al., J. Biol. Chem, 2002, 277:26733-26740; Shinkawa T. et al., J. Biol. Chem, 2003, 278:3466-3473.
[0347]
[0372] The CDC activity of the antibodies or antigen-binding fragments provided herein can be altered, for example, by improving or attenuating C1q binding and / or CDC (see, e.g., WO 99 / 51642; Duncan & Winter Nature 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821); and WO 94 / 29351 for other examples of Fc region variants. One or more amino acids selected from amino acid residues 329, 331, and 322 of the Fc region can be replaced with a different amino acid residue to alter C1q binding and / or reduce or eliminate complement-dependent cytotoxicity (CDC) (see U.S. Pat. No. 6,194,551 by Idusogie et al.). One or more amino acid substitution(s) can also be introduced to alter the antibody's ability to fix complement (see PCT Publication WO 94 / 29351 by Bodmer et al.).
[0348]
[0373] In certain embodiments, the Fc variants provided herein have reduced effector function compared to a wild-type Fc (e.g., an IgG1 Fc) and comprise one or more amino acid substitution(s) at a position selected from the group consisting of 220, 226, 228, 229, 233, 234, 235, 236, 237, 238, 267, 268, 269, 270, 297, 309, 318, 320, 322, 325, 328, 329, 330, 331, and 332 in the Fc region (WO 2016 / 196228; Richards et al. (2008) Mol. Cancer Therap. 7:2517; Moore et al. (2010) mAbs 2:181; and Strohl (2009) Current Opinion in Biotechnology 20:685-691), where the numbering of residues in the Fc region is that of the EU index as in Kabat. Exemplary substitutions for reduced effector function include, without limitation, 220S, 226S, 228P, 229S, 233P, 234V, 234G, 234A, 234F, 234A, 235A, 235G, 235E, 236E, 236R, 237A, 237K, 238S, 267R, 268A, 268Q, 269R, 297A, 297Q, 297G, 309L, 318A, 322A, 325L, 328R, 330S, 331S, or any combination thereof (see WO2016 / 196228; and Strohl (2009) Current Opinion in Biotechnology 20:685-691).
[0349]
[0374] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein have reduced effector function and comprise one or more amino acid substitution(s) in IgG1 at positions selected from the group consisting of 234, 235, 237, 238, 268, 297, 309, 330, and 331. In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG1 isotype and comprise one or more amino acid substitution(s) selected from the group consisting of N297A, N297Q, N297G, L235E, L234A, L235A, L234F, L235E, P331S, and any combination thereof.
[0350]
[0375] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG1 isotype and comprise L234A and L235A mutations. In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG1 isotype and comprise L234F, L235E, and P331S mutations. The set of substitutions L234F, L235E, and P331S (also referred to as the FES triple mutation), located in the CH2 region of the Fc domain, abrogates FcγR and C1q binding, resulting in an antibody unable to induce ADCC or CDC (Oganesyan et al., Acta Crystallogr. D 64:700-704 (2008)). PCT / US2013 / 36872 showed that combining these mutations in a variant Fc domain, e.g., an antibody variant Fc domain, results in an Fc domain with reduced thermal stability compared to the wild-type parent molecule, e.g., a wild-type IgG1 Fc. In certain embodiments, the Fc variant comprises the amino acid sequence of SEQ ID NO:81.
[0351]
[0376] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG2 isotype and contain one or more amino acid substitution(s) selected from the group consisting of H268Q, V309L, A330S, P331S, V234A, G237A, P238S, H268A, and any combination thereof (e.g., H268Q / V309L / A330S / P331S, V234A / G237A / P238S / H268A / V309L / A330S / P331S). In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG4 isotype and contain one or more amino acid substitution(s) selected from the group consisting of S228P, N297A, N297Q, N297G, L235E, F234A, L235A, and any combination thereof. In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are of the IgG2 / IgG4 cross-isotype. Examples of IgG2 / IgG4 cross-isotypes are described in Rother RP et al., Nat Biotechnol 25:1256-1264 (2007).
[0352]
[0377] In certain embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof contains one or more amino acid substitution(s) that improve pH-dependent binding to neonatal Fc receptor (FcRn). Such variants may have an extended pharmacokinetic half-life because they bind to FcRn at acidic pH, which allows them to escape lysosomal degradation and then be translocated and released extracellularly. Methods for engineering antibodies or antigen-binding fragments thereof to improve binding affinity to FcRn are well known in the art, see, for example, Vaughn, D. et al., Structure, 6(1):63-73, 1998; Kontermann, R. et al., Antibody Engineering, Volume 1, Chapter 27: Engineering of the Fc region for improved PK, published by Springer, 2010; Yeung, Y. et al., Cancer Research, 70:3269-3277 (2010); and Hinton, P. et al., J. Immunology, 176:346-356 (2006).
[0353]
[0378] In certain embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises one or more amino acid substitution(s) at the interface of the Fc region to facilitate and / or promote heterodimerization. These modifications include the introduction of a protuberance in the first Fc polypeptide and a cavity in the second Fc polypeptide, where the protuberance may be positioned within the cavity to promote interaction of the first and second Fc polypeptides to form a heterodimer or complex. Methods for generating antibodies with these modifications are known in the art, for example, as described in U.S. Patent No. 5,731,168.
[0354] xv. Antigen-binding fragment
[0379] The PD-L1-binding moieties in the bifunctional molecules provided herein also encompass anti-PD-L1 antigen-binding fragments. Various types of antigen-binding fragments are known in the art and can be developed based on the anti-PD-L1 antibodies provided herein, including, for example, the exemplary antibodies whose CDRs are set forth above in Tables 1 and 3a and whose variable sequences are set forth in Tables 2 and 5, and their various variants (e.g., affinity variants, glycosylation variants, Fc variants, cysteine engineered variants, etc.).
[0355]
[0380] In certain embodiments, the anti-PD-L1 antigen-binding fragments provided herein are diabodies, Fab, Fab', F(ab')2, Fd, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (ds diabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), multispecific antibodies, camelized single-domain antibodies, nanobodies, domain antibodies, and bivalent domain antibodies.
[0356]
[0381] Various techniques can be used to produce such antigen-binding fragments. Exemplary methods include enzymatic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science 229:81 (1985)), recombinant expression in host cells such as E. coli (e.g., for Fab, Fv, and ScFv antibody fragments), screening from the phage display library discussed above (e.g., for ScFv), and chemical coupling of two Fab'-SH fragments to form an F(ab')2 fragment (Carter et al., Bio / Technology 10:163-167 (1992)). Other techniques for producing antibody fragments will be apparent to those skilled in the art.
[0357]
[0382] In certain embodiments, the antigen-binding fragment is an scFv. The production of scFv is described, for example, in WO93 / 16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. The scFv can be fused to an effector protein at either the amino or carboxyl terminus to provide a fusion protein (see, for example, Antibody Engineering, edited by Borrebaeck).
[0358]
[0383] In certain embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein are bivalent, tetravalent, hexavalent, or multivalent. Any molecule with more than two valencies is considered multivalent, including, for example, trivalent, tetravalent, hexavalent, etc.
[0359]
[0384] A bivalent molecule can be monospecific if the two binding sites are both specific for binding to the same antigen or epitope. In certain embodiments, this provides stronger binding to the antigen or epitope than its monovalent counterpart. Similarly, a multivalent molecule can also be monospecific. In certain embodiments, in a bivalent or multivalent antigen-binding moiety, the first valence of the binding site and the second valence of the binding site are structurally identical (i.e., have the same sequence) or structurally different (i.e., have the same specificity but different sequences).
[0360]
[0385] Bivalent molecules can also be bispecific when the two binding sites are specific for different antigens or epitopes. This also applies to multivalent molecules. For example, a trivalent molecule can be bispecific when two binding sites are monospecific for a first antigen (or epitope) and the third binding site is specific for a second antigen (or epitope).
[0361] xvi. Bispecific antibodies
[0386] In certain embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is bispecific. In certain embodiments, apart from the second moiety provided herein, the PD-L1-binding antibody or antigen-binding fragment thereof is further linked to an additional functional domain with a different binding specificity from the anti-PD-L1 antibody or antigen-binding fragment thereof.
[0362]
[0387] In certain embodiments, the bispecific antibodies or antigen-binding fragments thereof provided herein are capable of specifically binding to a second antigen other than PD-L1 (and other than the target bound by the second moiety) or a second epitope on PD-L1 (or a second epitope on the target bound by the second moiety).
[0363] xvii. Bifunctional molecules
[0388] In certain embodiments, the bifunctional molecules provided herein are capable of binding to both PD-L1 and a target bound by a second moiety. In certain embodiments, the bifunctional molecules provided herein are capable of binding to both PD-L1 and TGFβ, or to both PD-L1 and IL-1, or to both PD-L1 and IL-1R, or to both PD-L1 and MHCII, or to both PD-L1 and CD47, or to both PD-L1 and SIRPα.
[0364]
[0389] In certain embodiments, bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure have an EC of 2.0 nM or less (e.g., 2.0 nM or less, 1.2 nM or less, 1.1 nM or less, 1.0 nM or less, 0.9 nM or less, 0.8 nM or less) as measured by ELISA assay. 50specifically binds to human TGFβ1 with a K of 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, or 0.4 nM or less, as measured by a Biacore assay. In certain embodiments, proteins targeting PD-L1 and TGFβ of the present disclosure are capable of simultaneously binding to PD-L1 and TGFβ as measured by an ELISA assay. In certain embodiments, bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure have a K of 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, or 0.4 nM or less, as measured by a Biacore assay. D In certain embodiments, bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure are capable of specifically binding to human PD-L1 with a K of 2.0 nM or less (e.g., 2.0 nM or less, 1.2 nM or less, 1.1 nM or less, 1.0 nM or less, 0.9 nM or less, 0.8 nM or less) as measured by an ELISA assay. D It is capable of specifically binding to human TGFβ1 at low levels.
[0365]
[0390] In certain embodiments, the bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure can exhibit synergistic effects on tumor growth inhibition in a dose-dependent manner.
[0366]
[0391] In certain embodiments, bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure can exhibit enhanced infiltration of anti-tumor immune cells into the tumor microenvironment compared to molecules comprising only immune checkpoint molecules.
[0367]
[0392] In certain embodiments, the bifunctional molecules targeting PD-L1 and TGFβ of the present disclosure are capable of selectively reducing TGFβ1 in plasma by at least 90% (e.g., at least 80%, 70%, 60%, 50%, 40%, 30%, or 20%), and such reduction may be maintained for at least 10, 14, or 21 days.
[0368]
[0393] In certain embodiments, the bifunctional molecule comprises a heterodimeric heavy chain. The heavy chain is heterodimeric with respect to the presence or position of the second moiety. In certain embodiments, the heterodimeric heavy chain comprises one heavy chain with a second moiety and the other heavy chain without, wherein the second moiety comprises a CD47-binding domain (e.g., soluble SIRPα) or a SIRPα-binding domain.
[0369]
[0394] In a bifunctional molecule, the heterodimeric heavy chain comprises one heavy chain with a second moiety and the other without. The heterodimeric heavy chain may further comprise a heterodimeric Fc region associated to prevent homodimerization and / or support heterodimerization. For example, the heterodimeric Fc regions may be selected so that they are not identical and preferentially form heterodimers with each other rather than homodimerize among themselves. In certain embodiments, the heterodimeric Fc regions are capable of associating into heterodimers through knob-into-hole formation, hydrophobic interactions, electrostatic interactions, hydrophilic interactions, or increased mobility. In certain embodiments, the heterodimeric Fc regions comprise CH2 and / or CH3 domains, each of which has been mutated to form knob-into-holes. The knob can be obtained by replacing a small amino acid residue in the first CH2 / CH3 polypeptide with a larger one, and the hole can be obtained by replacing a large residue with a small one. In certain embodiments, the heterodimeric Fc region comprises a first CH3 domain of an IgG1 isotype containing S354C and T366W substitutions (SEQ ID NO: 96, Knob) and a second CH3 domain of an IgG1 isotype containing Y349C, T366S, L368A and Y407V substitutions (SEQ ID NO: 97, Hole).
[0370]
[0395] In certain embodiments, the bifunctional molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:118 or SEQ ID NO:120, and / or a light chain comprising the amino acid sequence of SEQ ID NO:119 or SEQ ID NO:121.
[0371] xviii. Conjugates
[0396] In some embodiments, the bifunctional molecule further comprises one or more conjugate moieties. The conjugate moiety can be linked to the bifunctional molecule. The conjugate moiety is a moiety that can be bound to the bifunctional molecule. It has been discussed that various conjugate moieties can be linked to the bifunctional molecules provided herein (see, for example, "Conjugate Vaccines," Contributions to Microbiology and Immunology, JM Cruse and RE Lewis, Jr. (eds.), Carger Press, New York, (1989)). These conjugate moieties can be linked to the bifunctional molecule by, among other methods, covalent bonding, affinity bonding, intercalation, coordinate bonding, complexation, association, mixing, or addition. In some embodiments, the bifunctional molecule can be linked to one or more conjugates via a linker.
[0372]
[0397] In certain embodiments, the bifunctional molecules provided herein can be engineered to contain, in addition to the epitope-binding moiety, specific sites that can be utilized for binding to one or more conjugate moieties. For example, such sites can include one or more reactive amino acid residues, such as cysteine or histidine residues, to facilitate covalent binding to a conjugate moiety.
[0373]
[0398] In certain embodiments, bifunctional molecules can be indirectly linked to conjugate moiety or through another conjugate moiety.For example, the bifunctional molecules provided herein can be conjugated to biotin, and then be indirectly conjugated to the second conjugate that is conjugated to avidin.In some embodiments, conjugate moiety comprises clearance modifier (for example, polymer such as PEG that extends half-life), chemotherapeutic agent, toxin, radioisotope, lanthanide, detectable label (for example, luminescent label, fluorescent label, enzyme substrate label), DNA alkylating agent, topoisomerase inhibitor, tubulin binding agent, moiety for purification or other anti-cancer drug.
[0374]
[0399] A "toxin" can be any agent that is harmful to cells or can damage or kill cells. Examples of toxins include, but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, MMAE, MMAF, DM1, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin and its analogs, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil), and the like. chlorambucil), melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamineplatinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), mitotic inhibitors (e.g., vincristine and vinblastine), topoisomerase inhibitors, and tubulin-binding agents.
[0375]
[0400] Examples of detectable labels include fluorescent labels (e.g., fluorescein, rhodamine, dansyl, phycoerythrin, or Texas Red), enzyme substrate labels (e.g., horseradish peroxidase, alkaline phosphatase, luciferase, glucoamylase, lysozyme, glycoxidase, or β-D-galactosidase), radioisotopes (e.g., 123I, 124I, 125I, 131I, 35S, 3H, 111In, 112In, 14C, 64Cu, 67Cu, 86Y, 88Y, 90Y, 177Lu, 211At, 186Re, 188Re, 153Sm, 212Bi, and 32P, other lanthanides), luminescent labels, chromogenic moieties, digoxigenin, biotin / avidin, detectable DNA molecules, or gold.
[0376]
[0401] In certain embodiments, the conjugate moiety may be a clearance-modifying agent that helps increase the half-life of the bifunctional molecule. Illustrative examples include water-soluble polymers such as PEG, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, ethylene glycol / propylene glycol copolymers, and the like. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules.
[0377]
[0402] In certain embodiments, the conjugate moiety may be a moiety for purification, such as a magnetic bead.
[0378]
[0403] In certain embodiments, the bifunctional molecules provided herein are used as the basis for conjugates.
[0379] III. Polynucleotides and Recombinant Methods
[0404] The present disclosure provides the isolated polynucleotide that encodes the bifunctional molecule provided herein.As used herein, the term " nucleic acid " or " polynucleotide " refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and their polymers, either in single-stranded form or double-stranded form.Unless otherwise indicated, specific polynucleotide sequence also implicitly encompasses its conservatively modified variant (such as degenerate codon substitution), allele, ortholog, SNP and complementary sequence as well as the explicitly indicated sequence. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0380]
[0405] DNA encoding a monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the antibody). The encoding DNA can also be obtained by synthetic methods.
[0381]
[0406] The isolated polynucleotide encoding the bifunctional molecule can be inserted into a vector for further cloning (DNA amplification) or for expression using recombinant techniques known in the art. Many vectors are available. Vector components generally include, but are not limited to, one or more of the following: a single sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter (e.g., SV40, CMV, EF-1α), and a transcription termination sequence.
[0382]
[0407] The present disclosure provides a vector comprising the isolated polynucleotide provided herein.In certain embodiments, the polynucleotide provided herein encodes a bifunctional molecule, at least one promoter (for example, SV40, CMV, EF-1α) operably linked to a nucleic acid sequence and at least one selectable marker.Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (for example, herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papovaviruses (for example, SV40), lambda phage and M13 phage, and plasmids such as pcDNA3.3, pMD18-T, pOptivec, pCMV, pEGFP, pIRES, pQD-Hyg-GSeu, pALTER, pBAD, pcDNA, pCal, pL, pET, and pGEM. EX, pGEX, pCI, pEGFT, pSV2, pFUSE, pVITRO, pVIVO, pMAL, pMONO, pSELECT, pUNO, pDUO, Psg5L, pBABE, pWPXL, pBI, p15TV-L, pPro18, pTD, pRS10, pLex A, pACT2.2, pCMV-SCRIPT.RTM., pCDM8, pCDNA1.1 / amp, pcDNA3.1, pRc / RSV, PCR2.1, pEF-1, pFB, pSG5, pXT1, pCDEF3, pSVSPORT, pEF-Bos, and the like.
[0383]
[0408] The vector containing the polynucleotide sequence encoding the bifunctional molecule can be introduced into a host cell for cloning and gene expression. Suitable host cells for cloning or expressing the DNA in the vector herein are the prokaryotes, yeast or higher eukaryotic cells described above. Suitable prokaryotes for this purpose include eubacteria, such as gram-negative or gram-positive organisms, for example, Enterobacteriaceae, such as Escherichia coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescans and Shigella, as well as bacilli, such as B. subtilis and B. licheniformis, Pseudomonas, such as P. aeruginosa, and Streptomyces.
[0384]
[0409] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding the bifunctional molecules. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, numerous other genera, species, and strains are commonly available and useful herein, for example, Schizosaccharomyces pombe; Kluyveromyces hosts, such as K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; Yarrowia (EP 402,226); Pichia pastoris (EP 183,070); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces, for example, Schwanniomyces occidentalis; and filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.
[0385]
[0410] Suitable host cells for expressing the glycosylated bifunctional molecules provided herein are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculovirus strains and variants have been identified, as well as corresponding permissive insect host cells derived from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruit fly), and Bombyx mori. Various virus strains for transfection, such as the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, are publicly available, and such viruses can be used as viruses herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be used as hosts.
[0386]
[0411] However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) is a routine procedure. Examples of useful mammalian host cell lines are the SV40-transformed monkey kidney CV1 line (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells / -DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY Acad. Sci. 383:44-68 (1982)); MRC5 cells; FS4 cells; and a human hepatoma line (Hep G2). In some embodiments, the host cells are mammalian cultured cell lines such as CHO, BHK, NS0, 293, and their derivatives.
[0387]
[0412] Host cells are transformed with the expression or cloning vectors described above for the production of bifunctional molecules and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying genes encoding the desired sequences. In another embodiment, bifunctional molecules can be produced by homologous recombination, as known in the art. In certain embodiments, host cells are capable of producing the bifunctional molecules provided herein.
[0388]
[0413] The present disclosure also provides a method for expressing the bifunctional molecules provided herein, comprising culturing the host cells provided herein under conditions in which the vectors of the present disclosure are expressed. The host cells used to produce the bifunctional molecules provided herein can be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM), Sigma) are suitable for culturing host cells. In addition, any medium described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO90 / 03430; WO87 / 00195; or U.S. Pat. Reissue No. 30,985 may also be used as a culture medium for the host cells. Any of these media may be supplemented as needed with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as the drug GENTAMYCIN™), trace elements (defined as inorganic compounds typically present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may be included at appropriate concentrations that would be known to those skilled in the art. Culture conditions, such as temperature, pH, and the like, will be those previously used with the host cell selected for expression and will be apparent to those skilled in the art.
[0389]
[0414] When using recombinant techniques, bifunctional molecules can be produced intracellularly, in the periplasmic space, or directly secreted into the culture medium. If the bifunctional molecule is produced intracellularly, as a first step, particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio / Technology 10:163-167 (1992), describes a procedure for isolating antibodies secreted into the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonyl fluoride (PMSF) for approximately 30 minutes. Cell debris can be removed by centrifugation. If the bifunctional molecule is secreted into the culture medium, supernatants from such expression systems are generally first concentrated using commercially available protein concentration filters, such as Amicon or Millipore Pellicon ultrafiltration devices. A protease inhibitor such as PMSF may be included in any of the above steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of adventitious contaminants.
[0390]
[0415] The bifunctional molecules prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, DEAE-cellulose ion exchange chromatography, ammonium sulfate precipitation, salting out, and affinity chromatography, with affinity chromatography being the preferred purification technique.
[0391]
[0416] In certain embodiments, solid-phase-immobilized protein A is used for immunoaffinity purification of antibodies and their antigen-binding fragments. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain present in the bifunctional molecule. Protein A can be used to purify antibodies based on human gamma 1, gamma 2, or gamma 4 heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human gamma 3 (Guss et al., EMBO J. 5:1567-1575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, although other matrices are also available. Mechanically stable matrices, such as controlled pore glass or poly(styrenedivinyl)benzene, allow for fast flow rates and shorter processing times than can be achieved with agarose. If the antibody contains a CH3 domain, Bakerbond ABX™ resin (JT Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification, such as fractionation on ion exchange columns, ethanol precipitation, reverse-phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™, chromatography on anion or cation exchange resins (such as polyaspartic acid columns), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation, are also available depending on the antibody being recovered.
[0392]
[0417] Following any preliminary purification step(s), the mixture containing the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography, preferably performed at a low salt concentration (e.g., about 0-0.25 M salt), using an elution buffer at a pH between about 2.5-4.5.
[0393] IV. Pharmaceutical Compositions
[0418] The present disclosure further provides pharmaceutical compositions comprising the bifunctional molecule and one or more pharmaceutically acceptable carriers.
[0394]
[0419] Pharmaceutically acceptable carriers for use in the pharmaceutical compositions disclosed herein can include, for example, pharmaceutically acceptable liquid, gel, or solid carriers, aqueous vehicles, non-aqueous vehicles, antibacterial agents, isotonic agents, buffers, antioxidants, anesthetics, suspending / dispending agents, sequestering or chelating agents, diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.
[0395]
[0420] Suitable components may include, for example, antioxidants, injection agents, binders, disintegrants, buffers, preservatives, lubricants, flavoring agents, thickeners, coloring agents, emulsifiers, or stabilizers such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxyanisole, butylated hydroxytoluene, and / or propyl gallate. As disclosed herein, the inclusion of one or more antioxidants, such as methionine, in compositions comprising the bifunctional molecules and conjugates provided herein reduces oxidation of the bifunctional molecules. This reduction in oxidation prevents or reduces the decrease in binding affinity, thereby improving antibody stability and maximizing shelf life. Thus, in certain embodiments, pharmaceutical compositions are provided comprising one or more bifunctional molecules disclosed herein and one or more antioxidants, such as methionine. Further provided are methods for preventing oxidation, extending the shelf life and / or improving the efficacy of the bifunctional molecules provided herein by combining the bifunctional molecules with one or more antioxidants, such as methionine.
[0396]
[0421] To further illustrate, pharmaceutically acceptable carriers include, for example, aqueous vehicles such as sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, or dextrose and lactose Ringer's injection, non-aqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil, antibacterial agents in bacteriostatic or fungistatic concentrations, isotonic agents such as sodium chloride or dextrose, buffers such as phosphate or citrate buffers, antioxidants such as sodium bisulfate, local anesthetics, Examples of suitable carriers include drugs such as procaine hydrochloride, suspending and dispersing agents such as sodium carboxymethylcellulose, hydroxypropylmethylcellulose, or polyvinylpyrrolidone, emulsifiers such as polysorbate 80 (TWEEN®-80), sequestering or chelating agents such as EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid), ethyl alcohol, polyethylene glycol, propylene glycol, sodium hydroxide, hydrochloric acid, citric acid, or lactic acid. Antibacterial agents used as carriers include phenol or cresol, mercury, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride, and can be added to pharmaceutical compositions in multi-dose containers. Suitable excipients include, for example, water, saline, dextrose, glycerol, or ethanol. Suitable nontoxic auxiliary substances can include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrins.
[0397]
[0422] The pharmaceutical compositions can be liquid solutions, suspensions, emulsions, pills, capsules, tablets, sustained-release formulations, or powders. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharin, cellulose, magnesium carbonate, etc.
[0398]
[0423] In certain embodiments, pharmaceutical compositions can be formulated into injectable compositions.Injectable pharmaceutical compositions can be prepared in any conventional form, for example, liquid solutions, suspensions, emulsions, or solid forms suitable for producing liquid solutions, suspensions, emulsions.Preparations for injection can include sterile and / or non-pyrogenic solutions prepared for injection, sterile dry soluble products, such as lyophilized powders prepared for mixing with solvents immediately before use, including tablets for subcutaneous tissue, sterile suspensions prepared for injection, sterile dry insoluble products prepared for mixing with vehicles immediately before use, and sterile and / or non-pyrogenic emulsions.Solutions can be either aqueous or non-aqueous.
[0399]
[0424] In certain embodiments, unit dose parenteral preparations are packaged in ampoules, vials, or syringes with needles. All preparations for parenteral administration must be sterile and non-pyrogenic, as known and practiced in the art.
[0400]
[0425] In certain embodiments, a sterile, lyophilized powder is prepared by dissolving the bifunctional molecule disclosed herein in a suitable solvent. The solvent may contain excipients that improve the stability or other pharmacological components of the powder or reconstituted solution prepared from the powder. Excipients that can be used include, but are not limited to, water, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable agents. The solvent may contain a buffer, such as citrate, sodium phosphate, or potassium phosphate, or other such buffers known to those skilled in the art, which in one embodiment have an approximately neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those skilled in the art provides the desired formulation. In one embodiment, the resulting solution is dispensed into vials for lyophilization. Each vial may contain a single dose or multiple doses of the bifunctional molecule or composition thereof. Overfilled vials containing a small amount (e.g., about 10%) in excess of what is needed for one dose or set of doses are acceptable to facilitate accurate sample withdrawal and accurate dosing. The lyophilized powder can be stored under appropriate conditions, such as at about 4° C. to room temperature.
[0401]
[0426] Reconstitution of the lyophilized powder with water for injection provides a formulation for use in parenteral administration. In one embodiment, sterile and / or non-pyrogenic water or other liquid suitable carrier is added to the lyophilized powder for reconstitution. The exact amount can be empirically determined depending on the selected treatment to be administered.
[0402] V. Kit
[0427] In certain embodiments, the present disclosure provides a kit comprising the bifunctional molecule provided herein and / or the pharmaceutical composition provided herein.In certain embodiments, the present disclosure provides a kit comprising the bifunctional molecule provided herein and a second therapeutic agent.In certain embodiments, the second therapeutic agent is selected from the group consisting of chemotherapeutic agents, anticancer drugs, radiation therapy, immunotherapy agents, angiogenesis inhibitors, targeted therapy, cell therapy, gene therapy, hormone therapy, antiviral agents, antibacterial agents, analgesics, antioxidants, metal chelators and cytokines.
[0403]
[0428] Such kits may, as would be readily apparent to one of ordinary skill in the art, optionally further include one or more of a variety of conventional pharmaceutical kit components, e.g., containers containing one or more pharmaceutically acceptable carriers, additional containers, etc. Instructions indicating the amounts of the components to be administered, directions for administration, and / or directions for mixing the components may also be included in the kit, either as an insert or label.
[0404] VI.How to use
[0429] In another aspect, the present disclosure provides a method of treating, preventing, or ameliorating a PD-L1-associated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a bifunctional molecule provided herein, or a pharmaceutical composition or kit provided herein.
[0405]
[0430] In certain embodiments, the subject is a human.
[0406]
[0431] The PD-1-associated condition or disorder may be an immune-related disease or disorder, cancer, an autoimmune disease, or an infectious disease.
[0407]
[0432] In certain embodiments, PD-1 associated conditions and disorders include cancer, e.g., non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, colorectal cancer, ovarian cancer, breast cancer, pancreatic cancer, gastric cancer, bladder cancer, esophageal cancer, mesothelioma, melanoma, head and neck cancer, thyroid cancer, sarcoma, prostate cancer, glioblastoma, cervical cancer, thymic carcinoma, leukemia, lymphoma, myeloma, mycosis fungoides, Merkel cell carcinoma, and other hematological malignancies, e.g., classical Hodgkin's lymphoma ( CHL), primary mediastinal large B-cell lymphoma, T-cell / histiocytocyte-rich B-cell lymphoma, EBV-positive and -negative PTLD, as well as EBV-associated diffuse large B-cell lymphoma (DLBCL), plasmablastic lymphoma, extranodal NK / T-cell lymphoma, nasopharyngeal carcinoma, and HHV8-associated primary effusion lymphoma, Hodgkin's lymphoma, and neoplasms of the central nervous system (CNS), such as primary CNS lymphoma, spinal axis tumor, and brainstem glioma. In certain embodiments, the tumors and cancers are metastatic, particularly metastatic tumors that express PD-L1.
[0408]
[0433] In certain embodiments, PD-1-associated conditions and disorders include autoimmune diseases, including, but not limited to, acquired immune deficiency syndrome (AIDS, a viral disease with an autoimmune component), alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diabetes, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behçet's disease, cardiomyopathy, celiac disease-dermatitis hepetiformis; chronic fatigue and immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricial pemphigoid, and the like. pemphigold), cold agglutinin disease, CREST syndrome, Crohn's disease, Degos disease, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, insulin-dependent diabetes mellitus, juvenile chronic arthritis (Still's disease), juvenile rheumatoid arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pernicious anemia anemia), polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma (also known as progressive systemic sclerosis (PSS), systemic sclerosis (SS)), Sjögren's syndrome, stiff man syndrome, systemic lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.
[0409]
[0434] In certain embodiments, PD-1-associated conditions and disorders include infectious diseases, such as chronic viral infections, e.g., fungal infections, parasitic / protozoal infections, or chronic viral infections, e.g., malaria, coccidioidmycosis immitis, histoplasmosis, onychomycosis, aspergillosis, blastomycosis, candidiasis, albicans), paracoccidioidomycosis, microsporidiosis, acanthamoeba keratitis, amebiasis, ascariasis, babesiosis, balantidiosis, raccoon ascariasis, Chagas disease, clonorchiasis, screwworm disease (Cochliomyiasis), cryptosporidiosis, diphyllobothriasis, dracunculiasis, echinococcosis, elephantiasis, enterobiasis, fascioliasis, filariasis, giardiasis, gnathostomiasis, hymenococcosis, isosporiasis, Katayama fever, leishmaniasis, Lyme disease, metagonism, myiasis, onchocerciasis, lice infestation, scabies, schistosomiasis , sleeping sickness, fecal nematode disease, taeniasis, toxocariasis, toxoplasmosis, trichinosis, trichuriasis, trypanosomiasis, helminth infection, hepatitis B (HBV), hepatitis C (HCV), herpesvirus, Epstein-Barr virus, HIV-1, HIV-2, cytomegalovirus, herpes simplex virus type I, herpes simplex virus type II, human papillomavirus, adenovirus, Kaposi's sarcoma-associated herpesvirus infection, Schinling virus (Torque teno virus), human T-lymphotropic virus I, human T-lymphotropic virus II, varicella-zoster virus, JC virus, or BK virus infection.
[0410]
[0435] In certain embodiments, the PD-L1-associated disease is a PD-L1-expressing cancer or a PD-L1-overexpressing cancer. A "PD-L1-expressing cancer" is one that comprises cancer cells or tumor cells that have PD-L1 protein on their cell surface. A "PD-L1-overexpressing cancer" is one that has significantly higher levels of PD-L1 on the cell surface of cancer or tumor cells compared to non-cancerous cells of the same tissue type.
[0411]
[0436] PD-L1 expression or overexpression can be determined in a diagnostic or prognostic assay by assessing elevated levels of PD-L1 present on the surface of cells (e.g., by immunohistochemistry; IHC). Alternatively, or in addition, one skilled in the art can measure the level of nucleic acid encoding PD-L1 in cells by, for example, fluorescence in situ hybridization (FISH; see WO98 / 45479, published October 1998), Southern blotting, or polymerase chain reaction (PCR) techniques, such as real-time quantitative PCR (RT-PCR). One skilled in the art can also test for PD-L1 overexpression by measuring shed antigens (e.g., PD-L1 extracellular domain or soluble PD-L1) in biological fluids, such as serum. In addition to the above assays, various in vivo assays are available to one skilled in the art. For example, one skilled in the art can expose cells within a patient to an anti-PD-L1 antibody that is optionally labeled with a detectable label, for example a radioisotope, and assess binding of the antibody to cells within the patient, for example by external scanning for radioactivity or by analyzing a biopsy taken from the patient that has been pre-exposed to the antibody.
[0412]
[0437] In some embodiments, the subject has been identified as likely to respond to a PD-1 antagonist. The presence or level of PD-L1 in a biological sample of interest can indicate whether the subject from which the biological sample is derived is likely to respond to a PD-1 antagonist. In some embodiments, the test sample is derived from cancer cells or tissues, or tumor-infiltrating immune cells. In certain embodiments, the presence or upregulated level of PD-L1 in the test biological sample indicates the likelihood of responsiveness. As used herein, the term "upregulated" refers to an overall increase of 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or more in the protein level of PD-L1 in the test sample compared to the protein level in a reference sample detected using the same antibody. The reference sample may be a control sample obtained from a healthy or non-diseased individual, or a healthy or non-diseased sample obtained from the same individual from which the test sample is obtained. For example, the reference sample may be a non-diseased sample adjacent to or near the test sample (e.g., tumor).
[0413]
[0438] In certain embodiments, the PD-L1-associated disease is resistant to PD-L1 / PD-1 monotherapy. As used herein, "PD-L1 / PD-1 monotherapy" refers to a monotherapy that acts by inhibiting or reducing PD-L1 and PD-1 interaction or signaling. Exemplary PD-L1 / PD-1 monotherapy may include anti-PD-L1 antibody therapy, anti-PD-1 antibody therapy, or a monotherapy comprising a small molecule inhibitor of PD-1 or PD-L1. "Resistance" means that the disease has no or reduced responsiveness or sensitivity to PD-L1 / PD-1 monotherapy. Reduced responsiveness may be indicated, for example, by the requirement for increased doses to achieve a given efficacy. In certain embodiments, the disease may be non-responsive to PD-L1 / PD-1 monotherapy. For example, cancer cell or tumor size increases despite treatment with PD-L1 / PD-1 monotherapy, or the disease shows regression back to its previous state, e.g., return of previous symptoms after partial recovery. Resistance to PD-L1 / PD-1 monotherapy may be de novo or acquired.
[0414]
[0439] In another aspect, the present disclosure provides a method of treating, preventing, or alleviating a disease or condition in a subject that would benefit from suppression of immunosuppressive cytokines, induction of a sustained immune response, or stimulation of anti-tumor immunity, comprising administering an effective amount of a bifunctional molecule provided herein, or a pharmaceutical composition provided herein.
[0415]
[0440] In some embodiments, the immunosuppressive cytokine is TGFβ or IL- 1. In some embodiments, the immunosuppressive cytokine is TGFβ1 or IL-1β.
[0416]
[0441] In some embodiments, the disease or condition is a TGFβ-associated disease or condition, hi some embodiments, the TGFβ-associated disease is cancer, a fibrotic disease, or a kidney disease.
[0417]
[0442] In certain embodiments, the TGFβ-related disease is cancer, hi certain embodiments, the cancer is selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, prostate cancer, renal cancer, cervical cancer, myeloma, lymphoma, leukemia, thyroid cancer, endometrial cancer, uterine cancer, bladder cancer, neuroendocrine cancer, head and neck cancer, liver cancer, nasopharyngeal cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell carcinoma, skin cancer, cutaneous squamous cell carcinoma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, glioblastoma, glioma, sarcoma, mesothelioma, and myelodysplastic syndrome.
[0418]
[0443] In certain embodiments, the TGFβ-related disease is a fibrotic disease.The fibrotic disease is a disease or condition that includes fibrosis.Fibrosis is a scarring process that is a common feature of chronic organ injury, for example, in the lung, liver, kidney, skin, heart, intestine or muscle.Fibrosis is characterized by the increased activity of transforming growth factor-beta (TGF-β), which leads to increased or altered deposition of extracellular matrix and other fibrosis-related proteins.
[0419]
[0444] Fibrotic diseases may include fibrotic diseases in the lungs, liver, kidneys, eyes, skin, heart, intestines, or muscles. Examples of fibrotic diseases in the lungs include pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, progressive massive fibrosis, bronchiolitis obliterans, airway remodeling associated with chronic asthma, or idiopathic pulmonary fibrosis. Examples of fibrotic diseases in the liver include cirrhosis or nonalcoholic steatohepatitis. Examples of fibrotic diseases in the kidneys include renal fibrosis, ischemic kidney injury, tubulointerstitial fibrosis, diabetic nephropathy, nephrosclerosis, or nephrotoxicity. Examples of fibrotic diseases in the eyes include corneal fibrosis and subretinal fibrosis. Examples of fibrotic diseases in the skin include nephrogenic systemic fibrosis, keloids, or scleroderma. Examples of fibrotic diseases in the heart include endomyocardial fibrosis or previous myocardial infarction.
[0420]
[0445] In some embodiments, the disease or condition is an IL-1 associated disease or condition, hi some embodiments, the IL-1 associated disease is an autoinflammatory disease, metabolic syndrome, acute inflammation, chronic inflammation, or malignancy.
[0421]
[0446] In some embodiments, the disease or condition benefits from the induction of a sustained immune response by stimulating MHCII signaling with an immunostimulatory polypeptide, e.g., soluble LAG-3. In some embodiments, the disease or condition is cancer, a viral infection, a parasitic infection, or a combination thereof.
[0422]
[0447] In some embodiments, the disease or condition benefits from stimulating anti-tumor immunity by inhibiting immunoinhibitory receptor signaling. In some embodiments, the immunoinhibitory receptor is SIRPα. In certain embodiments, the disease, disorder, or condition is SIRPα-associated, such as cancer, solid tumor, chronic infection, inflammatory disease, multiple sclerosis, autoimmune disease, neurological disease, brain injury, nerve injury, polycythemia, hemochromatosis, trauma, septic shock, fibrosis, atherosclerosis, obesity, type II diabetes, graft dysfunction, or arthritis. In some embodiments, the cancer is selected from the group consisting of anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, gallbladder cancer, stomach cancer, lung cancer, bronchial cancer, bone cancer, liver and bile duct cancer, pancreatic cancer, breast cancer, liver cancer, ovarian cancer, testicular cancer, kidney cancer, renal pelvis and ureter cancer, salivary gland cancer, small intestine cancer, urethral cancer, bladder cancer, head and neck cancer, spinal cancer, brain cancer, cervical cancer, uterine cancer, endometrial cancer, colon cancer, colorectal cancer, rectal cancer, anal cancer, esophageal cancer, stomach cancer, Intestinal cancer, skin cancer, prostate cancer, pituitary cancer, vaginal cancer, thyroid cancer, pharyngeal cancer, glioblastoma, melanoma, myelodysplastic syndrome, sarcoma, teratoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, T- or B-cell lymphoma, GI organ stromal tumor, soft tissue tumor, hepatocellular carcinoma, and adenocarcinoma. In some embodiments, the cancer is a CD47-expressing or CD47-overexpressing cancer.
[0423]
[0448] The therapeutically effective amount of the bifunctional molecules provided herein will depend on various factors known in the art, such as the subject's weight, age, past medical history, current medications, health status and potential cross-reactions, allergies, sensitivities and adverse side effects, as well as the route of administration and the extent of disease occurrence. As indicated by these and other circumstances or requirements, one skilled in the art (e.g., a physician or veterinarian) can proportionally reduce or increase the dosage.
[0424]
[0449] In certain embodiments, the bifunctional molecules provided herein can be administered at a therapeutically effective dosage of about 0.01 mg / kg to about 100 mg / kg. In certain embodiments, the dosage may vary over the course of treatment. For example, in certain embodiments, the initial dosage may be higher than subsequent dosages. In certain embodiments, the dosage may vary over the course of treatment depending on the subject's response.
[0425]
[0450] Dosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single dose can be administered or several divided doses can be administered over time.
[0426]
[0451] The bifunctional molecules provided herein can be administered by any route known in the art, such as, for example, parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, or intradermal injection) or non-parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.
[0427]
[0452] In some embodiments, the bifunctional molecule provided herein can be administered alone or in combination with a therapeutically effective amount of a second therapeutic agent.For example, the bifunctional molecule disclosed herein can be administered in combination with a second therapeutic agent, such as a chemotherapeutic agent, an anti-cancer drug, radiation therapy, immunotherapy, anti-angiogenesis agent, targeted therapy, cell therapy, gene therapy, hormone therapy, antiviral agent, antibiotic, analgesic, antioxidant, metal chelator or cytokine.
[0428]
[0453] As used herein, the term "immunotherapy" refers to a type of therapy that stimulates or generally promotes the immune system to fight diseases such as cancer. Examples of immunotherapy include, but are not limited to, checkpoint modulators, adoptive cell transfer, cytokines, oncolytic viruses, and therapeutic vaccines.
[0429]
[0454] "Targeted therapy" is a type of therapy that acts on specific molecules associated with cancer, such as specific proteins that are present or more abundant in cancer cells than in normal cells, or target molecules in the cancer microenvironment that contribute to the growth and survival of cancer. Targeted therapy targets therapeutic agents to tumors, thereby sparing the effects of the therapeutic agent from reaching normal tissues.
[0430]
[0455] In certain of these embodiments, the bifunctional molecules provided herein administered in combination with one or more additional therapeutic agents can be administered simultaneously with the one or more additional therapeutic agents; in certain of these embodiments, the bifunctional molecule and the additional therapeutic agent can be administered as part of the same pharmaceutical composition. However, a bifunctional molecule administered "in combination with" another therapeutic agent need not be administered simultaneously with that agent or in the same composition as that agent. A bifunctional molecule administered before or after another agent is considered to be administered "in combination with" that agent, as that term is used herein, even if the antibody or antigen-binding fragment and the second agent are administered by different routes. Where possible, additional therapeutic agents administered in combination with an antibody or antigen-binding fragment thereof disclosed herein are administered according to the schedule listed in the product information sheet of the additional therapeutic agent, or according to protocols known in the art, such as the Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th Edition, Medical Economics Company; ISBN: 1563634457; 57th Edition (November 2002)).
[0431]
[0456] In another aspect, the present disclosure also provides use of a bifunctional molecule provided herein and / or a pharmaceutical composition provided herein in the manufacture of a medicament for treating a PD-L1-associated disease, and / or a TGF-β-associated disease, and / or an IL-1-associated disease, and / or a CD47-associated disease in a subject.
[0432]
[0457] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. All specific compositions, materials, and methods described below are within the scope of the present invention, in whole or in part. These specific compositions, materials, and methods are not intended to limit the invention, but merely to illustrate specific embodiments within the scope of the invention. Those skilled in the art may develop equivalent compositions, materials, and methods without the exercise of inventive capacity and without departing from the scope of the invention. It will be understood that many modifications can be made to the procedures herein described while remaining within the scope of the invention. It is the intention of the inventors that such modifications be included within the scope of the invention. [Example]
[0433] Example 1 Generation, expression and purification of humanized 4B6 antibody
[0458] The anti-PD-L1 mAb 4B6, derived from patent WO2017161976A1, comprising the VH sequence of SEQ ID NO:46 and the VL sequence of SEQ ID NO:47, shown below, was a potent PD-1 / PD-L1 blocker. This antibody was generated from a mouse hybridoma antibody and therefore required appropriate humanization. The sequences of the variable domains of mouse antibody 4B6 were used to identify germline sequences with the highest homology to their corresponding mouse frameworks. Computer modeling was used to design humanized variants with complementarity-determining region (CDR) grafting and backmutations.
[0434]
[0459] Mouse / Chimeric Heavy Chain Variable Region (SEQ ID NO: 46): EVQLQQSGPELVKPGASVKISKASGYVFT DYYMN WVKQSHGKSLEWIG DINPNNGGTSYNHKFKG KATVTVDKSSRTAYMELLSLTSEDSAVYYCVK WGDGPFAY WGQGTLVTVSA
[0460] Mouse / Chimeric Light Chain Variable Region (SEQ ID NO: 47): DIVMTQSQKFMSTSVGDRVSITC KASQNVGAAVA WYQQKPGQSPKLLIY SASNRYT GVPDRFTGSGSGTDFLTISNMQSEDLADYFC QQYSNYPT FGSGTKLGIK
[0461] Note: The italicized parts represent the framework (FR) and the underlined parts represent the CDR sequences, in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0435]
[0462] Human germline framework sequences of VK / 1-33 for the light chain and VH / 1-2 for the heavy chain, respectively, were used for CDR grafting.
[0436]
[0463] Heavy chain variants 1, 2, 3 and 4 (i.e., VH variants 1, 2, 3 and 4) were obtained by directly grafting the three CDRs onto the VH germline sequence (SEQ ID NO: 48) and further backmutating M69V, R71V for VH variant 1 (SEQ ID NO: 49), M69V, R71V, A93V, R94 for VH variant 2 (SEQ ID NO: 50), M69V, R71V, T73K, T28V for VH variant 3 (SEQ ID NO: 51), and M69V, R71V, A93V, R94K, T73K, T28V, G44S for VH variant 4 (SEQ ID NO: 52), respectively.
[0437]
[0464] 4B6 VH germline sequence:
[0465] VH / 1-2 (4B6-VH germline, SEQ ID NO: 48): QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR
[0466] VH / 1-2 variant 1 (4B6_Ha, SEQ ID NO: 49): QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGDINPNNGGTSYNHKFKGRVTVTVDTSISTAYMELSRLRSDDTAVYYCARWGDGPFAYWGQGTLVTVSS
[0467] VH / 1-2 variant 2 (4B6_Hb, SEQ ID NO: 50): QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWMGDINPNNGGTSYNHKFKGRVTVTVDTSISTAYMELSRLRSDDTAVYYCVKWGDGPFAYWGQGTLVTVSS
[0468] VH / 1-2 variant 3 (Hu4B6_Hc, SEQ ID NO: 51): QVQLVQSGAEVKKPGASVKVSCKASGYVFTDYYMNWVRQAPGQGLEWMGDINPNNGGTSYNHKFKGRVTVTVDKSISTAYMELSRLRSDDTAVYYCARWGDGPFAYWGQGTLVTVSS
[0469] VH / 1-2 variant 4 (Hu4B6_Hd, SEQ ID NO: 52): QVQLVQSGAEVKKPGASVKVSCKASGYVFTDYYMNWVRQAPGQSLEWMGDINPNNGGTSYNHKFKGRVTVTVDKSISTAYMELSRLRSDDTAVYYCVKWGDGPFAYWGQGTLVTVSS
[0470] Light chain variants 1 and 2 (VL variants 1 and 2) were obtained by directly grafting the three CDRs onto the germline sequence (SEQ ID NO: 53) and by back-mutation of the F73L mutation for VL variant 1 (SEQ ID NO: 54) and the F73L, A43S, and S60D mutations for VL variant 2 (SEQ ID NO: 55), respectively.
[0438]
[0471] 4B6 VL germline sequence:
[0472] VK / 1-33 (4B6-VL-germline, SEQ ID NO: 53): DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLP
[0473] VK / 1-33 Variant 1 (Hu4B6_La, SEQ ID NO: 54): DIQMTQSPSSLSASVGDRVTITCKASQNVGAAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYSNYPTFGQGTKLEIK
[0474] VK / 1-33 Variant 2 (Hu4B6_Lb, SEQ ID NO: 55): DIQMTQSPSSLSASVGDRVTITCKASQNVGAAVAWYQQKPGKSPKLLIYSASNRYTGVPDRFSGSGSGTDFTLTISSLQPEDIATYYCQQYSNYPTFGQGTKLEIK
[0475] After synthesizing the cDNAs for the heavy and light chain variable regions, the sequences of human IgG1 and human kappa constant regions were fused to them. The resulting antibody gene sequences were cloned into expression vectors. Large-scale DNA was prepared for the expression of humanized 4B6 variants, as shown in Table 6, using the Plasmid Maxiprep System from Qiagen. Cell transfection was performed using ExpiFectamine™ CHO Reagent from Invitrogen according to the manufacturer's protocol. When cell viability exceeded 60%, the supernatant was collected and filtered through a 0.22 μm filtration capsule to remove cell debris. The filtered supernatant was then loaded onto a pre-equilibrated Protein A affinity column. After washing the Protein A resin with equilibration buffer (PBS), the antibody was eluted using 25 mM citric acid (pH 3.5). The purified antibody solution was adjusted to pH 6.0-7.0 using 1 M Tris base (pH 9.0). Endotoxin was controlled below 1 EU / mg. Finally, the purified antibodies were characterized by SDS-PAGE.
[0439]
[0476]
[0440] [Table 8]
[0441]
[0477] Note: This table shows various sequence combinations of different mutations. For example, Hu4B6_HaLa indicates that two types of mutations (heavy chain Hu4B6_Ha and light chain Hu4B6_La) are present on the humanized mouse antibody Hu4B6_HaLa. Hu4B6_L0 and Hu4B6_H0 were obtained by CDR grafting and lack important back mutations, and therefore, they are not used for expression.
[0442] Example 2 Binding to human PD-L1 by ELISA assay
[0478] The binding of the humanized antibodies was assessed by ELISA. Briefly, human PD-L1-His was immobilized on a plate. The humanized 4B6 antibody listed in Table 6 was serially diluted in PBS and added for 1 hour of incubation. Then, a goat pAb against human IgG-HRP and TMB were added for binding detection at OD450nm.
[0443]
[0479] All humanized variants were tested to screen the best one, as shown in Figure 1. All variants retained their binding activity, and Hu4B6_HdLa showed better binding activity than the others.
[0444]
[0480] The inventors analyzed the CDR sequence of this antibody and found that there was an NG motif in CDR2 of the heavy chain. During expression and purification, there may be a risk of deamination. To remove the deamidation hotspot, the inventors introduced a G55A mutation (expanded in bold below) into Hu4B6_Hd. Hu4B6_Hg (SEQ ID NO: 56) was then obtained, and as shown in Figure 2, its affinity for human PD-L1 was not affected.
[0445]
[0481] Hu4B6_Hg (SEQ ID NO: 56): QVQLVQSGAEVKKPGASVKVSCKASGYVFTDYYMNWVRQAPGQSLEWMGDINPNNAGTSYNHKFKGRVTVTVDKSISTAYMELSRLRSDDTAVYYCVKWGDGPFAYWGQGTLVTVSS Example 3 Monoclonal phage ELISA and sequence analysis
[0482] Hu4B6-HgLa retained the activity derived from the chimeric 4B6 as an antagonist drug, but its higher affinity was favored. Based on the Hu4B6-HgLa sequence, site-directed mutagenesis in the CDRs and several cycles of in vitro panning for dissociation rate-dependent selection were further used for affinity maturation. First, the VL and VH domains of 4B6-HgLa were amplified and linked by a peptide linker (G4S)3 to form scFvs by overlap PCR, which were then subcloned into the phagemid vector pComb3x (Wuhan MiaoLingBio, P0862) via the SfiI cleavage site as the wild-type sequence for affinity maturation.
[0446]
[0483] Because antibody CDR3s of both heavy and light chains typically play an important role in antigen binding, we constructed one SPM (small perturbation mutagenesis) phage library for each of the CDRs to investigate the individual contributions of CDR1 and CDR2 of both chains to 4B6 affinity maturation. The CDR1 and CDR2 sequences of both chains were aligned with germline sequences, and the germline sequences of the heavy and light chain variable regions were IGHV1-2 and IGKV1-33, respectively. The results of bioinformatics analysis of the germline CDR sequences were used to guide the design of the library.
[0447]
[0484] After determining the amino acid mutation sites and substitution sequences, degenerate primers were designed to increase the diversity of the mutation library. The diversified CDR fragments were amplified to construct a 4B6 scFv gene mutant library. The scFv gene was ligated into the pComb3XSS phage display vector to generate the scFv library. Primers based on the codons of each CDR (including HCDR1, HCDR2, LCDR1, and LCDR2, listed in Table 2) were established as independent libraries, and the 4B6 affinity maturation library was divided into four libraries. The capacity was 1.76 x 10 for HCDR1. 8 1.81x10 for CFM, HCDR2 8 CFM, 2.34x10 for LCDR1 8 2.00x10 for CFM and LCDR2 8 CFM. Five or six clones from each library were randomly picked for colony sequencing. The results showed that the insertion rate of the constructed libraries was 100%.
[0448]
[0485] 10 μg / ml of hPD-L1 (Acro Biosystems, PD1-H5229) antigen was coated onto an ELISA plate, and 200 μL of phage (1 × 10) was incubated at 37 °C for 1 h. 10 The wells were incubated with 1000pfu / ml of phage display library. After washing, TG1 (Lucigen, 60502-2) with an OD of approximately 0.5 was added directly to the wells for infection and incubated with the phage for 15 min. A sufficient volume of M13KO7 helper phage (NEB, N0315S) was added to a mid-logarithmic culture for library phagemid rescue, and the phage was generated and purified for the next round of screening. The screening process was repeated for three rounds, with the antigen concentration reduced to 2.5 μg / ml for the second round and 1 μg / ml for the third round.
[0449]
[0486] To detect the titer of these polyclonal phage variants, ELISA binding assays were performed. After three rounds of panning, three libraries containing 4B6-H-CDR2, 4B6-L-CDR1, and 4B6-L-CDR2 were clearly enriched.
[0450]
[0487] For these three libraries, 96 clones from each library were picked and subjected to phage ELISA to detect their binding activity. Briefly, 1 μg / ml hPD-L1 (Acro Biosystems, PD1-H5229) antigen was coated onto an ELISA plate and incubated at 4°C overnight. 300 μL of 3% (w / v) skim milk was then added for blocking at room temperature for 1 hour. After 1 hour, 100 μL of supernatant containing monoclonal antibody fragment phages was added along with PBS as a negative control and incubated at 37°C for 1 hour. 0.5% PBS + Tween®-20 was used to wash three times, and 100 μL of HRP-conjugated anti-M13 mAb (1:20000, Sino Biological, 11973-MM05T-H) was added. After incubation at room temperature for 1 h, mixed TMB (InnoReagents, TMB-S-003) substrate reagent was added, and the plate was incubated at room temperature for 5 min. After adding 0.1 M H2SO4 to stop the reaction, the OD450nm was recorded. Positive clones were picked for DNA sequencing by Genewiz (Suzhou, China). The sequences are shown in Table 7.
[0451]
[0488]
[0452] [Table 9]
[0453] Example 4 Biolayer Interferometry (BLI) for Binding Affinity Detection
[0489] Biolayer interferometry (BLI) was used to test the binding affinity of the 4B6 scFv variants to the human PD-L1-Fc (Sino Biological, 70110-D02H) antigen. The materials and procedures are listed in Tables 8 and 9, respectively. The results are shown in Tables 10-12. Based on the binding affinity results, four light chain variants (L-CDR1-2, L-CDR1-3, L-CDR2-2, L-CDR2-3) and three heavy chain variants (H-CDR2-2, H-CDR2-3, H-CDR2-5) were selected for future construction.
[0454]
[0490]
[0455] [Table 10]
[0456]
[0491]
[0457] [Table 11]
[0458]
[0492]
[0459] [Table 12]
[0460]
[0493]
[0461] [Table 13]
[0462]
[0494]
[0463] [Table 14]
[0464] Example 5 Construction and expression of AM-4B6-hIgG1-TGFβRII(1-136) fusion protein
[0495] Selected heavy and light chain variants were cross-mixed and expressed together as a hIgG1-TGFβRII(1-136) fusion protein. TGFβRII(1-136) has the amino acid sequence set forth in SEQ ID NO: 79: TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD The amino acid sequence of hIgG1 is as follows (SEQ ID NO: 80): ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK TGFβRII(1-136) was linked to the carboxyl terminus of hIgG1 via the peptide linker (G4S)4G (SEQ ID NO: 68).
[0465] The amino acid sequence of hKappa is as follows (SEQ ID NO: 82): RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0496] The intact antibody variants are prefixed with AM (affinity matured). The sequence constructs of the heavy and light chains are shown in Table 13, and the design of the intact antibody is shown in Table 14. For example, as shown in Tables 13 and 14, the bifunctional molecule "AM-4B6-hIgG1-TGFβRII variant 1" has a heavy chain and a light chain, where the heavy chain comprises, from N-terminus to C-terminus, Hu4B6_Hg.2-_hIgG1-(G4S)4G-TGFβRII(1-136), and the light chain comprises, from N-terminus to C-terminus, Hu4B6_La.1-hKappa. The same nomenclature applies to the other variants in Table 14.
[0466]
[0497] Co-transfection of heavy and light chains was carried out using ExpiFectamine™ CHO Reagent from Invitrogen (Thermo, A29129) according to the manufacturer's protocol. Supernatants were harvested on day 10 and purified by affinity chromatography.
[0467]
[0498]
[0468] [Table 15]
[0469]
[0499]
[0470] [Table 16]
[0471] Example 6 Binding affinity of AM-4B6-hIgG1-TGFβRII variants to hPD-L1
[0500] Binding to hPD-L1 by ELISA assay
[0501] 1 μg / ml hPD-L1 (Acro Biosystems, PD1-H5229) antigen was coated onto an ELISA plate and incubated overnight at 4°C. 300 μl of 3% (w / v) skim milk was then added for blocking at room temperature for 1 hour. After 1 hour, 100 μl of AM-4B6-hIgG1-TGFβRII variants or original 4B6-hIgG1-TGFβRII at concentrations ranging from 100 nM to 0.006 nM (4-fold serial dilutions) was added along with PBS as a negative control and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used for three washes, and 100 μl of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the reaction was stopped by adding 0.1 M H2SO4. OD450nm was recorded by a microplate reader.
[0472]
[0502] As shown in Figures 3A-3C, all variants had enhanced binding signals and affinities compared to the original 4B6-hIgG1-TGFβRII. Given the limited differences between these variants, surface plasmon resonance technology was used to further evaluate their binding affinities.
[0473]
[0503] Binding to hPD-L1 by Biacore
[0504] 4μg / ml of AM-4B6-hIgG1-TGFβRII variant or original 4B6-hIgG1-TGFβRII was immobilized on the surface of an S-series Protein A chip. Human PD-L1 was diluted to an appropriate concentration gradient (0nM, 1.875nM, 3.75nM, 7.5nM, 15nM, 30nM, 60nM) and injected into the sample channel of a Biacore 2000. The results are shown in Table 15. The binding affinity of AM-4B6-hIgG1-TGFβRII variant 7 to human PD-L1 was approximately 15-fold improved over that of original 4B6-hIgG1-TGFβRII.
[0474]
[0505]
[0475] [Table 17]
[0476]
[0506] Binding to cell surface-expressed PD-L1 by FACS assay
[0507] 293T-PD-L1-CD3L cells were generated by MabSpace Bioscience for characterization of PD-L1 antibodies. Cells were transfected with both human PD-L1 and anti-CD3 scFv. AM-4B6-hIgG1-TGFβRII variants or original 4B6-hIgG1-TGFβRII were serially diluted (5-fold) to obtain eight concentrations in dilution buffer (PBS containing 2% BSA). 293T-PD-L1-CD3L cells were harvested and centrifuged. They were then diluted to 2x10 6 After resuspending in PBS at a density of 100 cells / ml, 100 μl per well was added to the plate. After centrifugation and removal of the supernatant, the diluted antibody was added to the plate and incubated for 30 min at 4°C. After washing twice with dilution buffer, PE-conjugated donkey anti-human IgG (H+L) (Jacksonimmuno, 709-116-149) was added to the plate and incubated for 30 min at 4°C. After washing, the cells were resuspended in 200 μl of PBS and analyzed by flow cytometry.
[0477]
[0508] As shown in Figure 4, these five variants bound to PD-L1 expressed on the surface of 293T-PD-L1-CD3L cells with similar EC50s. Variant 7 had a slightly lower EC50 than the others, which was consistent with the binding affinity results measured by Biacore.
[0478] Example 7 PD-1 / PD-L1 blocking activity of AM-4B6-hIgG1-TGFβRII variants
[0509] PD-1 / PD-L1 and B7-1 / PD-L1 blockade by ELISA assay To test ligand / receptor blocking activity, 0.5μg / ml hPD-L1-Fc antigen was coated onto ELISA plates and incubated overnight at 4℃. 300μL of blocking buffer was added for blocking at room temperature for 1 hour. After 1 hour, 50μl of AM-4B6-hIgG1-TGFβRII variant 7 or original 4B6-hIgG1-TGFβRII at concentrations ranging from 100nM to 0.024nM (4-fold serial dilutions) was added along with 50μl of PD-L1-his at a concentration of 1μg / ml and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used to wash three times, and 100μl of HRP-conjugated streptavidin (1:5000, Abcam, catalog no. ab7403) was added. After 1.5 h of incubation at room temperature, the mixed TMB substrate reagent was added. After 5 min of incubation at room temperature, the reaction was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader. As shown in Figures 5A-5B, both samples were able to block PD-L1 / PD-1 or PD-L1 / B7-1, but AM-4B6-hIgG1-TGFβRII variant 7 had a lower IC50, indicating that variant 7 had improved activity.
[0479]
[0510] PD-1 / PD-L1 blockade by cell-based assay
[0511] In this assay, 293T-PD-L1-CD3L cells express PD-L1 and anti-CD3 scFv, while Jurkat-NFAT-Luc-PD1 cells express PD-1 and carry NFAT signaling, which can be activated by CD3 stimulation. NFAT activation leads to transcription and expression of the downstream luciferase gene, which can be detected by its substrate. The two cell lines were generated by MabSpace Bioscience.
[0480]
[0512] Briefly, 293T-PD-L1-CD3L cells were harvested and 2x106 The cells were resuspended at a density of 100 cells / ml. 20 μl of cells per well were added to half-well plates. AM-4B6-hIgG1-TGFβRII variants or original 4B6-hIgG1-TGFβRII were serially diluted (3-fold) to obtain eight concentrations in RPMI medium containing 2% FBS. 20 μl of antibody per well was added to the half-well plates, and the plates were incubated at 37°C, 5% CO2 for 30 min. Jurkat-NFAT-Luc-PD1 cells were harvested and resuspended at 4x10 cells / ml in RPMI medium containing 2% FBS. 6 The cells were resuspended at a density of 1000 cells / ml. Finally, 20 μl of cells per well were added to a half-well plate with 5 ng / ml TGF-beta (R&D, 240-B-010) and incubated at 37°C, 5% CO2 for 5 h. 60 μl of OneGlo detection reagent (Promega, E6120) was added to each well and incubated at room temperature for 5 min. Luminescence signals were read using a microplate reader. Data were analyzed using GraphPad Prism.
[0481]
[0513] As shown in Figure 6, variant 7 had the most potent blocking activity in this cell-based assay compared with the other variants, consistent with the previous ELISA results. Therefore, the 4B6 Fab portion of AM-4B6-hIgG1-TGFβRII variant 7 was abbreviated as AM4B6, and the AM-4B6-hIgG1-TGFβRII fusion protein was further evaluated in the following experiments.
[0482] Example 8 Generation and characterization of AM4B6-hIgG1-TGFβRII' in vitro
[0514] Cloning and expression of AM4B6-hIgG1-TGFβRII
[0515] It has been reported that truncated TGFβRII ECD_20-136 is soluble and retains the ability to bind to TGFβ1 (Kim-Ming Lo et al., US9676863B2, 2017; Christian C. et al., Protein Expression and Purification, 2000, 20:98-104). Next, we replaced the full-length extracellular domain of TGFβRII_1-136 with the truncated one and evaluated its developability and stability. SDS-PAGE results from stable cell lines showed that protein expression was good for both truncated and full-length TGFβRII ECDs, but protein stability was much better for truncated TGFβRII ECD_20-136 than for full-length TGFβRII ECD (Figure 7). The sequence of truncated TGFβRII ECD_20-136 is as follows:
[0516] A stable TGF-β trap, the sequence of the TGF-βRII extracellular domain (20-136) GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 66)
[0517] A bifunctional molecule containing a truncated TGF-βRII (i.e., TGF-βRII(20-136), SEQ ID NO: 66) was used in this example and also in Examples 9 to 11. Such a bifunctional molecule is designated as TGFβRII' to distinguish it from TGF-βRII(1-136). For example, AM4B6-hIgG1-TGFβRII' denotes a molecule containing TGF-βRII(20-136).
[0483]
[0518] Binding to PD-L1 from various species by ELISA assay
[0519] ELISA plates were coated with 1 μg / ml human PD-L1 (Acro Biosystems, PD1-H5229) or cynomolgus monkey PD-L1 antigen and incubated overnight at 4°C. Then, 300 μL of 3% (w / v) skim milk was added for blocking at room temperature for 1 hour. After 1 hour, 100 μL of AM4B6-hIgG1-TGFβRII' or control hIgG1-TGFβRII' at concentrations ranging from 100 nM to 0.02 nM (4-fold serial dilutions) was added and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used for three washes, and 100 μL of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the reaction was stopped by adding 0.1 M H2SO4. OD450nm was recorded by a microplate reader.
[0484]
[0520] As shown in Figures 8A and 8B, AM4B6-hIgG1-TGFβRII' cross-reacted with cynomolgus monkey PD-L1 with an EC50 similar to that of human PD-L1.
[0485]
[0521] Binding to TGFβ1, TGFβ2, and TGFβ3 from various species by ELISA
[0522] According to the sequences of TGFβ1, TGFβ2, and TGFβ3 from four common species: human, cynomolgus monkey, mouse, and rat, published on the Uniprot website (https: / / www.uniprot.org / ), the TGFβ members are highly conserved. The sequences of human TGFβ1 and cynomolgus monkey TGFβ1 are identical; mouse TGFβ1 and rat TGFβ1 are identical; human TGFβ2 and cynomolgus monkey TGFβ2 are identical; mouse TGFβ2 and rat TGFβ2 are identical; and human TGFβ3, cynomolgus monkey TGFβ3, and mouse TGFβ3 are identical.
[0486]
[0523] For TGFβ1 and TGFβ3, the procedure was as follows: 0.5 μg / ml human TGFβ1 (Sino Biological, 10804-HNAC) or mouse TGFβ1 (Novoprotein, CK33) or human TGFβ3 (Genscript, Z03430) or rat TGFβ3 (Novoprotein, CJ44) antigen was coated onto an ELISA plate and incubated overnight at 4°C. Then, 300 μL of 3% (w / v) skim milk was added for blocking at room temperature for 1 h. After 1 h, 100 μL of AM4B6-hIgG1-TGFβRII' or control hIgG1-TGFβRII' at concentrations ranging from 100 nM to 0.006 nM (4-fold serial dilutions) was added and incubated at room temperature for 1 h. 0.5% PBS + Tween®-20 was used for three washes, and 100 μl of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the incubation was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader.
[0487]
[0524] For TGFβ2, the test procedure was different: 2 μg / ml of AM4B6-hIgG1-TGFβRII' or control hIgG1-TGFβRII' was coated onto an ELISA plate and incubated overnight at 4°C. Then, 300 μL of 3% (w / v) skim milk was added for blocking at room temperature for 1 h. After 1 h, 100 μL of human TGFβ2 or mouse TGFβ2 at concentrations ranging from 39.4 nM to 0.3 nM (2-fold serial dilutions) was added and incubated at room temperature for 1 h. 0.5% PBS + Tween®-20 was used for three washes, and 100 μL of TGFβ2 biotinylated antibody (1:10000, R&D, BAF302) was added. After incubation at room temperature for 1 h and washing, 100 μl of HRP-streptavidin (1:5000, Abcam, ab7403) was added and the plate was incubated at room temperature for 1 h. After washing, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, incubated at room temperature for 5 min, and stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader.
[0488]
[0525] The results are summarized in Table 16. For binding affinity to TGFβ1, the EC50 values were very similar among different species. Furthermore, the binding affinity to TGFβ1 and TGFβ3 was significantly higher than that to TGFβ2, indicating that the blocking activity of TGFβ1 and TGFβ3 may be stronger than that of TGFβ2.
[0489]
[0526]
[0490] [Table 18]
[0491]
[0527] Binding to other members of the B7 family or TGFβ superfamily by ELISA assay
[0528] For the B7 family, ELISA plates were coated with 0.5 μg / ml hPD-L1 (Acro Biosystems, PD1-H5229), hPD-L2, B7-2, B7-1, B7-H2, B7-H3, B7-H4, or VISTA and incubated overnight at 4°C. For the TGFβ superfamily, 0.5 μg / ml human activin A, BMP-2, LAP, or TGFβ1 was coated overnight at 4°C. Then, 300 μL of 3% (w / v) skim milk was added for blocking at room temperature for 1 hour. After 1 hour, 100 μL of AM4B6-hIgG1-TGFβRII' was added at concentrations ranging from 100 nM to 0.006 nM (serial dilution) and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used for three washes, and 100 μl of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the incubation was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader.
[0492]
[0529] As shown in Figures 9A-9B, AM4B6-hIgG1-TGFβRII' specifically bound to PD-L1 rather than other antigens that also belong to the B7 family. As shown in Figure 9C, AM4B6-hIgG1-TGFβRII' specifically bound to TGFβ1 rather than other antigens that also belong to the TGFβ superfamily.
[0493]
[0530] Binding of AM4B6-hIgG1-TGFβRII' to PD-L1-expressing cells
[0531] MC38 / hPD-L1 was generated by CRISPR-Cas9 deletion of mPD-L1 followed by lentivirus-mediated transduction of hPD-L1. This cell line was kindly provided by the laboratory of Professor Qin Xiaofeng at the Center of Systems Medicine, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences (Huang, Anfei et al., Scientific Reports 7(2017):42687). MC-38 / hPD-L1 cells were cultured in RPMI1640 + 10% FBS. EMT-6 / hPD-L1 is a mouse breast cancer cell line stably expressing a transfected human PD-L1 gene. EMT-6 / hPD-L1 cells were cultured in Waymouth's (1x) MB752 / 1 + 15% FBS. NCI-H460 cells were purchased from COBIOER Ltd. It is a human lung epithelial tumor cell line that expresses PD-L1. NCI-H460 cells were cultured in RPMI1640 + 10% FBS. NCI-H292 cells were purchased from COBIOER Ltd. It is a human lung epithelial tumor cell line that expresses PD-L1. NCI-H292 cells were cultured in RPMI1640 + 10% FBS + 1 nM sodium pyruvate solution. The FACS analysis protocol was the same as in Section 3 of Example 6.
[0494]
[0532] Human or cynomolgus monkey PBMCs (TPCS, Cat. No. PB025C) were harvested from liquid nitrogen and resuspended in RPMI 1640 containing 10% FBS. PBMC activation was stimulated by the addition of 5 μg / ml PHA (Sigma, Cat. No. L8902), and the cells were cultured for 3 days. Activated PBMCs were harvested, centrifuged, and 2x10 6The cells were resuspended in PBS at a density of 100 cells / ml and added to the plate at 100 μl per well. AM4B6-hIgG1-TGFβRII', AM4B6, or control hIgG1-TGFβRII' were serially diluted (5-fold) to obtain 10 concentrations in dilution buffer (PBS containing 2% BSA). After centrifugation and removal of the supernatant, the diluted antibodies were added to the plate along with activated PBMCs and incubated at 4°C for 1 hour. After washing twice with dilution buffer, Alexa488-labeled mouse anti-human CD3 (Biolegend, catalog no. 300320) and APC-labeled anti-human IgG secondary antibody (BD, catalog no. 550931) were added and incubated at 4°C for 30 minutes. After washing, the cells were resuspended in 150 μl of PBS and analyzed by flow cytometry.
[0495]
[0533] As shown in Figures 10A-F, AM4B6-hIgG1-TGFβRII' was able to bind to PD-L1 expressed on these cancer cell lines and activated human or cynomolgus monkey T cells with affinity similar to that of AM4B6 mAb alone.
[0496]
[0534] Binding to activated human T cells
[0535] Human PBMCs (TPCS, Cat. No. PB025C) were harvested from liquid nitrogen and resuspended in RPMI 1640 containing 10% FBS. PBMC activation was stimulated by the addition of 5 μg / ml PHA (Sigma, Cat. No. L8902), and the cells were cultured for 3 days. Activated PBMCs were harvested, centrifuged, and 2x10 6The cells were resuspended in PBS at a density of 100 cells / ml and added to the plate at 100 μl per well. AM4B6-hIgG1-TGFβRII', AM4B6, or control hIgG1-TGFβRII' were serially diluted (5-fold) to obtain 10 concentrations in dilution buffer (PBS containing 2% BSA). After centrifugation and removal of the supernatant, the diluted antibodies were added to the plate along with activated PBMCs and incubated at 4°C for 1 hour. After washing twice with dilution buffer, Alexa488-labeled mouse anti-human CD3 (Biolegend, catalog no. 300320) and APC-labeled anti-human IgG secondary antibody (BD, catalog no. 550931) were added and incubated at 4°C for 30 minutes. After washing, the cells were resuspended in 150 μl of PBS and analyzed by flow cytometry.
[0497]
[0536] As shown in Figure 11, AM4B6-hIgG1-TGFβRII' was able to bind to PD-L1 expressed on activated human T cells.
[0498]
[0537] Blockade of hPD-L1 / hPD-1 and cynomolgus PD-L1 / cynomolgus PD-1 by ELISA assay
[0538] ELISA plates were coated with 0.5μg / ml hPD-L1-Fc or 0.5μg / ml cynomolgus PD-L1-Fc and incubated overnight at 4℃. 300μL of 3% (w / v) skim milk was added for blocking at room temperature for 1 hour. After 1 hour, 100μL of AM4B6-hIgG1-TGFβRII' or AM4B6 at concentrations ranging from 100nM to 0.02nM (4-fold serial dilutions) was added along with 0.5μg / ml hPD-1-Fc-biotin or cynomolgus PD-1-Fc-biotin and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used to wash three times, and 100μL of HRP-conjugated streptavidin (1:5000) was added. After 1 h incubation at room temperature, the mixed TMB substrate reagent was added, and after 5 min incubation at room temperature, the reaction was stopped by adding 0.1 M H2SO4. The OD450 nm was recorded by a microplate reader.
[0499]
[0539] As shown in Figures 12A-B, AM4B6-hIgG1-TGFβRII' was also able to completely block cynomolgus PD-L1 / cynomolgus PD-1 with an IC50 similar to that of blockade of human PD-L1 / human PD-1.
[0500]
[0540] Simultaneous binding to hPD-L1 and hTGFβ1
[0541] 0.5μg / ml hTGFβ-1 was coated onto an ELISA plate and incubated overnight at 4℃. 300μL of blocking buffer was then added for blocking at room temperature for 1 hour. After 1 hour, 100μL of AM4B6-hIgG1-TGFβRII', AM4B6, or control hIgG1-TGFβRII' at concentrations ranging from 100nM to 0.02nM (4-fold serial dilutions) was added and incubated at room temperature for 1 hour. 0.5% PBS + Tween®-20 was used to wash three times, and then 0.5μg / ml hPD-L1-biotin was added to each well. After 1 hour, 100μL of HRP-conjugated streptavidin (1:5000) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the reaction was stopped by adding 0.1 M H2SO4. OD450nm was recorded by a microplate reader.
[0501]
[0542] As shown in Figure 13, AM4B6-hIgG1-TGFβRII', composed of the anti-PD-L1 antibody AM4B6 and TGFβRII', was able to bind to two targets simultaneously, demonstrating its bispecific or bifunctional properties.
[0502]
[0543] Blockade of hPD-L1 / hPD-1 by reporter cell assay
[0544] The protocol was the same as in Section 2 of Example 15. As shown in Figure 14, AM4B6-hIgG1-TGFβRII, like AM4B6 mAb alone, was able to block the inhibitory effect of PD-L1 / PD-1 and subsequently reverse signaling activation.
[0503]
[0545] Blockade of TGFβ1 signaling by reporter cell assay
[0546] The TGFβ reporter HEK-293 cell line was purchased from Genomeditech (catalog no. GM-C05346) and cultured in DMEM medium containing 10% FBS, 4 μg / ml blasticidin, 400 μg / ml neomycin, 125 μg / ml hygromycin, 0.75 μg / ml puromycin, and 1% Pen / Strep in a 37°C incubator containing 5% carbon dioxide.
[0504]
[0547] Cells were harvested in logarithmic growth phase and resuspended in DMEM medium at 2x10 cells per well. 4 Cells were seeded into 96-well plates at a density of 100 μl cells / 100 μl. After overnight culture, the medium was replaced with 75 μl of culture medium containing 10 ng / ml human TGFβ1. 75 μl of AM4B6-hIgG1-TGFβRII' or AM4B6 was added at final concentrations ranging from 100 nM to 0.02 nM (3-fold serial dilutions). The plates were incubated for 16 hours in a 37°C incubator. ONE-Glo™ Luciferase Assay System was added at 150 μl / well. After 10 minutes of incubation at room temperature, the plates were read using a microplate reader.
[0505]
[0548] As shown in Figure 15, AM4B6-hIgG1-TGFβRII' exhibited potent blocking activity against TGFβ1 signaling with an IC50 of 0.35 nM, whereas AM4B6 mAb alone had no blocking activity, indicating that the blocking activity was TGFβ1-specific.
[0506]
[0549] Effect of AM4B6-hIgG1-TGFβRII' on IFN-γ release from PBMC stimulated with tuberculin (TB)
[0550] Human PBMCs were harvested from liquid nitrogen and cultured at 2x10 6 The cells were resuspended at a density of 1x10 cells / mL. TB was added to a final concentration of 1.33 μg / mL and cultured at 37°C for 5 days. On day 6, the induced PBMCs were collected, centrifuged, washed once with PBS, resuspended in fresh medium, and diluted to 1x10 cells / mL. 6The antibody was adjusted to a density of 1 / ml and seeded into a 96-well cell plate at 180 μL / well. 20 μL / well of the diluted antibody was added to the 96-well cell culture plate. The control and blank groups were added with 20 μL of PBS. The cell culture plate was incubated at 37°C in a 5% CO2 incubator for 3 days. At the end of the incubation, the cell supernatant was diluted 10-fold, and the secretion level of IFN-γ was detected using an IFN-γ ELISA detection kit (R&D, DY285B).
[0507]
[0551] As shown in Figure 16, AM4B6-hIgG1-TGFβRII' induced significantly higher levels of IFN-γ release than AM4B6 mAb alone, indicating that its activating activity is more potent due to its bispecific binding and blocking activity.
[0508]
[0552] ADCC / CDC activity of AM4B6-hIgG1-TGFβRII'
[0553] For ADCC assay, effector cells: Jurkat-NFAT Luc-FcγRIIIa-158V cell line was constructed by Mabspace Biosciences (Suzhou) Co., Limited. Target cells: HEK-293T-hPD-L1 cells (purchased from Crown Biosciences Inc., catalog number 2005).
[0509]
[0554] HEK-293T-hPD-L1 cells were added to cell culture plates at 10,000 cells / 12.5 μl per well. AM4B6-hIgG1-TGFβRII' dilutions, ranging from 200 nM to 0.003 nM in final concentrations, were then added at 12.5 μl / well. The plate was then placed in an incubator at 37°C, and the antibody and cells were incubated for 30 minutes. Jurkat-NFAT Luc-FcγRIIIa-158V cells were then added to the wells at 60,000 cells / 25 μl per well. The plate was then placed in an incubator at 37°C for 6 hours. ONE-Glo™ Luciferase Assay System was added at 50 μl / well, and after 10 minutes of incubation at room temperature, the plate was read using a microplate reader.
[0510]
[0555] For the CDC assay, the target cells were also HEK-293T-hPD-L1 cells. HEK-293T-hPD-L1 cells were added to a cell culture plate at 10,000 cells / 25 well. AM4B6-hIgG1-TGFβRII' dilutions were then added at 12.5μl / well, with final concentrations ranging from 200nM to 0.3nM. The plate was then placed in a 37°C incubator, and the antibody and cells were incubated for 30 minutes. HEK-293T-hPD-L1 cells were treated with 40% complement at 50μl / well (final concentration 20%) and then incubated at 37°C for 80 minutes. ONE-Glo™ Luciferase Assay System was added at 100μl / well, and after 10 minutes of incubation at room temperature, the plate was read using a microplate reader.
[0511]
[0556] The results suggested that AM4B6-hIgG1-TGFβRII' had neither ADCC nor CDC activity against HEK-293T-hPD-L1 cells (data not shown).
[0512] Example 9 Efficacy of AM4B6-hIgG1-TGFβRII' in vivo
[0557] MC38-hPD-L1 tumor model in C57BL / 6 mice
[0558] Endogenous mouse PD-L1 was knocked out in the mouse tumor cell line MC38 (ATCC) using a highly efficient CRISPR / Cas system recently developed by the inventors. Briefly, an sgRNA targeting the first coding exon of the mouse PD-L1 gene was designed, and cells were transfected with the hit-and-run CRISPR / Cas9+sgRNA construct and selected for knockout cells. Cells in which endogenous mouse PD-L1 was completely knocked out were identified by FACS analysis for steady-state PD-L1 cell surface expression or verified by TA cloning and sequencing of the targeted genomic region after stimulation with interferon gamma. To generate human PD-L1 replacement cell lines, the coding sequence of human PD-L1 cDNA was cloned into an FG12-derived lentiviral vector. The mouse PD-L1 knockout cells were then infected with a lentivirus expressing human PD-L1, and high-level and stable expression of human PD-L1 in the established cell lines was confirmed by FACS analysis. This engineered cell line of MC38 was designated MC38-hPD-L1.
[0513]
[0559] MC38-hPD-L1 cells were maintained in vitro as monolayer cultures in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Exponentially growing tumor cells were harvested and counted for tumor inoculation. Each female SPF-grade C57BL / 6 mouse was inoculated with 2x10 MC38-hPD-L1 cells mixed with 50% Matrigel. 6 MC38-hPD-L1 cells were inoculated. The tumor size was approximately 90 mm. 3At the time of tumor development, tumor-bearing mice were selected and randomized into five groups (n=8). Animals were treated with 2.5 mg / kg isotype control, 3 mg / kg isotype control-TGFβRII', 2.5 mg / kg AM4B6, 0.3 mg / kg AM4B6-hIgG1-TGFβRII', 1 mg / kg AM4B6-hIgG1-TGFβRII', and 3 mg / kg AM4B6-hIgG1-TGFβRII'. All antibodies were administered by ip injection twice a week for 4 weeks. Tumor size was measured twice or three times a week in two dimensions using calipers (INSIZE) and calculated using the formula: V=0.5×b 2 where a and b are the long and short diameters of the tumor, respectively, in mm 3 The volume was expressed as . The results were analyzed using Prism GraphPad and expressed as mean ± SEM. Comparison between two groups was performed by T-test, and p < 0.05. * <0.05 and ** Differences are considered significant if <0.01.
[0514]
[0560] As shown in Figures 17A-17B, 3 mg / kg of the isotype control-TGFβRII' did not inhibit tumor growth at all, indicating that TGFβRII' alone was less effective. 2.5 mg / kg of AM4B6, like 0.3 mg / kg of AM4B6-hIgG1-TGFβRII', only had a partial inhibitory effect, which was considered insufficient to control tumor growth. With increasing dosage, tumor volume gradually decreased. 3 mg / kg of AM4B6-hIgG1-TGFβRII' almost completely stopped tumor growth, with a TGI of 84% (Table 17).
[0515]
[0561]
[0516] [Table 19]
[0517]
[0562] H460 tumor and human PBMC co-inoculation model in NOD-SCID mice
[0563] H460 cells were purchased from COBIOER Ltd. H460 cells were maintained in vitro as monolayer cultures in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere containing 5% CO2 in air. Exponentially growing tumor cells were harvested and counted for tumor inoculation. Each female SPF grade NOD-SCID mouse was injected with a mixed 3x10 6 H460 cells (model group) or 1.5x10 6 3x10 mixed with human PBMCs 6 H460 cells were inoculated. All cell suspensions were thoroughly mixed with Matrigel at a 1:1 ratio before inoculation. Approximately 4 hours after inoculation, animals were divided into 7 groups (n=10) and differentially dosed. Animals were treated with either 16.7 mg / kg control hIgG1, or 20 mg / kg control hIgG1-TGFβRII', or 16.7 mg / kg AM4B6, or 5 mg / kg AM4B6-hIgG1-TGFβRII', or 10 mg / kg AM4B6-hIgG1-TGFβRII', or 20 mg / kg AM4B6-hIgG1-TGFβRII'. The model group was untreated. All antibodies were administered twice a week by ip injection for 5 weeks. Tumor size was measured in two dimensions using a vernier caliper (INSIZE) twice or three times a week and calculated using the formula: V=0.5×b 2 where a and b are the long and short diameters of the tumor, respectively, in mm 3 The volume was expressed as . The results were analyzed using GraphPad Prism and expressed as mean ± SEM. Comparison between two groups was performed by T-test, and p * <0.05 and ** Differences are considered significant if <0.01.
[0518]
[0564] As shown in Figures 18A-B, 20 mg / kg of the isotype control-TGFβRII' did not inhibit tumor growth at all. While 5 mg / kg of AM4B6-hIgG1-TGFβRII' already had significantly better tumor inhibition, 16.7 mg / kg of AM4B6 only had a partial inhibitory effect, indicating that the TGFβRII fusion increased the antitumor efficacy of the AM4B6 mAb alone. Furthermore, a clear dose response of AM4B6-hIgG1-TGFβRII' was observed in this model, again suggesting that efficacy was dependent on AM4B6-hIgG1-TGFβRII'.
[0519]
[0565] EMT6-hPD-L1 tumor model in C57BL / 6 mice
[0566] Endogenous mouse PD-L1 was knocked out in the mouse tumor cell line EMT6 (ATCC), and human PD-L1 was knocked in into the cells; the engineered EMT6 cells were designated EMT6-hPD-L1.
[0520]
[0567] Mice were subcutaneously inoculated with EMT6 / hPD-L1 tumor cells and randomly divided into seven groups with 10 mice per group according to tumor volume. After grouping, animals in groups 1 through 7 were intraperitoneally injected twice weekly for 4 weeks with 24.9 mg / kg control hIgG1, 30 mg / kg control hIgG1-TGFβRII', 24.9 mg / kg AM4B6, 3 mg / kg AM4B6-hIgG1-TGFβRII', 10 mg / kg AM4B6-hIgG1-TGFβRII', or 30 mg / kg AM4B6-hIgG1-TGFβRII', respectively. Tumor volume and body weight of tumor-bearing mice were monitored twice weekly. As shown in Figures 19A-19B, AM4B6-hIgG1-TGFβRII' dose-dependently inhibited tumor growth with TGI of 21.43%, 46.83%, and 79.39% at 3, 10, and 30 mg / kg, respectively, on day 29 after administration. At equimolar doses, the antitumor activity of AM4B6-hIgG1-TGFβRII' at 30 mg / kg was more pronounced than that of AM4B6 at 24.9 mg / kg, and in that group, the TGI was 29.67% on day 29.
[0521] Example 10 The effect of AM4B6-hIgG1-TGFβRII' treatment on tumor-infiltrating lymphocytes (TIL) in the MC38-hPD-L1 tumor model
[0568] MC38-hPD-L1 tumor cells were cultured and inoculated according to the same process as in Example 9. Tumor sizes between 250 and 300 mm 3When tumor-bearing mice reached 100 mg / kg, they were randomized into four groups (n=6). Animals were treated with PBS, 3 mg / kg isotype control-TGFβRII', 2.5 mg / kg AM4B6, or 3 mg / kg AM4B6-hIgG1-TGFβRII'. All antibodies were administered by intravenous injection twice weekly for 1 or 2 weeks. Tumors were harvested 24 hours after the second and fourth doses, respectively, and then dissociated using a gentle MACS Dissociator (Miltenyi Biotec, 130-093-235) and digested with a Mouse Tumor Dissociation Kit (Miltenyi Biotec, 130-096-730) at 37°C for 40 min. The isolated single tumor cell suspensions from each group were stained with PE anti-mouse CD45 (BD bioscience, catalog number 553081), APC anti-mouse CD8a (Biolegend, catalog number 100712), APC anti-mouse NK1.1 (Biolegend, catalog number 108710), FITC anti-mouse granzyme B (Biolegend, catalog number 515403) and FITC anti-mouse IFN gamma (Invitrogen, catalog number 11-7311-82) as shown in Table 18 and Table 19, and then analyzed for the percentage of TIL subpopulations using FACS.
[0522]
[0569]
[0523] [Table 20]
[0524]
[0570]
[0525] [Table 21]
[0526]
[0571] After the second dose, there was no significant change in the percentage of TIL subpopulations among the different treatment groups (Table 18). However, after the fourth dose, the CD8+ / CD45+% in the AM4B6 group and the AM4B6-hIgG1-TGFβRII' group significantly increased compared with that in the isotype control-TGFβRII' group (Table 19). The CD8+GZMB+% and NK1.1+% also significantly increased compared with that in the isotype control-TGFβRII' group. These findings indicate that CD8+ T cells and NK1.1 T cells can be stimulated by AM4B6 or AM4B6-hIgG1-TGFβRII' to be activated and proliferate, and can be enriched in the tumor microenvironment to facilitate tumor cell killing. Compared to AM4B6, AM4B6-hIgG1-TGFβRII′ had even higher CD8+GZMB+% and NK1.1+%, which correlated with its more potent antitumor activity as measured by the TGI described above.
[0527] Example 11 In vivo pharmacokinetic and pharmacodynamic study of AM4B6-hIgG1-TGFβRII'
[0572] C57BL / 6 female mice were randomized into six groups (n=3). Animals were treated with 3 mg / kg isotype control-TGFβRII', 2.5 mg / kg AM4B6, 0.3 mg / kg AM4B6-hIgG1-TGFβRII', 1 mg / kg AM4B6-hIgG1-TGFβRII', 3 mg / kg AM4B6-hIgG1-TGFβRII', or 3 mg / kg M7824-analogue. The M7824-analogue was produced by MabSpace Biosciences according to the sequence disclosed in US9676863. All antibodies were administered by a single intravenous injection. After injection, 200 μl of blood from each mouse was collected at different time points: pre-dose, 30 min, 2 h, 8 h, 24 h, 48 h, D4, D7, D10, D14, and D21 after injection. 80 μl of plasma from each mouse was collected and tested for antibody concentration.
[0528]
[0573] Two methods were used to measure antibody concentrations in plasma. The first was to detect the entire bifunctional molecule containing both the AM4B6 arm and the TGFβRII' arm. Typically, 1 μg / ml of human PD-L1-his was coated onto a 96-well ELISA plate for 2 hours at room temperature. After blocking, serially diluted standards and plasma samples were added and incubated for 1.5 hours. After washing, 0.1 μg / ml of biotinylated anti-human TGFβRII' was added, followed by washing and streptavidin-HRP. Finally, TMB was added to develop the color, which was then stopped with dilute sulfuric acid. The plate was read at OD450nm and OD620nm using a microplate reader. Data were analyzed by OD450nm-OD620nm.
[0529]
[0574] The second one detects only the AM4B6 antibody arm. Similar to the procedure above, 1 μg / ml human PD-L1-his was coated, and serially diluted standards and plasma samples were added and incubated for 1.5 hours. After washing, diluted goat HRP-conjugated anti-human IgG Fc antibody was added. Finally, TMB was added to develop color, and the color was stopped with dilute sulfuric acid. The plate was read at OD450nm and OD620nm using a microplate reader. Data were analyzed by OD450nm-OD620nm.
[0530]
[0575] To assess the correlation between plasma antibody concentrations and changes in TGFβ, we examined changes in plasma TGFβ1 and TGFβ2 concentrations. Briefly, 4 μg / ml mouse TGF-β1 capture antibody or 2 μg / ml mouse TGF-β2 capture antibody was coated onto a 96-well ELISA plate for 2 hours at room temperature. 10 μl of 1N HCl was added to 50 μl of each plasma sample and incubated for 10 minutes at room temperature. Oxidized samples were neutralized by adding 10 μl of 1.2N NaOH / 0.5M HEPES to ensure a final pH within 7.2-7.6. After blocking, serially diluted standards and plasma samples were added and incubated for 1.5 hours. After washing, TGF-β1 or TGF-β2 detection antibody was added, followed by streptavidin-HRP. Finally, TMB was added to develop the color, which was then stopped with dilute sulfuric acid. The plates were read at OD450nm and OD620nm using a microplate reader. Data was analyzed by OD450nm-OD620nm.
[0531]
[0576] Figure 20A shows the changes in antibody concentration in plasma. There was no significant difference in the PK profiles using the two methods, indicating that the full bifunctional molecule AM4B6-hIgG1-TGFβRII' was highly stable in vivo without abnormal cleavage and clearance, similar to that of the AM4B6 mAb. At the same time, AM4B6-hIgG1-TGFβRII' depleted TGF-β1 within 30 min after intravenous injection, even at the lowest dose of 0.3 mg / kg, as shown in Figure 20B. The M7824-analogue and isotype control-TGFβRII' also depleted TGF-β1, but the M7824-analogue failed to maintain its effect from day 2, whereas AM4B6-hIgG1-TGFβRII' maintained low levels of TGF-β1 until day 21. This result was consistent with the PK profile (Figure 20C), indicating that TGF-β1 could serve as a good pharmacodynamic marker for AM4B6-hIgG1-TGFβRII' target engagement in plasma. A clear depletion of TGF-β2 was detected in mouse plasma (data not shown).
[0532] Example 12 Construction and expression of AM4B6-hIgG1-IL-1RA fusion protein
[0577] Selected heavy and light chain variants were cross-mixed and co-expressed with hIgG1-IL-1RA(34-177) (UniProtKB, P18510) fusion protein. The heavy and light chain sequences are shown in Table 20.
[0533]
[0578]
[0534] [Table 22]
[0535]
[0579] Similar to the AM4B6-hIgG1-TGFβRII' bifunctional molecule, truncated human IL-1RA_34-177 was fused with AM4B6 to obtain better activity and stability. AM4B6-hIgG1-IL-1RA was an abbreviation of AM4B6-hIgG1-IL-1RA(34-177). The sequence of truncated human IL-1RA_34-177 is as follows: (SEQ ID NO: 67) KMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
[0580] Co-transfection of heavy and light chains was carried out using ExpiFectamine™ CHO Reagent from Invitrogen (Thermo, A29129) according to the manufacturer's protocol. Supernatants were harvested on day 10 and purified by affinity chromatography.
[0536] Example 13 Affinity of the AM4B6-hIgG1-IL-1RA bifunctional molecule for hPD-L1
[0581] Binding to human PD-L1 based on ELISA assay
[0582] ELISA plates were coated with 1 μg / ml hPD-L1 (Acro Biosystems, PD1-H5229) antigen overnight at 4°C. 300 μL of 2% (w / v) BSA was then added for blocking at room temperature for 1 hour. After 1 hour of incubation, 100 μL of AM4B6-hIgG1-IL-1RA bifunctional molecule or AM4B6-hIgG1 monoclonal antibody at concentrations ranging from 10 nM to 0.00017 nM (3-fold serial dilutions) was added, along with PBST as a negative control, and incubated at room temperature for 1 hour. PBS containing 0.5% Tween®-20 was used for three washes, and 100 μL of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After 1 h of incubation at room temperature, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after 5 min of incubation at room temperature, the reaction was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader. Data were analyzed using GraphPad Prism.
[0537]
[0583] As shown in FIG. 21, compared to the AM4B6 monoclonal antibody, the AM4B6-hIgG1-IL-1RA bifunctional molecule has similar binding signals and affinities.
[0538]
[0584] Binding of AM4B6-hIgG1-IL-1RA to PD-L1 expressed on the cell surface by FACS assay
[0585] 293T-PD-L1-CD3L cells were generated by MabSpace Biosciences for characterization of PD-L1 antibodies. Cells were transfected with both human PD-L1 and anti-CD3 scFv. The AM4B6-hIgG1-IL-1RA bifunctional molecule or AM4B6 monoclonal antibody was serially diluted by 3-fold to obtain 11 concentrations in dilution buffer (PBS containing 2% BSA). 293T-PD-L1-CD3L cells were harvested and centrifuged. They were then diluted to 2x10 6Cells were resuspended in PBS at a density of 100 cells / ml and added to the plate at 100 μl per well. After centrifugation and removal of the supernatant, the diluted antibody was added to the plate and incubated at 4°C for 30 min. After washing twice with dilution buffer, PE-conjugated donkey anti-human IgG (H+L) (Jacksonimmuno, 709-116-149) was added to the plate and incubated at 4°C for 30 min. After washing, cells were resuspended in 200 μl of PBS and analyzed by flow cytometry. Data were analyzed using GraphPad Prism.
[0539]
[0586] As shown in Figure 22, the AM4B6-hIgG1-IL-1RA bifunctional molecule and AM4B6-hIgG1 were able to bind to PD-L1 expressed on the surface of cells with similar EC50, which was consistent with the affinity results measured by ELISA.
[0540] Example 14 PD1 / PD-L1 blocking activity of AM4B6-hIgG1-IL-1RA
[0587] In this assay, 293T-PD-L1-CD3L cells express PD-L1 and anti-CD3 scFv, while Jurkat-NFAT-Luc-PD1 cells express PD-1 and carry NFAT signaling, which can be activated by CD3 stimulation. NFAT activation leads to transcription and expression of the luciferase gene, which can be detected by its substrate. Both cells were generated by MabSpace Biosciences.
[0541]
[0588] Briefly, 293T-PD-L1-CD3L cells were harvested and 2x10 6The cells were resuspended at a density of 100 cells / ml. 20 μl of cells were added per well to a half-well plate. The AM4B6-hIgG1-IL-1RA bifunctional molecule and AM4B6-hIgG1 were serially diluted (3-fold) to obtain eight concentrations in RPMI medium containing 2% FBS. 20 μl of antibody per well was added to the half-well plate, and the plate was incubated at 37°C, 5% CO2 for 30 min. Jurkat-NFAT-Luc-PD1 cells were harvested and resuspended at a density of 4x10 cells / ml in RPMI medium containing 2% FBS. 6 The cells were resuspended at a density of 1000 cells / ml. Finally, 20 μl of cells per well were added to half-well plates and incubated at 37°C, 5% CO2 for 5 h. 60 μl of OneGlo detection reagent (Promega, E6120) was added to each well and incubated at room temperature for 5 min. Luminescence signals were read using a microplate reader. Data were analyzed using GraphPad Prism.
[0542]
[0589] As shown in Figure 23, the AM4B6-hIgG1-IL-1RA bifunctional molecule and AM4B6-hIgG1 had similar blocking activity against PD-L1 in this cell-based assay.
[0543] Example 15 Blocking activity of AM4B6-hIgG1-IL-1RA against human IL-1β
[0590] Blocking activity of AM4B6-hIgG1-IL-1RA BsAb against hIL-1β based on ELISA
[0591] To test ligand / receptor blocking activity, 5 μg / ml human IL-1β protein (Sino Biological, catalog no. 10139) was coated onto ELISA plates and incubated overnight at 4°C. 300 μL of blocking buffer was added for 1 h at room temperature. After 1 h, 50 μl of serial concentrations of AM4B6-hIgG1-IL-1RA BsAb or IL-1RA protein (Sino Biological, catalog no. 10123-HNAE) ranging from 200 nM to 0.03 nM (3-fold serial dilutions) were added to the wells along with 50 μl of 10 nM human IL-1RI-his (Sino Biological, catalog no. 10126-H08H) and incubated at room temperature for 1 h. PBS containing 0.5% Tween®-20 was used for three washes, and 100 μl of HRP-conjugated his-tag antibody (1:20,000 dilution, Genscript, Cat. No. A00612) was added and incubated at room temperature for 1 h. Mixed TMB substrate reagent (InnoReagents, Cat. No. TMB-S-003) was then added and incubated at room temperature for 5 min, after which the incubation was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader. Data were analyzed using GraphPad Prism.
[0544]
[0592] As shown in Figure 24, AM4B6-hIgG1-IL-1RA was able to block IL-1β in a dose-dependent manner, and the blocking activity of AM4B6-hIgG1-IL-1RA against IL-1RI was better than that of IL-1RA protein.
[0545]
[0593] Blocking activity of AM4B6-hIgG1-IL-1RA bifunctional molecule against hIL-1β on reporter cells
[0594] For this assay, HEK-Blue™ CD40L cells were purchased from Invivogen (catalog number hkb-cd40). These cells were generated by stable transfection of HEK293 cells with the human CD40 gene and an NF-κB-inducible SEAP construct. Binding of CD40L to its receptor CD40 triggers a cascade that leads to NF-κB activation and subsequent production of SEAP, which can be monitored by QUANTI-Blue. HEK293 cells endogenously express a receptor for the cytokine IL-1β, which shares a common signaling pathway with CD40L. Therefore, IL-1β-mediated SEAP production can be blocked using a neutralizing antibody.
[0546]
[0595] Briefly, HEK293-CD40L cells were collected in log phase and 5x10 4 Cells were seeded into 96-well plates at a density of 100 μl / well (100 μl / well) and allowed to adhere overnight. The AM4B6-hIgG1-IL-1RA bispecific antibody and IL-1RA protein were serially diluted (5-fold) to obtain 10 concentrations in complete culture medium. 50 μl / well of diluted antibody (or IL-1RA protein) and 50 μl / well of human IL-1β were added to the cells and incubated at 37°C for 24 h. The following day, 160 μl of QUANTI-Blue™ solution (Invivogen, catalog number rep-qbs) was added to a new plate, and 40 μl of cell culture supernatant was added to the plate. The plate was incubated at 37°C for 2 h. SEAP levels were determined using a spectrophotometer at 620 nm. Data were analyzed using GraphPad Prism.
[0547]
[0596] As shown in Figure 25, AM4B6-hIgG1-IL-1RA was able to block IL-1β in a dose-dependent manner, and the blocking activity of AM4B6-hIgG1-IL-1RA against IL-1β was more potent than that of IL-1RA protein, which was consistent with the blocking results measured by ELISA.
[0548] Example 16 Construction, expression, and purification of AM4B6-SIRPα bifunctional antibody
[0597] SIRPα_CV1 is an engineered high-affinity SIRPα variant that potently antagonized CD47 on cancer cells but did not induce macrophage phagocytosis by itself (Kipp Weiskopf et al., Science 341, 88 (2013)). The inventors have invented bifunctional antibodies that target both PD-L1 and CD47, including symmetric antibodies (AM4B6-hIgG1-SIRPα and 3280A-hIgG1-SIRPα) and asymmetric antibodies (AM4B6-hIgG1-SIRPα(KIH) and 3280A-hIgG1-SIRPα(KIH)) (where KIH is an abbreviation for knobs-into-holes). The construction of these molecules is described in Table 21, and the sequenced SIRPα_CV1 is also listed below.
[0549]
[0598] SIRPα_CV1 sequence (SEQ ID NO: 84):
[0599] EEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPS
[0600]
[0550] [Table 23]
[0551]
[0601] All four bifunctional antibodies were expressed using Expi-CHO cells according to the manufacturer's protocol. Highly pure antibodies were obtained for the two symmetric bifunctional antibodies using one-step Mabselect SuRe purification, but the asymmetric bifunctional antibody could not be purified by conventional one-step Mabselect SuRe purification. To obtain highly pure asymmetric antibodies, we polished the antibodies using HiTrap PrismA resin, and the purity of the asymmetric antibodies was better than 95%. The polishing purification procedure is described as follows:
[0552]
[0602] Buffers used:
[0603] Equilibration buffer: 50mM Tris-HAc, 150mM NaCl, pH7.4.
[0553]
[0604] Wash buffer: 50mM NaAc / HAc, 500mM NaCl, 5% PEG, pH5.5.
[0554]
[0605] Elution buffer: 50mM HAc, 500mM NaCl, 5% PEG, pH 3.0.
[0555]
[0606] The HiTrap PrismA column is equilibrated with equilibration buffer for at least 5 column volumes (CV) until the UV baseline, eluent pH, and conductivity remain unchanged.
[0556]
[0607] The sample is loaded onto a pre-equilibrated HiTrap PrismA column.
[0557]
[0608] Wash with 5-10 CV of wash buffer until the UV trace returns to baseline.
[0558]
[0609] Elute with 0-100% elution buffer over 10-20 CV, collecting 5-10 fractions in several tubes. Adjust the pH to approximately 6.0-7.0 using 1 M Tris base (pH 9.0).
[0559]
[0610] The fractions were then characterized by SEC-HPLC. Figure 26 shows that the purity of 3280A-hIgG1-SIRPα(KIH) and AM4B6-hIgG1-SIRPα(KIH) was 95.33% and 96.5%, respectively.
[0560]
[0611] The affinity for human PD-L1 or human CD47 was tested using ELISA. Figure 27 and Figure 28 show that the affinity of the bifunctional antibody for the antigen is comparable to that of the parent monoclonal antibody (4B6 mAb control) or the fusion protein (SIRPα-Fc(FES)).
[0561]
[0612] Example 17 Construction and expression of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bispecific antibodies (bsAbs)
[0613] The sequence of the single-chain fragment (scFv) AM4B6 is shown in the table below. The anti-IL-1β antibodies gevokizumab (XOMA052) and canakinumab (ACZ885) were from Novartis. The scFv of AM4B6 was linked to the C-terminus of the anti-IL-1β antibody heavy chain to achieve better activity and stability. The scFv has a GS linker (GGGGSGGGGSGGGGSGGGGS) connecting the VH to the VL and contains an interdomain disulfide bond between residues H44C and L100C (Kabat numbering). The sequences of the anti-IL-1β antibodies (XOMA052 and ACZ885) are shown in Table 22. The constructed bispecific antibodies were designated IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6, respectively.
[0562]
[0614] Co-transfection of the heavy and light chains of bsAb was carried out using ExpiFectamine™ CHO Reagent from Invitrogen (Thermo, A29129) according to the manufacturer's protocol. Supernatants were harvested on day 10 and purified by affinity chromatography.
[0563]
[0615] Example 18 Binding activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs to hIL-1β
[0616] Binding to human IL-1β protein based on ELISA assay
[0617] 100 μL of 1 μg / mL hIL-1β protein (Sino Biological, catalog no. 10139-HNAE) was coated onto an ELISA plate and allowed to coat overnight at 4°C. 200 μL of 2% (w / v) BSA was then added for blocking at room temperature for 2 h. After incubation, 100 μL of IgG-scFv-ACZ885-AM4B6, IgG-scFv-XOMA052-AM4B6 bsAb, ACZ885, and XOMA052 at concentrations ranging from 20 nM to 0.000339 nM (3-fold serial dilutions) was added along with PBST as a negative control and incubated at room temperature for 1 h. PBS containing 0.5% Tween®-20 was used for three washes, and 100 μl of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the mixture was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader. Data were analyzed using GraphPad Prism.
[0564]
[0618] As shown in Figure 29, compared to the ACZ885 and XOMA052 monoclonal antibodies, the IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs have similar binding activity to hIL-1β protein, respectively.
[0565]
[0619] Example 19 Binding activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs to hPD-L1
[0620] Binding to human PD-L1 based on ELISA assay
[0621] 100μL of 1μg / mL hPD-L1 (Acro Biosystems, PD1-H5229) antigen was coated onto an ELISA plate and allowed to coat overnight at 4℃. 300μL of 2% (w / v) BSA was then added for blocking at room temperature for 1 hour. After 1 hour of incubation, 100μL of IgG-scFv-ACZ885-AM4B6, IgG-scFv-XOMA052-AM4B6 bsAb, or AM4B6-hIgG1 monoclonal antibody (AM4B6 mAb) at concentrations ranging from 20nM to 0.000339nM (3-fold serial dilutions) was added, along with PBST as a negative control, and the plate was incubated at room temperature for 1 hour. PBS containing 0.5% Tween®-20 was used for three washes, and 100 μl of HRP-conjugated anti-human Fc antibody (1:20000, Abcam, ab98624) was added. After incubation at room temperature for 1 h, mixed TMB substrate reagent (InnoReagents, TMB-S-003) was added, and after incubation at room temperature for 5 min, the mixture was stopped by adding 0.1 M H2SO4. OD450nm was recorded using a microplate reader. Data were analyzed using GraphPad Prism.
[0566]
[0622] As shown in Figure 30, compared to the AM4B6 monoclonal antibody, the IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 bsAbs have similar binding activity to hPD-L1 protein.
[0567]
[0623] Binding of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 to PD-L1-expressing 293T cells by FACS analysis
[0624] 293T-PD-L1-CD3L cells were generated by MabSpace Biosciences for characterization of PD-L1 antibodies. Cells were transfected with both human PD-L1 and anti-CD3 scFv. IgG-scFv-ACZ885-AM4B6, IgG-scFv-XOMA052-AM4B6, or AM4B6 mAb was serially diluted by 4-fold dilutions to obtain nine concentrations in dilution buffer (PBS containing 2% BSA). 293T-PD-L1-CD3L cells were harvested and centrifuged. They were then diluted to 2x10 6 Cells were resuspended in PBS at a density of 100 cells / ml and added to the plate at 100 μl per well. After centrifugation and removal of the supernatant, the diluted antibody was added to the plate and incubated at 4°C for 30 min. After washing twice with dilution buffer, PE-conjugated donkey anti-human IgG (H+L) (Jacksonimmuno, 709-116-149) was added to the plate and incubated at 4°C for 30 min. After washing, cells were resuspended in 200 μl of PBS and analyzed by flow cytometry. Data were analyzed using GraphPad Prism.
[0568]
[0625] As shown in Figure 31, IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6 have similar EC 50 The antibody was able to bind to PD-L1 expressed on the cell surface at 100 μg / mL, consistent with the affinity measured by ELISA.
[0569] Example 20 PD1 / PD-L1 blocking activity of IgG-scFv-ACZ885-AM4B6 and IgG-scFv-XOMA052-AM4B6
[0626] In this assay, 293T-PD-L1-CD3L cells express PD-L1 and anti-CD3 scFv, while Jurkat-NFAT-Luc-PD1 cells express PD-1 and carry NFAT signaling, which can be activated by CD3 stimulation. NFAT activation leads to transcription and expression of the luciferase gene, which can be detected by its substrate. The two cell lines were generated by MabSpace Biosciences.
[0570]
[0627] Briefly, 293T-PD-L1-CD3L cells were harvested and 2x10 6 The cells were resuspended at a density of 100 cells / ml. 20 μl of cells were added per well to a half-well plate. IgG-scFv-ACZ885-AM4B6, IgG-scFv-XOMA052-AM4B6, and AM4B6-hIgG1 were serially diluted (3-fold) to obtain nine concentrations in RPMI medium containing 2% FBS. 20 μl of antibody was added per well to the half-well plate, and the plate was incubated at 37°C, 5% CO2 for 30 min. Jurkat-NFAT-Luc-PD1 cells were harvested and resuspended at 4x10 cells / ml in RPMI medium containing 2% FBS. 6 The cells were resuspended at a density of 1000 cells / ml. Finally, 20 μl of cells per well were added to half-well plates and incubated at 37°C, 5% CO2 for 5 h. 60 μl of OneGlo detection reagent (Promega, E6120) was added to each well and incubated at room temperature for 5 min. Luminescence signals were read using a microplate reader. Data were analyzed using GraphPad Prism.
[0571]
[0628] As shown in Figure 32, IgG-scFv-ACZ885-AM4B6, IgG-scFv-XOMA052-AM4B6 and AM4B6-hIgG1 had similar blocking activity against PD-L1 in this cell-based assay.
[0572] Example 21 Blocking activity of IgG-scFv-XOMA052-AM4B6 against human IL-1β on human dermal fibroblast (HDF) cells
[0629] Blocking activity of IgG-scFv-XOMA052-AM4B6 against human IL-1β on HDF cells.
[0573]
[0630] To test ligand / receptor blocking activity, 4x10 4 HDF cells (cells / mL) were stimulated with 50 pg / mL recombinant human IL-1β (Sino Biological, Catalog No. 10139) at 100 μL / well. As a negative control, cells were not stimulated with IL-1β. IgG-scFv-XOMA052-AM4B6 and XOMA052 were then added at 100 μL / well at serial concentrations ranging from 100 nM to 0.00038 nM (4-fold serial dilutions) and incubated overnight (16–17 h) at room temperature. After stimulation, IL-6 release in the cell culture supernatant was detected using an IL-6 ELISA Kit (R&D, DY206, P209026) as instructed by the kit's instructions.
[0574]
[0631] As shown in Figure 33, IgG-scFv-XOMA052-AM4B6 and XOMA052 were able to block IL-1β in a dose-dependent manner, and the blocking activity of IgG-scFv-XOMA052-AM4B6 against IL-1β was similar to that of XOMA052 on HDF cells.
[0575]
[0632] Blocking activity of IgG-scFv-ACZ885-AM4B6 against hIL-1β on reporter cells
[0633] For this assay, HEK-Blue™ CD40L cells were purchased from Invivogen (catalog number hkb-cd40). These cells were generated by stable transfection of HEK293 cells with the human CD40 gene and an NF-κB-inducible SEAP construct. Binding of CD40L to its receptor CD40 triggers a cascade that leads to NF-κB activation and subsequent production of SEAP, which can be monitored by QUANTI-Blue. HEK293 cells endogenously express a receptor for the cytokine IL-1β, which shares a common signaling pathway with CD40L. Therefore, IL-1β-mediated SEAP production can be blocked using a neutralizing antibody.
[0576]
[0634] Briefly, HEK293-CD40L cells were collected in log phase and 5x10 4 Cells were seeded into 96-well plates at a density of 100 μl / well (100 μl / well) and allowed to adhere overnight. IgG-scFv-ACZ885-AM4B6 and ACZ885 were serially diluted (4-fold) from 100 nM to obtain nine concentrations in complete culture medium. 50 μl / well of diluted antibody and 50 μl / well of human IL-1β (1 ng / mL) were added to the cells and incubated at 37°C for 24 h. The following day, 160 μl of QUANTI-Blue™ solution (Invivogen, catalog number rep-qbs) was added to a new plate, and 40 μl of cell culture supernatant was added to the plate. The plate was incubated at 37°C for 2 h. SEAP levels were determined using a spectrophotometer at 620 nm. Data were analyzed using GraphPad Prism.
[0577]
[0635] As shown in Figure 34, IgG-scFv-ACZ885-AM4B6 and ACZ885 (canakinumab) can block IL-1β in a dose-dependent manner, but the blocking activity of IgG-scFv-ACZ885-AM4B6 was similar to that of ACZ885 (canakinumab) on HEK293-CD40L reporter cells.
[0578]
[0636]
[0579] Table 24-1
[0580] Table 24-2
[0581] Table 24-3
[0582] Table 24-4
[0583] Table 24-5
[0584] Table 24-6
[0585] Table 24-7
[0586] Table 24-8
[0587] Table 24-9
[0588] Table 24-10
[0589] Table 24-11
[0590] Table 24-12
[0591] Table 24-13
[0592] Table 24-14
[0593] Table 24-15
[0594] Table 24-16
[0595] Table 24-17
Claims
(A) a first portion that binds to PD-L1; and (B) a second moiety that a) blocks the activity of an immunosuppressive cytokine, or b) stimulates immunity. A bifunctional molecule comprising: the first portion comprises an antibody or antigen-binding fragment thereof against PD-L1, the antibody or antigen-binding fragment comprising a heavy chain variable (VH) region and / or a light chain variable (VL) region; The heavy chain variable region is a) HCDR1 comprising DYYMN (SEQ ID NO: 1) or a homologous sequence having at least 80% sequence identity thereto; b) DINPNNX 1 X 2 T.X. 3 HCDR2 comprising YNHKFKG (SEQ ID NO: 19) or a homologous sequence having at least 80% sequence identity thereto; and c) HCDR3 comprising WGDGPFAY (SEQ ID NO: 3) or a homologous sequence having at least 80% sequence identity thereto. and / or The light chain variable region is d) KASQNVX 4 X 5 X 6 LCDR1 comprising a sequence selected from the group consisting of VA (SEQ ID NO: 20) or a homologous sequence having at least 80% sequence identity thereto; e) SX 7 S.X. 8 RYT (SEQ ID NO: 21) or a homologous sequence having at least 80% sequence identity thereto; and f) LCDR3 comprising a sequence selected from the group consisting of QQYSNYPT (SEQ ID NO: 6) or a homologous sequence having at least 80% sequence identity thereto. Including, In the formula, X 1 is G or A, and X 2 is G or D or Q or E or L, and X 3 is S or M or Q or L or V, and X 4 is G, P or K, and X 5 is A or G, and X 6 is A or I, and X 7 is A or N or R or V, and X 8 is N or H or V or D.
2. The heavy chain variable region is a) HCDR1 comprising the sequence of SEQ ID NO:1, b) a HCDR2 comprising a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:18; and c) HCDR3 comprising the sequence of SEQ ID NO:3; and / or The light chain variable region is d) LCDR1 comprising a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9; e) an LCDR2 comprising a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12; and f) LCDR3 comprising the sequence of SEQ ID NO:6 The bifunctional molecule of claim 1 , comprising:
3. The heavy chain variable region is a) a heavy chain variable region comprising a HCDR1 comprising the sequence of SEQ ID NO:1, a HCDR2 comprising the sequence of SEQ ID NO:2, and a HCDR3 comprising the sequence of SEQ ID NO:3; b) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO:1, an HCDR2 comprising the sequence of SEQ ID NO:13, and an HCDR3 comprising the sequence of SEQ ID NO:3; c) a heavy chain variable region comprising a HCDR1 comprising the sequence of SEQ ID NO:1, a HCDR2 comprising the sequence of SEQ ID NO:14, and a HCDR3 comprising the sequence of SEQ ID NO:3; d) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO:1, an HCDR2 comprising the sequence of SEQ ID NO:15, and an HCDR3 comprising the sequence of SEQ ID NO:3; and e) a heavy chain variable region comprising HCDR1 comprising the sequence of SEQ ID NO:1, HCDR2 comprising the sequence of SEQ ID NO:17, and HCDR3 comprising the sequence of SEQ ID NO:3; and The light chain variable region is a) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO:4, an LCDR2 comprising the sequence of SEQ ID NO:5, and an LCDR3 comprising the sequence of SEQ ID NO:6; b) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO:9, an LCDR2 comprising the sequence of SEQ ID NO:5, and an LCDR3 comprising the sequence of SEQ ID NO:6; c) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO:8, an LCDR2 comprising the sequence of SEQ ID NO:5, and an LCDR3 comprising the sequence of SEQ ID NO:6; d) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO:4, an LCDR2 comprising the sequence of SEQ ID NO:12, and an LCDR3 comprising the sequence of SEQ ID NO:6; and e) a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO:4, an LCDR2 comprising the sequence of SEQ ID NO:11, and an LCDR3 comprising the sequence of SEQ ID NO:
6. The bifunctional molecule of claim 1, selected from the group consisting of:
4. the antibody or antigen-binding fragment thereof against PD-L1 further comprises one or more of heavy chains HFR1, HFR2, HFR3, and HFR4, and / or one or more of light chains LFR1, LFR2, LFR3, and LFR4; a) HFR1 is QVQLVQSGAEVKKPGASVKVSCKASGYX 9 FT (SEQ ID NO: 40) or a homologous sequence having at least 80% sequence identity thereto; b) HFR2 is WVRQAPGQX 10 LEWMG (SEQ ID NO:41) or a homologous sequence having at least 80% sequence identity thereto; c) The HFR3 sequence is RVTX 16 TVDX 11 SISTAYMELSRLRSDDDTAVYYCX 12 X 13 (SEQ ID NO: 42) or a homologous sequence having at least 80% sequence identity thereto; d) HFR4 comprises WGQGTLVTVSS (SEQ ID NO: 25) or a homologous sequence having at least 80% sequence identity thereto; e) LFR1 comprises DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 26) or a homologous sequence having at least 80% sequence identity thereto; f) LFR2 is WYQQKPGKX 14 PKLLIY (SEQ ID NO: 43) or a homologous sequence having at least 80% sequence identity thereto; g) LFR3 is GVPX 15 RFSGSGSGTDFTX 17 TISSLQPEDIATYYC (SEQ ID NO: 44) or a homologous sequence having at least 80% sequence identity thereto; h) LFR4 comprises FGQGTKLEIK (SEQ ID NO:29) or a homologous sequence having at least 80% sequence identity thereto; In the formula, X 9 is T or V, and X 10 is G or S, and X 11 is T or K, and X 12 is A or V, and X 13 is R or K, and X 14 is A or S, and X 15 is S or D, and X 16 is M or V, and X 17 The bifunctional molecule of claim 1 , wherein is F or L.
5. HFR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 22 and 30; HFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 23 and 31; HFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 24 and 32-35; HFR4 comprises the sequence of SEQ ID NO: 25; LFR1 comprises a sequence from the group consisting of SEQ ID NO: 26; LFR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 27 and 36; LFR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 28, and 37-38, 39, 45; The bifunctional molecule of claim 4 , wherein LFR4 comprises the sequence of SEQ ID NO:
29.
6. the heavy chain variable region comprises a sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and homologous sequences thereof having at least 80% sequence identity thereto; or 6. The bifunctional molecule of any one of claims 1 to 5, wherein the light chain variable region comprises a sequence selected from the group consisting of SEQ ID NO:47, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and homologous sequences thereof having at least 80% sequence identity thereto.
7. 7. The bifunctional molecule of claim 6, wherein the antibody or antigen-binding fragment thereof against PD-L1 comprises a pair of heavy chain and light chain variable region sequences selected from the group consisting of SEQ ID NOs: 49 / 54, 50 / 54, 51 / 54, 52 / 54, 49 / 55, 50 / 55, 51 / 55, 52 / 55, 58 / 62, 58 / 63, 58 / 64, 58 / 65, 59 / 62, 59 / 63, 59 / 64, 59 / 65, 60 / 62, 60 / 63, 60 / 64, and 60 / 65.
8. the antibody or antigen-binding fragment thereof against PD-L1 further comprises an immunoglobulin constant region, optionally a human Ig constant region, or optionally a human IgG constant region; Optionally, the constant region comprises a human IgG1, IgG2, IgG3, or IgG4 Fc region, or the constant region comprises an Fc variant having reduced effector function relative to a corresponding wild-type Fc region; Optionally, the Fc variant is 220S, 226S, 228P, 229S, 233P, 234V, 234G, 234A, 234F, 234A, 235A, 235G, 235E, 236E, 236R, 237A, 237K, 238S, 267R, 268A, 268Q, 269R, 297A, 297Q, 297G, 309L, 318A, 322A, or optionally the Fc variant comprises one or more amino acid residue substitutions selected from the group consisting of: 325L, 328R, 330S, 331S, and any combination thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat; or optionally the Fc variant comprises: a) K322A, L234A, and L235A; b) P331S, L23 8. The bifunctional molecule of any one of claims 1 to 7, comprising a combination of mutations selected from the group consisting of: Fc region, H268Q, V309L, A330S and P331S (IgG2); V234A, G237A, P238S, H268A, V309L, A330S and P331S (IgG2), wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat; or optionally wherein the Fc variant comprises the amino acid sequence of SEQ ID NO:
81.
9. 9. The bifunctional molecule of any one of claims 1 to 8, wherein the immunosuppressive cytokine comprises a cytokine in the transforming growth factor beta (TGF-β) superfamily, IL-1, or vascular endothelial growth factor (VEGF).
10. The bifunctional molecule of any one of claims 1 to 9, wherein the second portion comprises a TGF-β binding moiety, an IL-1 binding moiety, or an IL-1 receptor (IL-1R) binding moiety.
11. I) the TGF-β binding portion comprises a soluble TGFβ receptor (TGFβR), a TGF-β binding fragment or variant thereof, or an antibody against TGFβ or an antigen-binding fragment thereof; II) the IL-1 binding portion comprises a soluble IL-1R, an IL-1 binding fragment or variant of IL-1R, or an antibody to IL-1 or an antigen-binding fragment thereof; or III) the IL-1R binding portion comprises IL-1Ra or an IL-1-binding fragment or variant thereof, or an antibody to IL-1R or an antigen-binding fragment thereof; The bifunctional molecule of claim 10.
12. I) The soluble TGFβR comprises the extracellular domain (ECD) of TGFβR or a TGF-β binding fragment or variant thereof, and optionally, the TGFβR is selected from the group consisting of TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), TGFβ receptor III (TGFβRIII), and any combination thereof; II) the IL-1 binding portion comprises IL-1RI, the ECD of IL-1RI, IL-1RII, the ECD of IL-1RII, IL-1RAP, the ECD of IL-1RAP, IL-1sRI or IL-1sRII, or an IL-1 binding fragment or variant of any of IL-1RI, the ECD of IL-1RII, IL-1RII, the ECD of IL-1RII, IL-1RAP, the ECD of IL-1RAP, IL-1sRI or IL-1sRII; III) The antibody or antigen-binding fragment thereof against IL-1 comprises a heavy chain variable region and a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102, and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab, and gevokizumab, or the antibody or antigen-binding fragment thereof against IL-1 comprises a) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104, an HCDR2 comprising the sequence of SEQ ID NO: 105, and an HCDR3 comprising the sequence of SEQ ID NO: 106, and a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107, an LCDR2 comprising the sequence of SEQ ID NO: 108, and an LCDR3 comprising the sequence of SEQ ID NO: 109; or b) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 113 and an HCDR3 comprising the sequence of SEQ ID NO: 114, and a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 116 and an LCDR3 comprising the sequence of SEQ ID NO:
117. contains; or IV) The antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and a light chain variable region derived from an antibody selected from the group consisting of spesolimab, ategolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034 and CSC012; The bifunctional molecule of claim 11.
13. I) the ECD of TGFβR comprises the amino acid sequence of SEQ ID NO: 66, 79, 78, 77, or a sequence having at least 80% sequence identity thereto that still retains specific binding specificity and / or affinity for TGF-β; II) An antibody or an antigen-binding fragment thereof against IL-1, a) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto; b) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and its homologous sequences having at least 80% sequence identity thereto, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and its homologous sequences having at least 80% sequence identity thereto; or c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 118 or SEQ ID NO: 120, and a light chain comprising the amino acid sequence of SEQ ID NO: 119 or SEQ ID NO:
121. contains; or III) the IL-1R binding portion comprises an amino acid sequence of SEQ ID NO: 67 or 76, or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 67 or 76, or an IL-1 binding fragment or variant thereof; A bifunctional molecule according to claim 11 or 12.
14. The bifunctional molecule of any one of claims 1 to 8, wherein the second portion stimulates anti-tumor immunity and comprises an immunostimulatory polypeptide or an antagonist of immunoinhibitory receptor signaling.
15. I) The immunostimulatory polypeptide comprises interleukin (IL)-2 (IL-2), IL-15, IL-21, IL-10, IL-12, IL-23, IL-27, IL-35, granulocyte-macrophage colony-stimulating factor (GM-CSF), soluble CD4, soluble LAG-3, IFN-α, or a functional equivalent thereof; or II) The immune inhibitory receptor is signal regulatory protein alpha (SIRPα); The bifunctional molecule of claim 14.
16. I) soluble LAG-3 comprises the extracellular domain (ECD) of LAG-3 or an MHCII-binding variant thereof; or II) the second portion comprises a CD47-binding domain or a SIRPα-binding domain that blocks the interaction between CD47 and SIRPα, where the CD47-binding domain comprises a soluble SIRPα or a CD47-binding fragment or variant thereof, or an anti-CD47 antibody or an antigen-binding fragment thereof, or the SIRPα-binding domain comprises a soluble CD47 or a SIRPα-binding fragment or variant thereof, or an anti-SIRPα antibody or an antigen-binding fragment thereof; The bifunctional molecule of claim 15.
17. The method of claim 1, wherein the CD47-binding domain comprises the amino acid sequence of SEQ ID NO:84, or an amino acid sequence having at least 80% sequence identity thereto, wherein the amino acid sequence still retains binding specificity for CD47; II) the soluble SIRPα comprises the extracellular domain (ECD) of SIRPα or a CD47-binding variant thereof; or III) The soluble CD47 comprises the extracellular domain (ECD) of CD47 or a SIRPα-binding fragment or variant thereof; The bifunctional molecule of claim 16.
18. one or more second portions; i) at least one of the second moieties is linked to the N-terminus or C-terminus of the polypeptide chain of the first moiety; or ii) at least one of the second moieties is linked to a) the N-terminus or C-terminus of a heavy chain of the first moiety, or b) the N-terminus or C-terminus of a light chain of the first moiety; or iii) at least one of the second portions is linked to the C-terminus of the heavy chain constant region of the first portion; or iv) each of the second portions is linked to the C-terminus of each heavy chain constant region of the first portion, respectively; or v) comprising more than one second moiety linked respectively to the N-terminus of the heavy chain of the first moiety, the C-terminus of the heavy chain of the first moiety, the N-terminus of the light chain of the first moiety, the C-terminus of the light chain of the first moiety, or any combination thereof; A bifunctional molecule according to any one of claims 1 to 17.
19. 20. The bifunctional molecule of claim 18, wherein the heavy chain is heterodimeric with respect to the presence or position of the second moiety.
20. The method of claim 20, wherein the heterodimeric heavy chain comprises one heavy chain having the second portion and the other heavy chain not having the second portion; and / or ii) the heterodimeric heavy chain further comprises a heterodimeric Fc region that is associated to prevent homodimerization and / or to favor heterodimerization; and / or iii) the heterodimeric Fc region is capable of associating into heterodimers via knobs-into-holes, hydrophobic interactions, electrostatic interactions, hydrophilic interactions, or increased mobility; and / or iv) the heterodimeric Fc region comprises Y349C, T366S, L368A, or Y407V, or any combination thereof, in one Fc polypeptide chain, and S354C or T366W, or any combination thereof, in another Fc polypeptide chain, wherein the numbering of the residues in the Fc polypeptide chains is that of the EU index as in Kabat; The bifunctional molecule of claim 19.
21. A bifunctional molecule comprising a first portion that binds to an immune checkpoint molecule and a second portion that blocks the activity of interleukin-1 (IL-1).
22. an agonist of an immunostimulatory checkpoint molecule, wherein the first portion is selected from the group consisting of CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278) and ICOSLG (CD275), CD2, ICAM-1, LFA-1 (CD11a / CD18), CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, and CD83; or an antagonist of an immune inhibitory checkpoint molecule optionally selected from the group consisting of A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), SIGLEC9 (CD329), CD160, LAIR1, 2B4 (CD244), CD47, B7-H5.
23. 22. The bifunctional molecule of claim 21 , wherein the first portion comprises an antibody or antigen-binding fragment thereof against PD-L1 and the second portion comprises an IL-1 binding portion or an IL-1 receptor (IL-1R) binding portion.
24. I) the IL-1 binding portion comprises IL-1R or a fragment or variant thereof, or an antibody to IL-1 or an antigen-binding fragment thereof; or II) the IL-1R binding portion comprises an interleukin-1 receptor antagonist or a fragment or variant thereof, or an antibody to IL-1R or an antigen-binding fragment thereof; The bifunctional molecule of claim 23.
25. I) An antibody against IL-1 or an antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region derived from an anti-IL-1α antibody selected from the group consisting of XB2001, rutikizumab, LY2189102, and bermekimab, or an anti-IL-1β antibody selected from the group consisting of SSGJ-613, CDP484, canakinumab, and gevokizumab, or an antibody against IL-1 or an antigen-binding fragment thereof is a) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 104, an HCDR2 comprising the sequence of SEQ ID NO: 105, and an HCDR3 comprising the sequence of SEQ ID NO: 106, and a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 107, an LCDR2 comprising the sequence of SEQ ID NO: 108, and an LCDR3 comprising the sequence of SEQ ID NO: 109; b) a heavy chain variable region comprising an HCDR1 comprising the sequence of SEQ ID NO: 112, an HCDR2 comprising the sequence of SEQ ID NO: 113, and an HCDR3 comprising the sequence of SEQ ID NO: 114, and a light chain variable region comprising an LCDR1 comprising the sequence of SEQ ID NO: 115, an LCDR2 comprising the sequence of SEQ ID NO: 116, and an LCDR3 comprising the sequence of SEQ ID NO: 117; c) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 102 and its homologous sequences having at least 80% sequence identity thereto, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 103 and its homologous sequences having at least 80% sequence identity thereto; or d) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 110 and its homologous sequences having at least 80% sequence identity thereto, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NO: 111 and its homologous sequences having at least 80% sequence identity thereto. contains; or II) The antibody or antigen-binding fragment thereof against IL-1R comprises a heavy chain variable region and a light chain variable region derived from an antibody selected from the group consisting of spesolimab, ategolimab, imsidolimab, AMG108, merlilimab, nidanilimab, MEDI8968, REGN6490, HB0034 and CSC012; The bifunctional molecule of claim 24.
26. 26. The bifunctional molecule of any one of claims 1 to 25, further comprising a linker connecting the first portion and the second portion, wherein the linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.
27. 27. The bifunctional molecule of claim 26, wherein the linker comprises an amino acid sequence of ((G)nS)m, where m and n are independently integers selected from 0 to 30.
28. 28. The bifunctional molecule of any one of claims 1 to 27, further linked to one or more conjugate moieties comprising other anti-cancer drugs such as clearance modifiers, chemotherapeutic agents, toxins, radioisotopes, lanthanides, luminescent labels, fluorescent labels, enzyme substrate labels, DNA alkylating agents, topoisomerase inhibitors, tubulin binding agents, or androgen receptor inhibitors.
29. 29. A pharmaceutical composition or kit comprising the bifunctional molecule of any one of claims 1 to 28 and a pharma- ceutically acceptable carrier.
30. 29. An isolated polynucleotide encoding the bifunctional molecule of any one of claims 1 to 28.
31. Use of a bifunctional molecule described in any one of claims 1 to 28 in the manufacture of a medicament for use in a method for treating, preventing or ameliorating a PD-L1 associated disease in a subject.
32. The method of claim 1, wherein the disease is an immune-related disease or disorder, cancer, or an infectious disease; II) the PD-L1-associated disease is resistant to PD-L1 / PD-1 monotherapy; III) the subject is a human; and / or IV) the subject has been identified as having PD-L1-expressing cancer cells; 32. The use according to claim 31.
33. 33. The use according to claim 32, wherein the cancer is selected from the group consisting of lung cancer (e.g. non-small cell lung cancer), liver cancer, pancreatic cancer, breast cancer, bronchial cancer, bone cancer, liver and bile duct cancer, ovarian cancer, testicular cancer, kidney cancer, bladder cancer, head and neck cancer, spinal cancer, brain cancer, cervical cancer, uterine cancer, endometrial cancer, colon cancer, colorectal cancer, prostate cancer, gastro-esophageal cancer, rectal cancer, anal cancer, gastrointestinal cancer, skin cancer, pituitary cancer, gastric cancer, vaginal cancer, thyroid cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, sarcoma, teratoma, glioma and adenocarcinoma.
34. The use of any one of claims 31 to 33, wherein the method further comprises administering a therapeutically effective amount of a second therapeutic agent.
35. 35. The use of claim 34, wherein the second therapeutic agent is selected from a chemotherapeutic agent, an anti-cancer drug, radiation therapy, an immunotherapy agent, an angiogenesis inhibitor, a targeted therapy agent, a cell therapy agent, a gene therapy agent, a hormone therapy agent, or a cytokine.
36. 30. Use of a bifunctional molecule according to any one of claims 1 to 28 in the manufacture of a medicament for treating, preventing or ameliorating a disease or condition in a subject that would benefit from the suppression of immunosuppressive cytokines, from the induction of a sustained immune response, or from the stimulation of anti-tumor immunity.
37. I) The immunosuppressive cytokine is TGFβ; II) the disease or condition is a TGF-β-related disease or condition; III) the disease is cancer, a fibrotic disease, or a renal disease; IV) the immunosuppressive cytokine is IL-1; V) the disease or condition is an IL-1 associated disease or condition; VI) the disease or condition would benefit from the induction of a sustained immune response by stimulating MHCII signaling with an immunostimulatory polypeptide; VII) the immunostimulatory polypeptide is soluble LAG-3; VIII) the disease or condition would benefit from stimulation of anti-tumor immunity by inhibiting immunoinhibitory receptor signaling; and / or IX) the immune inhibitory receptor is SIRPα; 37. The use according to claim 36.
